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1 
Summary 
Transcriptional regulation plays an intricate role in metabolic adaptation.  Cellular metabolism is thus 
regulated through a system of transcriptional activators and repressors.  These coregulators are able to 
modulate transcription of various metabolic programs to maintain energy homeostasis in response to 
altered energy demands or environmental cues.  Peroxisome proliferator-activated receptor (PPAR) 
coactivator 1 alpha (PGC-1α) is a transcriptional coactivator, which is import for cellular metabolic 
adaptation.  PGC-1α is expressed in mitochondria-rich tissues and regulates distinct metabolic gene 
programs, such as fatty acid oxidation and mitochondrial oxidative phosphorylation through interaction 
with various transcription factors.  The pervasive role of PGC-1α in metabolic regulation has made this 
transcriptional coregulator a promising therapeutic target in several disorders with a mitochondrial 
bioenergetic etiology.  However, to comprehend the therapeutic potential of PGC-1α activation, it is 
essential to gain a full understanding of the transcriptional networks modulated by this coactivator and 
its impact on cellular- and organismal physiology.  Moreover, it is important to validate whether PGC-1α 
activation is necessary to mediate the beneficial metabolic effects (i.e. increased energy expenditure or 
improved glucose tolerance) of various pharmacological compounds.  Such experiments will confirm the 
potential use of PGC-1α as a therapeutic target, and will give a better insight into the molecular 
mechanisms how these compounds exert their effects.  Ultimately, the characterization of PGC-1α as a 
therapeutic target will aid in the design of more efficient drug therapies.   
The role of PGC-1α is well established in organs such as liver and skeletal muscle.  However, 
despite the prevalence of mitochondrial dysfunction in the pathogenesis of renal disorders, the role of 
PGC-1α in kidney physiology and its potential therapeutic use in this organ is still unknown.  To define the 
role of PGC-1α in renal physiology, we generated and characterized a nephron-specific PGC-1α knockout 
mouse model.  We observed that deletion of PGC-1α in kidney led to a reduced transcription of gene 
programs involved in mitochondrial oxidative metabolism.  PGC-1α was also required for the induction of 
PPARα target genes and renal fatty acid oxidation during high fat diet feeding.  Renal deletion of PGC-1α 
resulted in mild hypertension and increased urinary sodium excretion.  However, mice deficient for PGC-
1α in the kidney could still adapt their salt and water homeostasis in response to salt stress.  This indicates 
that PGC-1α is dispensable for the adaptive regulation of tubular reabsorption and secretion.  However, 
due to the high basal energy demand of the kidney, there is a strong link between mitochondrial 
dysfunction and renal disorders.  While the loss of PGC-1α did not affect basal renal physiology, it has a 
central role as a regulator of metabolic and mitochondrial transcriptional programs in the kidney.  Hence, 
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PGC-1α could be a potential therapeutic target to ameliorate renal metabolic disorders associated with 
mitochondrial dysfunction and lipotoxicity.   
 
In the second study, we investigated the role of skeletal muscle PGC-1α in mediating the 
therapeutic effects of the SIRT1-activaiting compounds resveratrol (RSV) and SRT1720.  The beneficial 
systemic effects of these compounds, such as an enhanced metabolic rate and improved glucose 
tolerance, were independent of skeletal muscle PGC-1α.  PGC-1α was however necessary for 
transcriptional activation of mitochondrial genes in skeletal muscle with RSV and SRT1720 treatment.  
Intriguingly, while postulated to act through the same signaling pathways, we could also demonstrate 
differential effects of RSV and SRT1720 treatment on mitochondrial and metabolic processes in liver and 
white adipose tissue (WAT).  Importantly, both RSV and SRT1720 enhanced transcription of PGC-1α target 
genes in WAT and liver, respectively.  Finally, in the third part of this thesis, we investigated the role of 
PGC-1α in the regulation of skeletal muscle ketone body oxidation.  Ketone bodies are important 
metabolic fuels during prolonged starvation and dietary ketosis has been postulated to possess several 
therapeutic effects, such as improved epileptic seizure control, reduced cancer growth rates and 
enhanced mitochondrial biogenesis in brown adipose tissue and brain.  However, relatively little is known 
how ketolytic capacity in skeletal muscle is regulated.  We demonstrated that PGC-1α, together with the 
estrogen-related receptor alpha (ERRα), regulates transcription of ketolytic enzymes in skeletal muscle, 
both in a basal state and in response to exercise.  Importantly, modulation of PGC-1α levels in skeletal 
muscle affected systemic ketone body homeostasis during exercise, fasting and feeding of a low-
carbohydrate ketogenic diet.  Moreover, elevation of PGC-1α levels in skeletal muscle was sufficient to 
ameliorate diabetic ketoacidosis in mice.  Hence, we identified PGC-1α as a potential therapeutic target 
to reduce hyperketonemia in diabetic patients. 
In summary, the work presented in this thesis describes several new aspects of PGC-1α biology.  
We have revealed novel insights into the role of PGC-1α in renal physiology and its potential role as a 
therapeutic target in kidney.  Additionally, we have evaluated the role of skeletal muscle PGC-1α as a 
molecular effector of the beneficial effects of RSV and SRT1720 on whole body metabolism.  Finally, we 
have described a novel role of PGC-1α as a transcriptional regulator of ketone body oxidation.  Collectively, 
our findings demonstrates a crucial role of PGC-1α in many different biological processes which are all 
ultimately connected to mitochondrial metabolism.  These data expand our knowledge on the 
transcriptional networks and cellular processes regulated by PGC-1α and will help to develop more 
efficient therapeutic strategies against metabolic disorders. 
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1.  General introduction 
1.1 - PGC-1α - a multifaceted transcriptional regulator 
Peroxisome proliferator-activated receptor gamma (PPARγ) co-activator 1 alpha (PGC-1α) is a protein, 
which belongs to the PGC-1 family of transcriptional coactivators [Liang and Ward 2006].  The other 
members of this family are PGC-1β [Kressler et al. 2002, Lin et al. 2002a, Meirhaeghe et al. 2003] and 
PGC-1-related coactivator (PRC) [Andersson and Scarpulla 2001].  PGC-1α was discovered through its 
ability to interact with PPARγ (hence its name), and thereby induce uncoupling protein 1 (UCP1) 
expression and a thermogenic gene program in brown adipose tissue (BAT) [Puigserver et al. 1998].  PGC-
1α also interacts with several other transcription factors (TF) belonging to the nuclear receptor (NR) family 
of TFs (i.e. thyroid receptor beta, TRβ; retinoid X receptor alpha, RXRα) [Puigserver et al. 1998].  PGC-1α 
does not contain a DNA-binding domain, and can therefore not bind directly to DNA.  Hence, TF-binding 
is essential for the function of PGC-1α [Puigserver and Spiegelman 2003].  PGC-1α is expressed at high 
levels in organs with a high basal oxidative capacity, such as skeletal muscle, BAT, brain, heart and kidney 
[Puigserver et al. 1998, Larrouy et al. 1999, Handschin and Spiegelman 2006].  Other organs such as liver 
and white adipose tissue (WAT) display lower basal levels of PGC-1α [Puigserver et al. 1998, Liang and 
Ward 2006].  However, transcription of PGC-1α can be strongly induced in these organs in response to 
external stimuli such as fasting in liver [Handschin and Spiegelman 2006], or cold exposure in WAT depots 
[Barbatelli et al. 2010].  Cold exposure also increases PGC-1α levels in both BAT and skeletal muscle 
[Puigserver et al. 1998], and exercise has been shown to induce PGC-1α expression in skeletal muscle 
[Baar et al. 2002, Pilegaard et al. 2003, Terada and Tabata 2004].  PGC-1α thus acts as a sensor of several 
distinct external stimuli, and in response enhances transcription of tissue-specific gene programs involved 
in mitochondrial function and oxidative capacity (discussed in more detail in section 1.2 of the 
introduction) to match the enhanced energy demand during cold adaptation or exercise. 
PGC-1β was the second PGC-1 family member to be cloned, and was identified due to its sequence 
similarities with PGC-1α [Kressler et al. 2002, Lin et al. 2002a, Meirhaeghe et al. 2003].  PGC-1β shows 
high sequence homology with PGC-1α at the N-terminal and C-terminal regions of the protein (Figure 1) 
[Lin et al. 2002a].  These are the regions where the major effector domains are found, and PGC-1β thus 
contains similar NR-interaction domains and RNA-recognition motifs as PGC-1α [Lin et al. 2002a, 
Meirhaeghe et al. 2003].  The expression pattern of PGC-1β is almost identical to PGC-1α, with higher 
expression in oxidative organs [Meirhaeghe et al. 2003].  PGC-1β can also interact with several TFs known 
1.  General introduction 
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to be coactivated by PGC-1α, such as nuclear respiratory factor 1 (NRF1), peroxisome proliferator-
activated receptor alpha (PPARα) and estrogen related receptor alpha (ERRα), and can thus induce 
identical transcriptional programs as PGC-1α [Lin et al. 2005a].  This has led to the idea that PGC-1α and 
PGC-1β are functionally redundant.  In line with this, whole body knock-out models of either PGC-1α [Lin 
et al. 2004, Leone et al. 2005] or PGC-1β [Lelliott et al. 2006, Vianna et al. 2006, Sonoda et al. 2007] are 
viable, while PGC-1α/PGC-1β double-knockout mice die soon after birth due to cardiac failure [Lai et al. 
2008].  Moreover, double-knockout of PGC-1α/PGC-1β in skeletal muscle leads to exacerbated 
mitochondrial dysfunction compared to single-knockout models of either PGC-1α or PGC-1β [Zechner et 
al. 2010].  Despite the apparent similarities between PGC-1α and PGC-1β, they differ in some important 
aspects.  In contrast to PGC-1α, PGC-1β is not induced in BAT with cold exposure [Lin et al. 2002a], while 
it can still be induced with fasting in liver [Lin et al. 2002a].  Moreover, PGC-1α and PGC-1β regulate 
distinct gene programs in liver.  PGC-1β coactivates the sterol responsive element binding protein 
(SREBP)-family of lipogenic TFs in liver, and can thus induce a lipogenic gene program [Lin et al. 2005b].  
On the other hand, it cannot interact with HNF4A and FOXO1, and is thus unable to induce a gluconeogenic 
gene program to the same extent as PGC-1α [Lin et al. 2003]. 
 
  
Figure 1 - The PGC-1 family of transcriptional coactivators 
Members of the PGC-1 family display high sequence similarities, especially within the N-terminal 
activation domain (red) and the C-terminal RNA-binding domain (purple). Adapted from [Lin et 
al. 2005a]. 
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The third PGC-1 family member, PGC-1-related coactivator (PRC) shares the NR-interaction and 
RNA-recognition motifs with PGC-1α and PGC-1β [Andersson and Scarpulla 2001] (Figure 1).  PRC can 
coactive several TFs involved in mitochondrial biogenesis, which are also coactivated by PGC-1α (i.e. NRF1 
and ERRα) [Andersson and Scarpulla 2001, Vercauteren et al. 2006, Mirebeau-Prunier et al. 2010].  
Consequently, overexpression of PRC is associated with increased mitochondrial biogenesis in skeletal 
muscle cells [Philp et al. 2011a].  PRC is ubiquitously expressed, and does not vary in expression levels 
between organs to the same extent as PGC-1α and PGC-1β.  Moreover, PRC, in contrast to PGC-1α, is not 
induced in response to cold stimuli in either BAT or skeletal muscle [Andersson and Scarpulla 2001].  
Conversely, PRC expression is increased by a variety of metabolic stressors [Vercauteren et al. 2006, 
Gleyzer and Scarpulla 2011], and is also induced in fibroblasts upon cell-cycle entry.  Hence, PRC is 
postulated to be important for maintaining mitochondrial transcription in proliferating cells [Andersson 
and Scarpulla 2001, Vercauteren et al. 2006].  Since this thesis is aimed at elucidating the specific role of 
PGC-1α in kidney and skeletal muscle physiology, the remainder of this introduction will accordingly be 
focused mainly on transcriptional regulation mediated by PGC-1α. 
Transcriptional partners of PGC-1α 
PGC-1α does not contain a DNA-binding domain, and it is therefore dependent on interactions with TFs 
to be able to associate with the DNA.  PGC-1α binds TFs through several interaction domains, out of which, 
the best characterized is the NR-binding L2-motif (LXXLL) [Knutti and Kralli 2001] (Figure 2).  Through the 
L2-motif, PGC-1α has been shown to interact in a ligand dependent manner with NRs such as PPARα [Vega 
et al. 2000], estrogen receptor-α (ERα) [Tcherepanova et al. 2000] and RXRα [Delerive et al. 2002], and 
in a ligand independent manner with hepatocyte nuclear factor 4 alpha (HNF4A) [Yoon et al. 2001].  
Binding of ERRs (ERRα/β/γ) also occurs in a ligand independent manner, but is dependent on the closely 
related L3-motif (LLXYL) [Huss et al. 2002] (Figure 2).  PGC-1α contains three NR-recognition motifs 
(LLXXL), but can also interact with TFs such as PPARγ [Puigserver et al. 1998], forkhead box protein O1 
(FOXO1) [Puigserver et al. 2003] and myocyte enhancer factor 2C (MEF2C) [Michael et al. 2001] through 
other regions along the protein (Figure 2).  Once bound to the DNA together with its transcriptional 
partners, PGC-1α activates transcription through two main mechanisms; removal of corepressors and 
recruitment of transcriptional coactivators.  For instance, PGC-1α has been shown to antagonize binding 
of the corepressor small heterodimer partner (SHP) to the glucocorticoid receptor (GR), thereby increasing 
transcription of gluconeogenic genes [Borgius et al. 2002].  Several transcriptional partners of PGC-1α (i.e. 
PPARs and ERRs) are also targeted by corepressors such as receptor-interacting protein 140 (RIP140) and 
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nuclear receptor co-repressor 1 (NCoR1) [Qi and Ding 2012].  Gene transcription is thus controlled 
through a balance between coactivator- and corepressor complexes binding to TFs.  One example can be 
found in skeletal muscle, where NCoR1 acts as a repressor of ERRα-mediated transcription [Yamamoto et 
al. 2011, Perez-Schindler et al. 2012].  ERRα is furthermore coactivated by PGC-1α and this results in an 
opposite regulation of several mitochondrial and metabolic gene programs in muscle through binding of 
either NCoR1 or PGC-1α to ERRα [Perez-Schindler et al. 2012].  
 
To mediate full transcriptional activation, PGC-1α interacts with several other regulatory proteins 
to form a coactivator complex.  Through its N-terminal domain, PGC-1α binds histone acetyltransferases 
(HAT) such as CREB-binding protein (CBP), steroid receptor coactivator-1 (SRC-1) and E1A binding protein 
p300 (p300) [Puigserver et al. 1999, Wallberg et al. 2003].  These proteins are known to increase local 
histone acetylation, which leads to a relaxation and enhanced accessibility of the chromatin structure for 
the transcriptional machinery.  PGC-1α also increases DNA accessibility through recruitment of the 
nucleosome remodeling complex; SWItch/Sucrose NonFermentable (SWI/SNF) complex through the 
Figure 2 - Diagram of domain structure of PGC-1α and NT-PGC-1α 
NLS, nuclear localization sequence; RS, arginine-serine-rich domain; ERR, estrogen-related receptor; 
RRM, RNA recognition motif. Adapted from [Zhang et al. 2009]. 
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interaction protein BRG1-associated factor 60a (BAF60a) [Li et al. 2008].  Moreover, PGC-1α also interacts 
with the multi-subunit; thyroid hormone receptor-associated protein/vitamin D receptor interacting 
protein (TRAP/DRIP) mediator complex through its C-terminal domain, which links PGC-1α to the pre-
initiation RNA Polymerase II complex [Wallberg et al. 2003], and thereby forms a link between PGC-1α 
and the transcriptional machinery.  The C-terminal domain of PGC-1α also contains a serine/arginine-rich 
domain (RS) and a putative RNA recognition domain (RRM) (Figure 2), which are found in proteins involved 
in pre-mRNA processing [Knutti and Kralli 2001].  These domains have furthermore been shown to be 
necessary for correct transcriptional induction of several PGC-1α target genes [Monsalve et al. 2000].  
However, the N-terminal truncated version of PGC-1α (NT-PGC-1α) (Figure 2) which consequently lacks 
the C-terminal domain can still induce transcription of several PGC-1α target genes despite absence of the 
RS and RRM domains [Zhang et al. 2009]. This indicates that the mRNA-processing abilities of PGC-1α are 
not necessary for correct transcription of all PGC-1α target genes. 
PGC-1α isoforms and splice variants 
PGC-1α can be transcribed from different promoters and subsequently spliced to yield several distinct 
PGC-1α protein isoforms [Miura et al. 2008, Zhang et al. 2009, Ruas et al. 2012].  Importantly, these 
different isoforms of PGC-1α can vary in their tissue distribution, response to external stimuli and target 
gene regulation.  Two novel isoforms of PGC-1α were found to be transcribed from an alternative 
upstream promoter [Miura et al. 2008].  These were subsequently termed PGC-1α-b and PGC-1α-c, while 
PGC-1α-a in this case denoted the PGC-1α isoform transcribed from the classical promoter (Figure 3A).  
PGC-1α-b and PGC-1α-c were found to be similar in function to PGC-1α-a, but differed in their response 
to external stimuli.  Exercise induces transcription of all three PGC-1α isoforms, however, transcriptional 
induction of PGC-1α-b and PGC-1α-c from the alternative promoter was dependent on β-adrenergic 
stimulation, while PGC-1α-a transcription was not [Miura et al. 2008, Tadaishi et al. 2011].  PGC-1α-a is 
the major isoform found in skeletal muscle and BAT in the basal state and furthermore the only PGC-1α 
isoform expressed in liver [Miura et al. 2008].  Also transcribed from the classical PGC-1α-promoter is the 
N-terminal truncated PGC-1α (NT-PGC-1α), which is produced through alternative 3’ splicing [Zhang et al. 
2009] (Figure 2).  NT-PGC-1α contains all the NR-recognition domains of full-length PGC-1α, and can thus 
interact with and coactivate NRs to a similar extent.  Similar to full-length PGC-1α, NT-PGC-1α is also 
induced by cold stimulus in BAT and in response to fasting in liver [Zhang et al. 2009].  This shorter splice 
variant of PGC-1α however lacks a nuclear localization signal, which drastically alters its subcellular 
localization and regulation.  In its unstimulated form, NT-PGC-1α resides mainly in the cytoplasm [Zhang 
1.  General introduction 
_____________________________________________________________________________________ 
 
 ____________________________________________________________________________________ 
10 
et al. 2009], and is consequently transcriptionally inactive.  This was shown to be dependent on nuclear 
exclusion of NT-PGC-1α through the nuclear export receptor chromosome region maintenance 1 (CRM1).  
However, protein kinase A (PKA)-mediated phosphorylation of NT-PGC-1α prevents interaction with 
CRM1, resulting in nuclear retention and increased transcriptional activity of NT-PGC-1α [Chang et al. 
2010].  While NT-PGC-1α originates from the classical promoter, a similar 3’ splice variant was also 
recently found to originate from the alternative promoter, yielding a truncated PGC-1α transcript variant 
termed PGC-1α4 [Ruas et al. 2012] (Figure 3B).  In contrast to full-length PGC-1α (termed PGC-1α1 in the 
study by Ruas et al; Figure 3B) and NT-PGC-1α, PGC-1α4 does not increase transcription of classical PGC-
1α target genes involved in mitochondrial and metabolic processes.  PGC-1α4 instead regulates 
transcription of genes involved in hypertrophic response in skeletal muscle [Ruas et al. 2012].  Expression 
of PGC-1α4 matches the levels of full-length PGC-1α in skeletal muscle, BAT and heart, while this PGC-1α 
isoform is not expressed in liver and kidney.  In the same study [Ruas et al. 2012], two novel transcript 
variants, PGC-1α2 and PGC-1α3 were also discovered to be transcribed from the alternative promoter 
(Figure 3B), but not much is known about their functions.  Taken together, these studies demonstrate that 
differential transcription and splicing of PGC-1α mRNA can regulate the responsiveness to external stimuli 
[Miura et al. 2008, Tadaishi et al. 2011], subcellular localization [Zhang et al. 2009, Chang et al. 2010] 
and target specificity of the PGC-1α protein [Ruas et al. 2012].   
  
Figure 3 - PGC-1α isoforms and splice variants 
(A) Alternative (exon 1b) and classical (exon 1a) exons of PGC-1α in mouse.  PGC-1α-a (full-
length PGC-1α).  Adapted from [Miura et al. 2008]. 
(B) Different splice variants of PGC-1α; PGC-1α1 (full-length PGC-1α), PGC-1α2, PGC-1α3 and 
PGC-1α4.  Adapted from [Ruas et al. 2012]. 
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1.2 - Transcriptional networks regulated by PGC-1α 
If we forego the upstream regulation of PGC-1α, then the transcriptional activity of PGC-1α is mainly 
dictated through interactions with its downstream transcriptional partners.  As mentioned in the previous 
section, PGC-1α binds NRs in either a ligand bound (PPARα, RXRα) [Vega et al. 2000, Delerive et al. 2002] 
or ligand independent manner (ERRα) [Huss et al. 2002] through its NR recognition-motifs.  Moreover, 
PGC-1α also interacts with several TFs outside the NR-family.  One such TF is FOXO1, which PGC-1α binds 
through its C-terminal domain (Figure 2), thereby regulating transcription of the important gluconeogenic 
genes phosphoenolpyruvate carboxykinase 1 (Pck1) and glucose-6-phosphatase (G6pc) in liver 
[Puigserver et al. 2003].  These genes are however also regulated by PGC-1α through an LXXLL-domain 
dependent interaction with the hepatic NR HNF4a [Yoon et al. 2001, Rhee et al. 2003].  Another important 
interaction-partner of PGC-1α which is not dependent on the LXXLL NR-motif is MEF2C.  PGC-1α was 
shown to interact with MEF2C through a region separate from the activation domain (Figure 2), and 
thereby increase glucose transporter 4 (GLUT4) expression in skeletal muscle [Michael et al. 2001].  In an 
effort to elucidate novel transcriptional partners of PGC-1α, Li et al. used a library of TF-Gal fusion proteins 
to screen for novel TFs coactivated by PGC-1α [Li et al. 2008].  Candidates from this screen were further 
evaluated for their ability to physically interact with PGC-1α, and yielded a list of 35 transcriptional 
partners of PGC-1α, a majority of these yet uncharacterized.  This study highlighted a role for BAF60a in 
the recruitment of the SWI/SNF-complex (as mentioned in the section “Transcription factor and 
coregulator interactions”).  Two recent studies successfully used a chromatin immunoprecipitation DNA-
sequencing (ChIP-Seq) approach to predict PGC-1α partners based on the binding pattern of PGC-1α in 
the genome [Charos et al. 2012, Baresic et al. 2014].  Using either muscle- or liver cells, these studies 
could predict new transcriptional partners of PGC-1α such as; heat shock factor protein 1 (HSF1) [Charos 
et al. 2012] and the activator protein-1 complex (AP1) [Baresic et al. 2014], along with known TF-partners 
such as ERRα [Charos et al. 2012, Baresic et al. 2014].  However, the majority of the predicted 
transcriptional partners does not overlap between the studies, and would likely represent inherent 
differences in the transcriptional programs targeted by PGC-1α in liver and muscle, respectively. 
Another level of transcriptional control is mediated through coregulator proteins which guide the 
interactions of PGC-1α with other TFs, and thereby increase target specificity of PGC-1α-interactions.  One 
such co-regulator protein is lipin 1, which is induced by PGC-1α in liver [Finck et al. 2006].  Lipin 1 increases 
transcription of PPARα and interacts with both PPARα and PGC-1α to boost activation of PGC-1α/PPARα 
regulated gene programs in liver in response to fasting [Finck et al. 2006].  Lipin 1 can furthermore be 
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induced through a PGC-1α-ERR pathway in heart [Mitra et al. 2011].  In skeletal muscle, three co-
regulators of PGC-1α activity have been discovered; striated muscle activator of rho signaling (STARS) 
[Wallace et al. 2011], hypoxia inducible factor 2 alpha (HIF2α) [Rasbach et al. 2010] and PGC-1- and ERR-
induced regulator in muscle 1 (PERM1) [Cho et al. 2013].  Collectively, the transcription of these proteins 
is induced by exercise, and furthermore depends on PGC-1α/ERRs for their expression [Rasbach et al. 
2010, Wallace et al. 2011, Cho et al. 2013].  Nonetheless, these co-regulators control separate processes 
in muscle.  STARS was shown to be important for the PGC-1α-mediated transcription of carnitine 
palmitoyltransferase 1b (Cpt1b), while it did not affect the transcription of the shared PGC-1α/ERRα target 
vascular endothelial growth factor a (VEGFA) [Wallace et al. 2011].  HIF2α is instead important for the 
switch in fiber type induced by PGC-1α [Rasbach et al. 2010].  PERM1 is responsible for the PGC-1α-
mediated induction of several genes (i.e. sirtuin 3, SIRT3), while other PGC-1α targets were not affected 
by modulation of PERM1 (i.e. mitochondrial transcription factor A, TFAM) [Cho et al. 2013].  Collectively, 
these PGC-1α-coregulatory proteins, together with the large number of TFs coactivated by PGC-1α, 
contribute to the target specificity of this coactivator.  Since the first cloning of PGC-1α 16 years ago (1998 
– 2014), its functions have been linked to a continuously expanding list of transcriptional partners.  Thus, 
it is not surprising that PGC-1α is a versatile transcriptional regulator.  As mentioned earlier, it is involved 
in the regulation of several tissue-specific gene programs (discussed in detail in section 1.3 as well as 
chapters 4 and 6) such as thermogenesis in BAT [Puigserver et al. 1998], gluconeogenesis in liver [Herzig 
et al. 2001, Yoon et al. 2001, Puigserver et al. 2003, Rhee et al. 2003] and metabolic remodeling of 
skeletal muscle [Handschin et al. 2007a, Handschin et al. 2007b, Handschin et al. 2007c].  There are 
however certain processes which are globally regulated by PGC-1α.  The most prominent of these are 
transcriptional regulation of mitochondrial function and oxidative phosphorylation [Wu et al. 1999, 
Fernandez-Marcos and Auwerx 2011, Scarpulla 2011]. 
PGC-1α – a master regulator of mitochondrial function and biogenesis 
PGC-1α is considered to be a transcriptional master regulator of mitochondrial genes [Lin et al. 2005a, 
Scarpulla 2011], which is evident by the reduced mitochondrial transcription associated with deletion of 
PGC-1α in skeletal muscle [Handschin et al. 2007b], brain [Lin et al. 2004], heart [Arany et al. 2005] and 
intestine [Bhalla et al. 2011], to name a few.  In line with this, several studies have shown that 
overexpression of PGC-1α is sufficient to increase mitochondrial biogenesis and energy metabolism in 
organs such as skeletal muscle [Lin et al. 2002b], adipose tissue [Puigserver et al. 1998] and heart 
[Lehman et al. 2000, Russell et al. 2004].  PGC-1α induces transcription of a range of mitochondrial 
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processes.  Amongst these we find genes encoding proteins involved in the electron transport chain 
[Puigserver et al. 1998], β-oxidation [Vega et al. 2000], reactive oxygen species (ROS)-detoxification 
[Valle et al. 2005, St-Pierre et al. 2006] and mitochondrial fission/fusion [Soriano et al. 2006] amongst 
others.  The versatility of PGC-1α in the regulation of mitochondrial transcription stems from its ability to 
coactivate several distinct TFs driving transcription of both nuclear- and mitochondrial-encoded genes.  
Two important TFs in this context are NRF1 and nuclear respiratory factor 2 (NRF2; also known as GA-
binding protein alpha chain, GABPA).  PGC-1α induces transcription of these TFs [Wu et al. 1999, Mootha 
et al. 2004], and also acts as a transcriptional coactivator of NRF1 [Wu et al. 1999].  NRF1 and NRF2 
increase transcription of nuclear-encoded mitochondrial genes involved in oxidative stress response and 
mitochondrial respiration.  Importantly, PGC-1α coactivates NRF1 on the TFAM-promoter, and thereby 
indirectly influences transcription of mitochondrial-encoded genes [Wu et al. 1999, Kelly and Scarpulla 
2004].  There is also evidence that PGC-1α directly interacts with TFAM on the mitochondrial DNA 
[Aquilano et al. 2010, Safdar et al. 2011], implying a more direct role of PGC-1α in the transcription of 
mitochondrial-encoded genes.  Apart from these central regulators of mitochondrial transcription, PGC-
1α also coactivates other TFs to modulate transcription of mitochondrial genes.  These TFs include ERRα 
[Mootha et al. 2004, Schreiber et al. 2004] and yin yang 1 (YY1) [Cunningham et al. 2007].  Especially 
ERRα has been shown to play an important role in the regulation of mitochondrial genes together with 
PGC-1α.  This since ERRα constitutes a powerful feed-forward mechanisms to boost mitochondrial gene-
transcription by acting as a transcriptional activator of NRF1, as well as its own promoter [Mootha et al. 
2004].  ERRα also increases transcription of PPARα [Huss et al. 2004], which is an important transcriptional 
regulator of mitochondrial fatty acid-import and β-oxidation, and which can be coactivated by PGC-1α 
[Vega et al. 2000].  These TF-interactions and feed-forward mechanisms constitute the basis of how PGC-
1α induces transcription of several distinct but yet codependent mitochondrial processes such as β-
oxidation, TCA-cycle and oxidative phosphorylation. 
Upstream regulation of PGC-1α activity 
PGC-1α transcription and activity is controlled by a range of upstream signaling pathways.  Post-
translational modifications (PTM) of PGC-1α regulates protein stability, subcellular localization as well as 
interaction of PGC-1α with its transcriptional partners.  This ensures a precise regulation of this 
transcriptional activator, and allows PGC-1α to respond to various external stimuli [Fernandez-Marcos 
and Auwerx 2011].   
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PGC-1α induces a thermogenic gene program in BAT in response to cold stimulus, and this effect 
can be reproduced in vitro through the addition of cyclic AMP (cAMP) to primary adipocytes [Puigserver 
et al. 1998].  In liver, cAMP response element-binding protein (CREB) was shown to mediate the effects 
of cAMP signaling through binding and activation of the PGC-1α promoter. (Figure 4) [Herzig et al. 2001].  
CREB is necessary for the induction of hepatic PGC-1α in response to fasting [Herzig et al. 2001], and is an 
important transcriptional activator of PGC-1α in skeletal muscle [Handschin et al. 2003, Akimoto et al. 
2004].  Induction of PKA-signaling also activates another important transcriptional regulator of PGC-1α; 
p38 mitogen-activated protein kinase (p38 MAPK) [Cao et al. 2004].  Importantly, p38 MAPK was shown 
to be necessary for CREB to induce PGC-1α transcription and hepatic gluconeogenesis in response to 
fasting [Cao et al. 2005].  In BAT, p38 MAPK is also required to induce PGC-1α transcription in response 
to β-adrenergic stimulation, however this is mediated primarily through activating transcription factor 2 
(ATF2) (Figure 4), and not through CREB [Cao et al. 2004].  Two other important transcriptional regulators 
of PGC-1α are MEF2C and MEF2D [Handschin et al. 2003, Akimoto et al. 2004].  In skeletal muscle, 
MEF2C/D are necessary transcriptional induction of PGC-1α through calcineurin A (CnA) [Handschin et al. 
2003] and in response to nerve stimulation [Akimoto et al. 2004].  Increased intracellular calcium during 
muscle contractions can modulate PGC-1α through CnA/MEF2, but also through activation of CREB 
Figure 4 - Upstream signaling pathways regulating PGC-1a transcription.  
Adapted from [Fernandez-Marcos and Auwerx 2011]. 
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through calcium/calmodulin-dependent protein kinase IV (CaMKIV) [Handschin et al. 2003] (Figure 4).  
Importantly, PGC-1α increases the transcriptional activity of MEF2C/D on its own promoter, and thereby 
forms a positive autoregulatory loop [Handschin et al. 2003], similar to what was mentioned earlier for 
ERRα [Mootha et al. 2004].   
Activation of PKA and p38 MAPK results in transcriptional activation of PGC-1α (Figure 4).  
However, these kinases have also been shown to directly modulate PGC-1α-activity through 
phosphorylation of PGC-1α.  PKA phosphorylates NT-PGC-1α at three separate sites and thereby increases 
the nuclear retention and transcriptional activity of this PGC-1α isoform [Chang et al. 2010].  Full length 
PGC-1α furthermore contains 12 predicted PKA-phosphorylation sites, and PKA mediates stabilization of 
full length PGC-1α in response to cAMP signaling [Shoag et al. 2013].  Phosphorylation of PGC-1α by p38 
MAPK [Knutti et al. 2001, Puigserver et al. 2001] (Figure 5) also increases protein stability [Puigserver et 
al. 2001], and prevents the interaction of PGC-1α with its repressor p160 myb binding protein (p160MBP) 
[Fan et al. 2004], hence increasing its transcriptional activity.  Other important kinases in the regulation 
of PGC-1α activity are Cdc2-like kinase 2 (CLK2), p70 ribosomal protein S6 kinase (S6K) and AKT [Schmidt 
and Mandrup 2011].  The activity of these kinases is influenced by insulin, and thus play an important role 
in the inhibition of hepatic PGC-1α activity during transition from a fasted to a fed state.  In response to 
insulin signaling, AKT inhibits the gluconeogenic gene program through phosphorylation and nuclear 
exclusion of FOXO1, which is an important transcriptional partner of PGC-1α in the regulation of 
gluconeogenic genes [Puigserver et al. 2003].  Moreover, AKT can also directly phosphorylate PGC-1α 
(Figure 5) and inhibit its transcriptional activity [Li et al. 2007].  AKT also phosphorylates and activates 
CLK2, which subsequently inhibits PGC-1α activity through an inhibitory phosphorylation (Figure 5) 
[Rodgers et al. 2010].  Another AKT target is CREB-regulated transcription coactivator 2 (CRTC2, TORC2).  
In its phosphorylated state CRTC2 remains in the cytoplasm, while during fasting it becomes 
dephosphorylated and translocates to the nucleus, where it coactivates CREB-mediated transcription of 
PGC-1α and gluconeogenic genes [Koo et al. 2005].  CRTCs are also associated with increased PGC-1α 
transcription in skeletal muscle [Wu et al. 2006] and BAT [Muraoka et al. 2009].  S6K is another insulin-
responsive kinase known to phosphorylate and inactivate transcription of gluconeogenic genes regulated 
by PGC-1α [Lustig et al. 2011].  However phosphorylation by S6K specifically inhibits the interaction of 
PGC-1α with HNF4a.  PGC-1α can in this context still coactivate ERRα and PPARα, and thus still induce 
processes such as mitochondrial biogenesis and β-oxidation [Lustig et al. 2011].  S6K can thus in a similar 
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fashion as STARS, PERM1 and Lipin1 fine-tune the activity of PGC-1α towards certain promoters, and thus 
add another layer of complexity to the regulation of PGC-1α.   
 
AMP-activated protein kinase (AMPK) is another kinase known to phosphorylate PGC-1α and 
thereby increase PGC-1α activity and transcriptional induction of mitochondrial genes in skeletal muscle 
cells [Jager et al. 2007].  Furthermore, AMPK signaling is also connected to the activation of another 
important energy sensor and regulator of PGC-1α activity; sirtuin 1 (SIRT1).  SIRT1 is a nicotinamide 
adenine dinucleotide (NAD+)-sensitive protein deacetylase, which can deacetylate and thereby activate 
PGC-1α [Nemoto et al. 2005].  PGC-1α activity is regulated through its acetylation status, since mutations 
of 13 of its acetylation residues (Figure 5) to arginine enhanced transcriptional activity of PGC-1α in liver, 
leading to increased gluconeogenic gene expression [Rodgers et al. 2005].  SIRT1 is thus an important 
regulator of hepatic gluconeogenesis through deacetylation and activation of PGC-1α in response to 
fasting [Rodgers et al. 2005].  Since PGC-1α is activated through deacetylation, it can consequently be 
inhibited by acetylation.  One important acetyltransferase which acetylates PGC-1α in both muscle [Philp 
Figure 5 - Post-translational modifications of the PGC-1a protein 
Adapted from [Fernandez-Marcos and Auwerx 2011]. 
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et al. 2011b] and liver [Lerin et al. 2006, Dominy et al. 2012] is general control nonrepressed protein 5 
(GCN5).  Increased acetylation through GCN5 leads to an enhanced association of PGC-1α with inactive 
transcriptional domains within the nucleus, thereby decreasing PGC-1α target gene transcription [Lerin 
et al. 2006].  Additionally, insulin was shown to increase GCN5-activity through activation of its upstream 
kinase; cyclin D1- cyclin-dependent kinase 4 (CDK4), thereby reducing PGC-1α activation [Lee et al. 2014].  
Other acetyltransferases such as p300, SRC-1 and SRC-3 have also been shown to interact with PGC-1α, 
however acetylation status and activation of PGC-1α was not affected through these interactions [Jeninga 
et al. 2010].  Apart from changes in phosphorylation- and acetylation status, PGC-1α activity is modulated 
by several other PTMs.  Arginine methylation of PGC-1α through protein arginine methyltransferase 1 
(PRMT1) is associated with increased transcriptional activity of PGC-1α [Teyssier et al. 2005], and a similar 
activating effect has been observed for O-GlcNAcylation of PGC-1α.  O-GlcNAcylation of PGC-1α leads to 
increased interaction of PGC-1α with the deubiquitinase BRCA1-Associated Protein 1 (BAP1), thereby 
relieving PGC-1α of its inhibitory ubiquitination [Ruan et al. 2012].  Moreover, Skp1/cullin/F-box-cell 
division control 4 (SCFCdc4) is an E3 ubiquitin ligase responsible for PGC-1α ubiquitination and proteosomal 
degradation [Olson et al. 2008].  Proteosomal degradation of PGC-1α was shown to mainly occur in the 
nucleus [Trausch-Azar et al. 2010], which could explain the increased stability of the mainly cytoplasmic 
NT-PGC-1α isoform.  In conclusion, PGC-1α activity is regulated through a variety of different PTMs, which 
are necessary for the responsiveness of PGC-1α to various external stimuli, and which ensures a controlled 
regulation of this transcriptional coactivator. 
 
1.3 – Organ-specific effects of PGC-1α 
In contrast to many other coactivator proteins, the expression of PGC-1α varies between organs and is 
highly regulated by environmental stimuli such as cold, fasting and exercise.  The majority of the research 
on tissue-specific effects of PGC-1α has been focused on the major metabolic organs skeletal muscle, liver 
and BAT.  In line with this, we will mainly focus on the role of PGC-1α in liver and adipose tissue in this 
section, and the role of PGC-1α in skeletal muscle will be discussed in more detail in chapters 6-9 of this 
thesis.  However, several studies have also investigated the role of PGC-1α in other cell types, highlighting 
new tissue-specific transcriptional programs modulated by PGC-1α.  In retina, PGC-1α protects against 
retinal deterioration [Egger et al. 2012], and promotes angiogenesis [Saint-Geniez et al. 2013].  In the 
skin PGC-1α regulates melanin production and hence pigmentation [Shoag et al. 2013].  In the intestine 
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PGC-1α protects against formation of tumors by regulating mitochondrial biogenesis [D'Errico et al. 2011].  
In adrenal glands, PGC-1α coactivates steroidogenic factor 1 (SF1) to regulate steroidogenesis [Zhu et al. 
2010], and in pancreatic β-cells, PGC-1α inhibits insulin release [Yoon et al. 2003].  Collectively, these 
studies give an indication of the multi-faceted role of PGC-1α based on the organ-specific context. 
Liver 
In a fed state, PGC-1α expression in liver is low compared to more oxidative organs such as heart, brain 
and skeletal muscle [Finck and Kelly 2006].  Upon fasting however, there is a strong induction of PGC-1α 
transcription and activity, resulting in an activation of genes involved in gluconeogenesis, β-oxidation, 
ketogenesis, heme biosynthesis and bile acid homeostasis [Liu and Lin 2011].  PGC-1α is an important 
regulator of hepatic gluconeogenesis, and this is evident in mouse models with a hepatic disruption of 
PGC-1α activity, which display hypoglycemia [Koo et al. 2004] and reduced transcription of gluconeogenic 
genes upon fasting [Koo et al. 2004, Handschin et al. 2005].  Surprisingly, global PGC-1α knockout mice 
display no impairment in the induction of gluconeogenic genes with fasting [Lin et al. 2004, Handschin et 
al. 2005, Leone et al. 2005].  These findings indicate that global deletion of PGC-1α leads to a complex 
systemic metabolic phenotype, which can preclude interpretation of the tissue-autonomous effects of 
PGC-1α on hepatic metabolism.  PGC-1α regulates transcription of gluconeogenic genes mainly through 
coactivation of FOXO1 [Puigserver et al. 2003], HNF4a [Yoon et al. 2001, Puigserver et al. 2003, Rhee et 
al. 2003] and GR [Yoon et al. 2001].  The increased hepatic PGC-1α transcription and activity in response 
to fasting, is induced through several distinct mechanisms (as discussed in the section “Upstream 
regulation of PGC-1α activity”).  In short, binding of glucagon to its receptor leads to an increase in 
intracellular cAMP levels.  This results in activation of PKA, and subsequent phosphorylation and induction 
of CREB and p38 MAPK, leading to transcriptional induction of PGC-1α during fasting [Herzig et al. 2001, 
Cao et al. 2005, Handschin and Spiegelman 2006].  Glucagon also leads to dephosphorylation and nuclear 
translocation of CRTC2, which increases the transcriptional activity of CREB on the PGC-1α promoter [Koo 
et al. 2005].  Another important regulator of hepatic gluconeogenesis is SIRT1, which increases the 
transcriptional activity of PGC-1α towards gluconeogenic genes through protein deacetylation [Rodgers 
et al. 2005].  GCN5 on the other hand increases PGC-1α acetylation in liver in response to insulin thereby 
leading to PGC-1α inactivation [Lee et al. 2014].  Insulin efficiently shuts down PGC-1α activity and the 
transcriptional activation of gluconeogenic genes in a fed state through activation of AKT.  AKT directly 
phosphorylates and inactivates PGC-1α [Li et al. 2007], as well as CRTC2 [Koo et al. 2005].  Insulin signaling 
also activates S6K, which prevents interaction of PGC-1α with HNF4a, thereby inhibiting gluconeogenesis 
1.  General introduction 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
19 
[Lustig et al. 2011].  In line with the repressive effect of insulin on PGC-1α transcriptional activity, PGC-1α 
activity is increased in livers of diabetic mice.  Moreover, liver-specific deletion of PGC-1α reduces 
hyperglycemia [Koo et al. 2004], which indicates that increased hepatic PGC-1α activity is involved in 
hepatic insulin resistance and development of diabetic hyperglycemia.  PGC-1α is also an important 
regulator of hepatic β-oxidation and ketogenesis.  This is evident in mice with reduced hepatic PGC-1α 
expression, which display a mild hypoketonemia in response to fasting.  These mice also develop fasting 
induced hepatic steatosis as a result of reduced fatty acid oxidation [Estall et al. 2009], a phenotype which 
is also observed in global PGC-1α knockout models [Leone et al. 2005].  PGC-1α regulates ketogenic and 
β-oxidation genes in liver through interaction with the TF PPARα, which is a known transcriptional partner 
of PGC-1α [Vega et al. 2000].  Consequently, knockout of PGC-1α in liver is associated with reduced 
transcription of β-oxidation genes [Koo et al. 2004].  PPARα is furthermore required for the induction of 
fibroblast growth factor 21 (FGF21) in liver during fasting.  FGF21 has been demonstrated to be important 
for the induction of PGC-1α in liver with fasting [Potthoff et al. 2009], thereby forming a feed-forward 
mechanism to enhance hepatic ketogenesis and β-oxidation upon fasting. 
Adipose tissue 
PGC-1α is expressed at a higher basal level in BAT compared to WAT, however thermogenic stimuli such 
as β-adrenergic stimulation, are known to increase PGC-1α levels in both depots.  PGC-1α is important for 
the induction of the thermogenic gene UCP1 through coactivation of PPARγ, TR [Puigserver et al. 1998] 
and interferon regulatory factor 4 (IRF4) [Kong et al. 2014] on the UCP1-promoter.  This leads to enhanced 
mitochondrial uncoupling and subsequent energy dissipation in BAT.  However, PGC-1α also induces 
mitochondrial metabolic processes to sustain the high metabolic activity in both WAT and BAT depots 
during cold adaptation.  This was demonstrated through ectopic expression of PGC-1α in either mouse 
[Puigserver et al. 1998] or human [Tiraby et al. 2003] adipocytes, which led to a concomitant induction 
of UCP1 expression and mitochondrial oxidative phosphorylation in these cells.  Activation of PGC-1α in 
adipocytes in response to cold is attributed to the activation of CREB and p38 MAPK/ATF2 through 
cAMP/PKA signaling [Cao et al. 2004].  In line with this, knockdown of PGC-1α in cultured adipocytes 
blunted the thermogenic response induced by cAMP-stimulation [Uldry et al. 2006].  PGC-1α transcription 
in BAT is furthermore driven by PR domain containing 16 (PRDM16), an important co-regulator for BAT 
differentiation [Seale et al. 2007], as well as the recently discovered thermogenic regulator IRF4 [Kong et 
al. 2014].  In line with the importance of PGC-1α in thermogenic adaptation in adipose tissue, whole-body 
PGC-1α knockout mice are cold sensitive [Lin et al. 2004, Leone et al. 2005].  This phenotype was evident 
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in both global PGC-1α knockout models [Lin et al. 2004, Leone et al. 2005], however it was only associated 
with blunted induction of UCP1 in response to cold in one of these models [Lin et al. 2004].  Surprisingly, 
adipose tissue specific PGC-1α knockout mice display no impairment in the basal expression of UCP1 in 
either WAT or BAT [Pardo et al. 2011].  Moreover, these mice display no impairment in basal transcription 
of mitochondrial genes or the induction of mitochondrial genes in response to rosiglitazone-treatment in 
the absence of PGC-1α [Pardo et al. 2011].  Hence, further studies are needed to elucidate the complete 
role of PGC-1α in both WAT and BAT depots. 
To fully understand the role that PGC-1α plays in the regulation of whole body metabolism, it is 
essential to study the effects of this coactivator in all major metabolic organs.  Further studies on the 
tissue-specific transcriptional programs regulated by PGC-1α will give a greater insight into the global role 
of PGC-1α, and how modulation of PGC-1α in these organs can be used in a therapeutic context.  In line 
with this, we will in chapter 4/manuscript 1 of this thesis present our data regarding the role of PGC-1α in 
the kidney.  Moreover, in chapter 7/manuscript 2 and chapter 8/manuscript 3 of this thesis we will focus 
on our data regarding skeletal muscle and the role of pharmacological activation of PGC-1α, as well as the 
role of PGC-1α in the regulation of skeletal muscle ketone body oxidation.  
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2.  Aims of the thesis 
Since the first cloning of PGC-1α over a decade-and-a-half ago, seminal studies have elucidated both the 
upstream- and downstream mechanisms responsible for regulating the effects of this coactivator.  
Importantly, these studies have also widened our knowledge of important metabolic processes such as 
thermogenesis, gluconeogenesis and exercise adaptation, which are all closely linked to PGC-1α activity.  
Consequently, our knowledge about the role of PGC-1α is best understood in metabolic and oxidative 
organs such as BAT, skeletal muscle and liver.  However, the kidney is amongst the organs with the highest 
baseline PGC-1α expression.  Despite its high basal expression of PGC-1α, relatively little is known 
regarding the role of this coactivator in the kidney.  Intriguingly, several renal pathologies are associated 
with defects in mitochondrial and metabolic processes in tubule cells and are furthermore associated with 
reduced PGC-1α expression.  This prompted us to generate a mouse model with an inducible nephron-
specific knockout of PGC-1α.  This model allowed us to study transcriptional networks regulated by PGC-
1α in the kidneys, and how ablation of PGC-1α affects renal physiology.  The data of this study are 
presented in chapter 4/manuscript 1 of this thesis.  The first aim of the present thesis can thus be 
summarized: 
1. Elucidate the role of PGC-1α in transcriptional regulation of renal physiology, both in the 
basal state and in response to salt and dietary stress. 
The second part of the thesis is aimed at elucidating the role of PGC-1α as a therapeutic target for calorie 
restriction (CR)/exercise-mimetics in skeletal muscle.  Resveratrol and SRT1720 are two CR/exercise 
mimetic compounds, which have been shown to activate PGC-1α in skeletal muscle, and to promote 
mitochondrial biogenesis and increase energy expenditure.  This is furthermore associated with an 
improved metabolic phenotype in obese mice treated with these compounds.  We were thus interested 
in whether skeletal muscle PGC-1α is the main mediator of the beneficial effects of resveratrol and 
SRT1720 in skeletal muscle, and in extension, how this affects whole body metabolism in obese mice.  
Moreover, we were interested in whether the structurally distinct compounds resveratrol and SRT1720 
would elicit analogous or differential effects in major metabolic organs such as skeletal muscle, liver and 
white adipose tissue.  These finding are presented in chapter 7/manuscript 2 of this thesis, and can be 
summarized with these two aims: 
2. Define the role of skeletal muscle PGC-1α as a potential mediator of the beneficial effects 
of resveratrol and SRT1720 in skeletal muscle, as well as on systemic metabolic parameters. 
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3. Compare the effects elicited by resveratrol and SRT1720 treatment in diet-induced obese 
mice; are the effects on organ-specific and systemic metabolic parameters analogous? 
Finally, we were interested in investigating the role of PGC-1α in the metabolic adaptation of skeletal 
muscle to a ketotic environment.  PGC-1α is known to modulate several metabolic processes involved in 
glucose and fatty acid oxidation in muscle.  Apart from glucose and fatty acids, ketone bodies are 
important metabolic fuels in skeletal muscle, especially during long-term fasting.  However, despite the 
high basal ketolytic capacity of oxidative muscles, the role of PGC-1α in the regulation of ketone body 
oxidation has to our knowledge so far not been investigated.  Our findings regarding the role of PGC-1α 
in the regulation of ketone body oxidation will be presented in chapter 8/manuscript 3 of this current 
thesis.  The fourth aim of this thesis can thus be summarized: 
4. Investigate the role of PGC-1α in the regulation of skeletal muscle ketone body oxidation, 
and its impact on systemic ketone body metabolism. 
During the work on this thesis, several side-projects have branched of the main lines of investigation 
mentioned above.  These are however not finished studies, and will thus be discussed in brief within the 
discussion-sections of the respective chapters (aim 5/chapter 5; aim 6/chapter 9).  The aims of these side-
projects can be summarized accordingly: 
5. Determine the role of PGC-1α in kidney glomeruli, and its role in the maintenance of the 
renal filtration barrier in physiological and pathophysiological states.  
 
6. Define the mitochondrial and metabolic adaptations in skeletal muscle during long-term 
ketosis, and which role PGC-1α plays in this.  
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3.  Introduction to renal physiology 
3.1 - Kidney – structure and function 
The major function of the renal system is to filter blood, and to ensure proper reabsorption of nutrients 
and electrolytes. At the same time, toxic compounds, metabolic waste products and excess acids are 
removed from the circulation.  The importance for the kidneys in whole organism health is underscored 
by the prevalence of hypertension, acidosis, anemia, bone disorders, malnutrition, cognitive impairment 
and inflammation in patients suffering from chronic kidney disease [Levey and Coresh 2012].  The 
extent of these complications indicate that the kidney is responsible for more than just passive filtration 
of blood and urine formation.  The kidney is an important endocrine organ involved in blood pressure 
regulation through secretion of renin, erythropoiesis through production of erythropoietin and mineral 
and bone homeostasis through activation of vitamin D3 within renal mitochondria [Sahay et al. 2012].  
The kidneys are also important for systemic glucose homeostasis. It has been demonstrated that renal 
gluconeogenesis matches the capacity of hepatic gluconeogenesis in a post-prandial state [Mitrakou 
2011]. However, the net glucose release from the kidney is lower due to the inability of renal cells to 
store and release glucose from glycogen stores [Stumvoll et al. 1997].  Renal gluconeogenesis has 
furthermore been shown to contribute significantly to hyperglycemia in diabetic patients [Mitrakou 
2011]. 
Apart from the important functions of the kidney in endocrine and metabolic processes, the 
main role of the kidney is to maintain systemic ion-, water- and nutrient-homeostasis through 
reabsorption and secretion of ions and nutrients across the renal tubular epithelium.  Urine formation is 
a complex process which takes place within the functional subunit of the kidney, the nephron, consisting 
of several morphologically and functionally distinct cell types.  The main function of the nephrons is to 
filter blood and excrete waste-products through urine formation. Approximately 180 liters of blood are 
filtered each day through the nephrons of an adult human [Boron and Boulpaep 2003].  Blood reaches 
the kidneys through the renal arteries, and is filtered in a complex capillary system within the renal 
glomeruli.  Endothelial cells together with podocyte cells form a fenestrated filtration barrier around the 
glomerular capillaries, to ensure proper filtration of water and electrolytes while retaining plasma 
proteins and blood cells within the vascular compartment [Miner 2011].  The glomerulus constitute the 
initial filtration unit of the nephron, and empties into the proximal tubules (Figure 1).   
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The proximal tubules are responsible for the reabsorption of approximately 70% of the filtered 
water, the majority of electrolytes and all filtered nutrients such as glucose and amino acids.  This 
efficient reabsorption is facilitated by the extensive brush border of the proximal tubule cells, coupled to 
a high basal transporter activity [Guyton and Hall 2000, Rhoades and Bell 2013].  Na+-K+-ATPases in the 
basolateral membrane of proximal tubule cells create a sodium gradient over the epithelial cells which 
drives reabsorption of water, but also glucose through sodium-dependent glucose transporters [Wright 
2001] and amino acids through amino acid sodium symporters [Verrey et al. 2009] to name a few.  The 
importance of the proximal tubules for the maintenance of systemic nutrient and ion homeostasis can 
be appreciated in patients suffering from renal Fanconi syndrome which is linked to a general 
dysfunction in sodium-linked transport in the proximal tubules.  These patients display a urinary loss of 
glucose, amino acids and phosphates, together with renal tubular acidosis [Sirac et al. 2011].  The 
proximal tubules are connected to the thin loop of Henle, which stretches into the renal medulla and 
which is essential for urine concentration (Figure 1) [Halperin et al. 2008].  The thick ascending part of 
the loop of Henle is responsible for further ion reabsorption from the primary filtrate.  The subsequent 
parts of the nephron are named the aldosterone-sensitive distal nephron (ASDN), which comprises parts 
Figure 1 - Structure of the renal nephron. 
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of the distal convoluted tubules, connecting tubules and collecting ducts [Loffing and Korbmacher 2009] 
and which are responsive to the steroid hormone aldosterone [Rossier et al. 2013].  While passive 
reabsorption in the initial parts of the nephron accounts for the majority (~90%) of salt and water re-
uptake, the final balance of sodium- and potassium uptake/excretion occurs in the ASDN [Rossier et al. 
2013]. Aldosterone binds to the mineralocorticoid receptor (MR) within ASDN cells, and induces 
transcription of several genes important for renal sodium uptake, such as sodium transporters 
(epithelial sodium channel; ENaC) and regulators of these channels (serum- and glucocorticoid-regulated 
kinase 1; SGK1) [Loffing and Korbmacher 2009], thereby increasing renal sodium uptake.  The primary 
filtrate, now considered urine, is then drained into the major calyx and subsequently the ureter.  Closely 
linked to the regulation of salt- and water homeostasis, the kidneys also regulates systemic blood 
pressure.  In response to a drop in blood pressure, the renal juxtaglomerular cells increase production 
and release of renin into the circulation.  Renin is the initial component of the renin-angiotensin-
aldosterone system (RAAS), which controls systemic blood pressure through regulation of extracellular 
fluid volume, cardiovascular activity and systemic vasoconstriction [Brewster and Perazella 2004].  
Renin is the first step in a proteolytic pathway yielding angiotensin II (ANGII) from hepatic 
angiotensinogen (Figure 2).  ANGII, which is a potent vasoconstrictor, also stimulates aldosterone-
release from the adrenal cortex, which in turn acts within the ASDN to increase sodium and water 
retention from the nephron [Brewster and Perazella 2004].  In combination to the systemic effects of 
the RAAS, there is also an intrarenal RAAS, since all components of the RAAS are expressed within 
different segment of the nephron [Moon 2013].  This leads to generation of intrarenal ANGII, which can 
regulate sodium re-uptake independently of aldosterone [Zaika et al. 2013].  Another important system 
involved in regulation of blood pressure is the kallikrein-kinin system (KKS) [Sharma et al. 1996].  Similar 
to the RAAS, the KKS has both a systemic and an intrarenal component, but in contrast to the RAAS, 
activation of KKS instead leads to vasodilation [Scicli and Carretero 1986], reduced sodium reabsorption 
[Zaika et al. 2011] and consequently 
reduced blood pressure. 
 
Figure 2 - The Renin-
Angiotensin-Aldosterone 
system (RAAS). 
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3.2 - Renal energy metabolism and PGC-1α 
The kidney is a highly metabolic organ which relies almost entirely on oxidative phosphorylation.  
The kidneys thus have a high oxygen consumption rate, only exceeded by that of the heart [O'Connor 
2006].  Renal mitochondria are integral to the function of the kidneys, since the majority of the ATP 
produced in kidney is derived from oxidative metabolism [Soltoff and Mandel 1984].  Mitochondrial 
content and oxidative capacity is highest within cells of the proximal tubules and thick ascending limb of 
henle, while other nephron segments such as glomeruli, thin loop of henle, distal- and collecting tubules 
have a lower mitochondrial content [Soltoff 1986].  Oxidative phosphorylation in the proximal tubules 
and thick loop of henle is necessary to maintain the high transport capacity of these segments, since the 
majority of transepithelial transport in these segments is driven through ATP-hydrolysis by basolateral 
Na+-K+-ATPase channels [Soltoff 1986].  The constant high rate of filtration and reabsorption within the 
nephron results in a dependence on mitochondrial ATP production for proper renal function.  This is 
evident in patients suffering from hereditary mitochondrial disorders, which often display a reduced 
proximal tubule function, associated with a loss of nutrients and electrolytes in the urine [Emma et al. 
2011, Rahman and Hall 2013, Che et al. 2014].  Reduced mitochondrial function is also found in several 
disease states associated with reduced renal function, such as sepsis [Tran et al. 2011, Parikh 2013], 
diabetes [Sharma et al. 2013] and ischemia/reperfusion injury [Brooks et al. 2009, Funk and 
Schnellmann 2013, Lempiainen et al. 2013].  The close link between mitochondrial dysfunction and 
renal disease implies that a reduction in mitochondrial oxidative capacity, which is often coupled to 
increased oxidative stress and reduced energy levels, could play an important role in both the etiology 
and the pathology of renal disease states.  
The kidney is one of the organs that expresses the highest baseline levels of PGC-1α [Larrouy et 
al. 1999], which is in agreement with the high mitochondrial content and oxidative capacity of this 
organ.  Interestingly, a common feature associated with reduced mitochondrial function in sepsis, 
diabetes and ischemia/reperfusion-injury is a concomitant reduction in renal PGC-1α levels [Tran et al. 
2011, Funk and Schnellmann 2013, Lempiainen et al. 2013]. Reduced PGC-1α levels and mitochondrial 
dysfunction in the kidney during renal disorders could point towards a therapeutic potential of 
activating PGC-1α in the context of renal diseases.  Several therapeutic strategies aimed at improving 
the impaired mitochondrial phenotype associated with renal disease have already been tested in rodent 
models. One study could show that targeted peptides, which act as ROS-scavengers and inhibitors of 
mitochondrial permeability transition could ameliorate renal damage during ischemia/reperfusion-injury 
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[Szeto et al. 2011].  Also treatment with the SIRT1-activator SRT1720 [Funk and Schnellmann 2013] or 
calorie restriction [Lempiainen et al. 2013] have been shown to improve the mitochondrial phenotype 
in kidney and reduce ischemia/reperfusion-injury, an occurrence closely linked to increased PGC-1α 
activation with these treatments [Funk and Schnellmann 2013, Lempiainen et al. 2013].  The results 
obtained in these studies point towards a beneficial effect of activating PGC-1α in the kidney.  Especially 
since PGC-1α overexpression is associated with improved oxidative phosphorylation and reduced 
oxidative stress in several transgenic rodent models [Lin et al. 2002, Liang et al. 2009, Svensson and 
Handschin 2014].  Aldosterone-induced epithelial-to-mesenchymal transition of proximal tubule 
epithelial cells is a pathological state associated with reduced mitochondrial function, and this 
phenotype could be ameliorated through overexpression of PGC-1α [Yuan et al. 2012].  Moreover, 
proximal tubule-specific ablation of PGC-1α has been shown to exacerbate endotoxemic acute kidney 
injury, and overexpression of PGC-1α could protect against tumor necrosis factor (TNF)-induced 
mitochondrial dysfunction in human proximal tubule cells [Tran et al. 2011].  Reduced PGC-1α activity 
has also been linked to high fat diet (HFD)-induced oxidative stress and lipotoxicity in the kidney [Chung 
et al. 2012, Kim et al. 2013, Hong et al. 2014].  Treatment of genetically obese mice with the PPARα-
agonist fenofibrate has been shown to normalize expression and activity of PGC-1α, and thus ameliorate 
HFD-induced lipotoxicity [Chung et al. 2012, Hong et al. 2014].  Activation of PGC-1α through 
resveratrol-treatment has also been associated with reduced glomerular damage in genetically obese 
mice [Kim et al. 2013].  Specifically in the glomerular podocytes, PGC-1α has been implicated to play a 
dual role. Overexpression of PGC-1α can protect podocytes against aldosterone-induced damage [Yuan 
et al. 2012] while another study demonstrated a role of PGC-1α in mediating podocyte apoptosis and 
growth arrest [Kim and Park 2013].  
Despite the strong connection between reduced PGC-1α activity and numerous renal disorders, 
relatively little is known regarding the actual role of PGC-1α in renal physiology and pathophysiology. 
The high basal oxidative capacity of the kidney implies a prominent role for PGC-1α in renal physiology, 
which is further supported by its abundant expression in this organ.  The mitochondrial impairment 
associated with several etiologically distinct renal disorders also indicates that decreased PGC-1α activity 
and a concomitant reduction in oxidative phosphorylation could be a common denominator for these 
renal disease states.  In light of this, we were interested in elucidating the role of PGC-1α in the kidney, 
and how ablation of PGC-1α would affect renal physiology. 
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3.3 - The role of PGC-1α in kidney – Aims 
The kidney is one of the organs with the highest energy demand in the body.  A high basal rate of 
mitochondrial oxidative phosphorylation is needed to drive the constant reabsorption of salts and 
nutrients over the tubular epithelium.  Considering the established role of PGC-1α in maintaining basal 
mitochondrial function and biogenesis, it is not surprising that this transcriptional coactivator is highly 
expressed in the kidneys.  In addition, several renal pathologies are closely linked to reduced PGC-1α 
activity and impaired renal oxidative capacity.  However, relatively little is known regarding the role of 
PGC-1α in the kidney.  Hence, in the first manuscript of this thesis, we have generated a mouse model 
with an inducible nephron-specific knockout of PGC-1α.  This allowed us to study transcriptional 
regulation by PGC-1α in the kidneys, and how the ablation of PGC-1α affects renal physiology.  The 
specific aims for the first manuscript of this thesis can be summarized as follows: 
1. Determine the transcriptional networks regulated by PGC-1α in the kidney, and identify the 
relevant transcriptional partners of PGC-1α in this context. 
 
2. Investigate how ablation of PGC-1α specifically in the nephron affects renal functions such as 
blood pressure regulation and salt/water homeostasis. 
 
3. Study the impact of PGC-1α-ablation on transcriptional regulation of renal mitochondrial and 
metabolic processes, in both lean and diet-induced obese mice. 
With the first study in this thesis we aim to improve the understanding of the role of PGC-1α in 
renal physiology.  This will not only further our understanding of renal transcriptional regulation and 
function, but will help to elucidate the potential therapeutic applications of modulating PGC-1α activity 
in a renal setting. 
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Abstract 
The kidney is a vital organ for maintenance of systemic salt and water homeostasis.  Reabsorption of 
nutrients and ions across the renal tubular membrane is driven by ATP-hydrolysis, and the kidneys are 
highly reliant on mitochondrial oxidative phosphorylation to maintain a high basal ATP-production rate.  
Consequently, renal mitochondrial dysfunction is a common denominator for several distinct renal 
pathologies.  Hence, it is important to understand how renal mitochondrial function is regulated.  
Peroxisome proliferator-activated receptor coactivator 1 alpha (PGC-1α) is an important transcriptional 
regulator of mitochondrial biogenesis and function.  To elucidate the role of PGC-1α in the regulation of 
renal oxidative energy metabolism and function, we generated inducible nephron-specific PGC-1α 
knockout (PiNKO) mice.  PGC-1α-ablation in the kidneys results in reduced transcription of several 
mitochondrial and metabolic processes.  PiNKO mice furthermore display a mild hypertensive and salt-
losing phenotype associated with altered transcription of several genes involved in transmembrane ion 
transport.  Finally, we demonstrate that PGC-1α is necessary for the induction of genes involved in fatty 
acid oxidation in the kidney during high fat diet feeding.  PGC-1α thus constitutes a promising therapeutic 
target to ameliorate renal disorders associated with metabolic and mitochondrial dysfunction, such as 
diabetic nephropathy, ischemia/reperfusion injury or sepsis. 
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Introduction 
The kidney is a highly complex organ responsible for removal of toxins and metabolic waste products from 
the body, through filtration of blood and subsequent urine formation [Tryggvason and Wartiovaara 2005].  
This passive filtration is coupled to a system of transporters along the nephron, responsible for maintaining 
systemic nutrient- and salt homeostasis [Zhuo and Li 2013].  Tubular reabsorption is an energy-demanding 
process mediated through ATP-hydrolysis by Na+-K+-ATPases in tubular epithelial cells.  Mitochondrial 
density is thus found to be highest in tubule segments associated with high basal transcellular transport, 
such as the proximal tubules and the thick loop of henle [Soltoff 1986].  The integral role of mitochondria 
in renal function is also underscored by the prevalence of renal dysfunction in patients suffering from 
hereditary mitochondrial disorders [Emma et al. 2011, Rahman and Hall 2013, Che et al. 2014].  The 
transcriptional coactivator, peroxisome proliferator-activated receptor coactivator 1 alpha (PGC-1α) is an 
important regulator of mitochondrial homeostasis [Puigserver and Spiegelman 2003].  PGC-1α was 
originally discovered through its ability to induce a thermogenic gene program in brown adipose tissue 
[Puigserver et al. 1998].  Since then, it has been shown that PGC-1α is a critical modulator of fasting-
induced gluconeogenesis and β-oxidation in liver [Liu and Lin 2011], and that it is furthermore important 
for the induction of an oxidative slow-twitch phenotype in skeletal muscle upon exercise [Svensson and 
Handschin 2014].  Apart from these tissue-specific effects, PGC-1α is a global regulator of mitochondrial 
biogenesis and oxidative function through coactivation and transcriptional activation of transcription 
factors such as nuclear respiratory factor 1 (NRF1), mitochondrial transcription factor A (TFAM) [Wu et al. 
1999] and estrogen-related receptor α (ERRα) [Mootha et al. 2004, Schreiber et al. 2004].  Despite the 
importance of mitochondrial energy metabolism for renal function, relatively little is known how PGC-1α 
influences mitochondrial homeostasis in the kidney.  Mice deficient for endothelial nitric oxide synthase 
(eNOS) display a strong reduction in renal PGC-1α levels, and reduced transcription of several 
mitochondrial PGC-1α target genes [Borniquel et al. 2006].  These mice furthermore have an increased 
susceptibility to develop diabetic nephropathy [Alpers and Hudkins 2011].  In line with this, several 
etiologically distinct renal disorders, such as diabetic nephropathy, ischemia/reperfusion injury and sepsis 
are associated with reduced mitochondrial function [Brooks et al. 2009, Tran et al. 2011, Funk and 
Schnellmann 2013, Lempiainen et al. 2013, Rahman and Hall 2013, Sharma et al. 2013].  These 
pathological states furthermore display a concurrent reduction in renal PGC-1α levels and activity [Funk 
et al. 2010, Tran et al. 2011, Yuan et al. 2012, Funk and Schnellmann 2013, Lempiainen et al. 2013], which 
could contribute to mitochondrial impairments and renal dysfunction in these diseases.  Indeed, 
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therapeutic strategies aimed at improving mitochondrial function [Szeto et al. 2011, Funk and 
Schnellmann 2013, Lempiainen et al. 2013] and increasing PGC-1α levels [Tran et al. 2011, Funk and 
Schnellmann 2013, Lempiainen et al. 2013] have been successful in ameliorating renal cellular 
pathologies.  Furthermore, several lines of evidence point towards a role of PGC-1α in the transcriptional 
regulation of blood pressure regulation and salt and water homeostasis.  Deletion or pharmacological 
inhibition of ERRα, which is a key transcriptional partners of PGC-1α, leads to a renal phenotype 
characterized by impaired blood pressure regulation and deregulated ion homeostasis [Tremblay et al. 
2010].  Moreover, also ERRβ and ERRγ have been implicated in the regulation of renal ion homeostasis 
[Alaynick et al. 2010, Krid et al. 2012].  Another PGC-1α-related transcription factor, PPARα, has been 
postulated to mediate protective effects in mice during salt-induced hypertension [Obih and Oyekan 2008, 
Lee et al. 2011].  Hence, coactivation of these transcription factors by PGC-1α could impact renal 
physiology beyond its role in mitochondrial energy metabolism.  In the current study, we have generated 
nephron-specific PGC-1α knockout mice to elucidate the transcriptional networks influenced by PGC-1α in 
the kidney, and its role in renal physiology. 
 
Material and methods 
Animals and diets - Animals were housed in a conventional facility with a 12-h light/12-h dark cycle with 
free access to food and water. All experiments were performed in accordance with federal guidelines and 
were approved by the Kantonales Veterinäramt of Kanton Basel-Stadt.  To generate a tubule-specific PGC-
1α knockout model, mice harboring a transgenic expression of the reverse tetracycline-dependent 
transactivator (rtTA) under the Pax8-promoter (Pax8-rtTA) [Traykova-Brauch et al. 2008] were crossed 
with transgenic (tetO-cre)-LC1 mice [Schonig et al. 2002].  These double-transgenic mice were 
subsequently crossed with mice harboring floxed PGC-1α alleles (PGC-1αfl/fl) [Lin et al. 2004] to generate 
inducible PGC-1α nephron knockout mice (PGC-1α-iNKO; PiNKO).  Addition of doxycycline (DOX) to the 
drinking water of PiNKO-mice induces binding of rtTA to the tet-operator (tetO)-promoter, and drives a 
Cre-mediated recombination of exons 3 to 5 of PGC-1α, specifically in Pax8-expressing cells.  To induce the 
knockout of PGC-1α, DOX (Sigma) (0.2 mg/mL) was administered ad libitum in the drinking water of twelve 
week old mice, with the addition of 2% sucrose (Sigma) to enhance palatability. After two weeks, mice 
were switched back to regular drinking water, and were allowed one week of rest before experiments 
ensued.  Recombination PCR was performed on DNA extracted from relevant organs, using primers binding 
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to a region surrounding exons 3–5 of PGC-1α; FWD 5’-TCCAGTAGGCAGAGATTTATGAC-3’, REV 5’-
CCAACTGTCTATAATTCCAGTTC-3’.  This primer pair yields a product when exons 3-5 of PGC-1α are excised 
[Lin et al. 2004].  The experimental diets used for this study were either obtained from Harlan Teklad; 
normal salt diet (NSD, 1% NaCL) (TD.90229), low salt diet (LSD, <0.02% NaCL) (TD.90228), high salt diet 
(HSD, 8% NaCL) (TD.92012), or from Research Diets Inc; high fat diet (HFD, 60 kcal% fat, D12492). 
Physiological measurements – Blood pressure and heart rate was measured in restrained conscious mice 
using a non-invasive tail-cuff blood pressure analyzer (BP-2000, Visitech system, Bioseb).  For collection of 
urine, mice were housed in single mouse metabolic cages (3600M021, Tecniplast) for 24 hours.  Amount 
of food and water consumed was recorded, and urine collected for further analysis.  Body composition 
was measured using an EchoMRI-100™ analyzer (EchoMRI Medical Systems). 
Blood & urine analysis - Blood glucose was measured in a tail vein blood sample using a handheld glucose 
meter (Accu-Chek, Roche).  Levels of sodium, chloride, potassium, calcium and creatinine levels in urine 
were determined using an automated biochemical analyzer (Cobas c 111 analyzer; Roche).  Urinary ion 
excretion was normalized to the urinary excretion of creatinine. 
RNA extraction and qRT-PCR - Frozen tissue was homogenized and total RNA was extracted using TRIzol 
reagent (Invitrogen). RNA concentration was adjusted and cDNA synthesis was performed using 1 µg of 
total RNA. Semi-quantitative Real-time PCR analysis was performed using Fast SYBR Green master mix 
(Applied Biosystems) on a StepOnePlus Real-Time PCR System (Applied Biosystems). Relative expression 
levels for each gene of interest were calculated with the ΔΔCt method, using eukaryotic elongation factor 
2 (eEF2) as normalization control.  
Gene expression array and analysis – Whole gene expression of CTRL and PiNKO kidneys were measured 
using 4 samples per group, with the Affymetrix GeneChip® Mouse Gene 2.0 ST microarrays.  For gene 
ontology (GO)-analysis, gene lists were entered into the functional annotation tool FatiGO [Al-Shahrour et 
al. 2004] to identify genes over-represented within distinct GO categories.  GO terms were considered 
significantly enriched if having a p-values <0.05.  To calculate the key transcription factors driving the 
changes observed in our gene expression array we used the Integrated System for Motif Activity Response 
Analysis (ISMARA) [Balwierz et al. 2014]. 
Statistical analysis - All data are presented as means ± SEM. Unpaired student two-tailed t test was used 
to determine differences between groups. 
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Results 
The heterogeneity of the renal cell population prevents efficient targeting of a transgene to all cell 
populations within the kidney.  However, by crossing transgenic Pax8rtTA-(tetO-cre)-LC1 mice [Schonig et 
al. 2002, Traykova-Brauch et al. 2008] with mice harboring floxed PGC-1α alleles (PGC-1αfl/fl) [Lin et al. 
2004], we could generate mice carrying a doxycycline (DOX)-inducible nephron-specific ablation of PGC-
1α (PGC-1α-iNKO; PiNKO).  The knockout of PGC-1α was induced through administration of DOX in the 
drinking water of the mice.  Successful recombination of exon 3-5 of PGC-1α was confirmed in PiNKO 
kidneys after DOX-administration (FIG 1A).  While we could not detect recombination in skeletal muscle, 
brain or heart, a recombination band was detect in the liver (FIG 1A).  Partial Pax8 expression is known to 
occur in a subset of periportal hepatocytes [Traykova-Brauch et al. 2008], and could explain the presence 
of a recombination band in liver.  PiNKO mice displayed roughly 80% reduction in PGC-1α transcript levels 
in kidney (FIG 1B), confirming an efficient knockout of PGC-1α in our model (FIG 1B).  We could detect no 
significant reduction in PGC-1α transcript levels in liver (FIG 1B), which is in agreement with only a partial 
recombination in this organ.  All other tissues tested showed unchanged PGC-1α transcript levels between 
CTRL and PiNKO mice (FIG 1B).  This indicates that knockout of PGC-1α in PiNKO mice is targeted specifically 
to the kidneys.  The ablation of PGC-1α in kidney led to no compensatory increase in the related family 
members, PGC-1β and PGC1-related coactivator (PRC) (FIG 1C), but resulted in significantly reduced 
transcript levels of known PGC-1α target genes fumarate hydratase 1 (Fh1) and citrate synthase (Cs) (FIG 
1C).  Deletion of PGC-1α in kidney affected neither body weight (FIG 1D) nor relative kidney weight (FIG 
1E) at either one, fifteen or twenty-four months after DOX-administration compared to CTRL mice. 
PGC-1α regulates transcription of metabolic and mitochondrial processes in kidney 
PGC-1α is a robust transcriptional regulator, and we were interested in how ablation of PGC-1α impacts 
the renal transcriptome.  We thus performed a gene expression array on samples from CTRL and PiNKO 
kidneys.  Using a cut-off of p<0.05 and a fold-change of >1.2, we could find 523 genes that were significantly 
down-regulated, and 516 genes that were significantly up-regulated in kidneys from PiNKO compared to 
CTRL mice (FIG S1A).  We performed gene ontology (GO)-analysis on the down-regulated transcripts and 
could find an overrepresentation of terms associated with metabolic and mitochondrial processes, such 
as; electron transport chain (GO:0022900), oxidative reduction (GO:0055114) (FIG 2A), oxidative 
phosphorylation and tricarboxylic acid cycle (TCA cycle) (FIG 2B).  Within the GO-categories oxidative 
phosphorylation, TCA cycle and glycolysis, we detected several genes that were significantly down-
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regulated in PiNKO compared to CTRL mice (FIG 2C), and a selection of these gene where further validated 
through RT-PCR (FIG 2D).  These data indicate an important role for PGC-1α in the transcriptional 
regulation of metabolic and mitochondrial processes in the kidney, which is in line with the known function 
of PGC-1α also in other organs [Liu and Lin 2011].  Amongst the up-regulated transcripts we could detect 
an overrepresentation of terms associated with binding of vitamin A and isoprenoids, metal ion binding as 
well as glycoprotein binding (FIG S1B).  Interestingly, cation channel activity (GO:0005261) was one of the 
overrepresented terms amongst the up-regulated transcripts (FIG S1B).  Within this GO-category we could 
find several transcripts belonging to the KCN-family of potassium transporters, which would indicate a 
transcriptional induction of this process in the kidney in the absence of PGC-1α.  We next performed motif 
activity response analysis of our gene expression array data using Integrated System for Motif Activity 
Response Analysis (ISMARA) [Balwierz et al. 2014], to predict transcription factors (TF) with a significantly 
altered activity in response to PGC-1α deletion.  We were especially interested in TFs that display a reduced 
activity in PiNKO mice, and could therefore be direct regulatory partners of PGC-1α in the kidney.  Amongst 
the TFs displaying a reduced activity (Z-value>1.5) in kidneys from PiNKO mice were the known 
transcriptional partners of PGC-1α steroidogenic factor 1 (SF-1, NR5A1.2.p2), estrogen-related receptor α 
(ERRα, ESRRA.p2) and the retinoid x receptor (RXR)-family of transcription factors (RXR(A,B,G).p2) (FIG 2E) 
[Delerive et al. 2002, Huss et al. 2002, Yazawa et al. 2010]. ERRα transcription is known to be regulated 
by PGC-1α [Schreiber et al. 2004], and in line with this we detected reduced ERRα transcript levels in PiNKO 
kidneys (FIG 2F), together with a reduction in the known ERRα target genes vascular endothelial growth 
factor A (Vegfa) and isocitrate dehydrogenase [NAD] subunit alpha (Idh3a) [Schreiber et al. 2004, Arany 
et al. 2008] (FIG 2F).  Also ERRβ transcription was reduced in PiNKO mice, while expression of ERRγ was 
unchanged.   
PiNKO mice display a mild hypertensive and salt-losing phenotype 
ERRα has been shown to regulate several genes involved in renal salt-and water homeostasis and blood 
pressure regulation in the kidney [Tremblay et al. 2010].  Considering the close link between ERRα and 
PGC-1α, we were interested in whether blood pressure regulation would be altered in PiNKO mice.  We 
thus measured resting blood pressure in CTRL and PiNKO mice.  PiNKO mice displayed a mild hypertensive 
phenotype, with significantly increased systolic (FIG 3A) and diastolic (FIG 3B) blood pressure compared to 
CTRL mice.  This slight increase in blood pressure was however not linked to any changes in heart rate (FIG 
S1C).  Transcriptional analysis by RT-PCR revealed several genes involved in renal blood pressure regulation 
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that were significantly altered in PiNKO compared to CTRL mice.  These were genes belonging to the renin-
angiotensin-aldosterone system (RAAS); angiotensinogen (Agt), renin (Ren1), the kallikrein-kinin system 
(KKS); kallikrein 1 (Klk1) and carboxypeptidase N (Cpn1) and genes involved in prostaglandin synthesis; 
prostaglandin D2 synthase (Ptgds) and prostaglandin E synthase 2 (Ptges2) (FIG 3C).  The enhanced Ren1 
transcription furthermore provides a likely explanation for the mild hypertensive phenotype of PiNKO mice 
(FIG 3A-B).  Importantly, enhanced transcription of both Ren1 and Cpn1 is also detected in global ERRα 
knockout mice [Tremblay et al. 2010].  However, expression of Ptgds and Agt were differentially regulated 
in ERRα knockout mice compared to PiNKO mice, indicating that these two genetic models differ slightly 
in their renal transcriptional profiles, which could potentially explain the different effect on blood pressure 
regulation between global ERRα knockout and PiNKO mice.  Closely linked to renal blood pressure 
regulation is the ability of the kidney to adjust the concentration of salts and other constituents of the 
primary filtrate.  Hence, we investigated whether PGC-1α deletion affects transcription of genes involved 
in transcellular transport.  To use an unbiased approach, we encompassed both up- and down-regulated 
genes (p<0.05, fold change >1.2; 1039 genes) and performed functional annotation for differentially 
regulated genes in kidney from PiNKO mice.  GO-analysis revealed that the most highly enriched term was 
associated with energy metabolism, oxidoreductase activity (GO:0016491) (FIG 3D), confirming our earlier 
findings using only down-regulated genes (FIG 2A-B).  Interestingly, we could also find an enrichment of 
terms associated with ion transport, such as transmembrane transporter activity (GO:0022857), cation 
transmembrane transporter activity (GO:0008324) and ion transmembrane transporter activity 
(GO:0015075) in kidney from PiNKO mice (FIG 3D).  Manual inspection of the genes associated within the 
term transmembrane transporter activity (GO:0022857) revealed two major clusters of genes associated 
with the solute carrier (SLC) family or the KCN-family of potassium transporters (FIG 3E).  These two 
clusters contained both up- and down-regulated transcripts (FIG 3E), suggesting both a direct- and an 
indirect regulation of these genes by PGC-1α.  A selection of genes contained within these clusters were 
validated by RT-PCR (FIG 3F).  Amongst the down-regulated genes was the known PGC-1α-target glucose 
transporter 4 (Slc2a4, GLUT4) [Michael et al. 2001], as well as the other members of the SLC-family; solute 
carrier family 43 (amino acid system L transporter), member 2 (Slc43a2, LAT4) and solute carrier family 12 
(potassium/chloride transporters), member 7 (Slc12a7, KCC4).  Conversely, transcription of solute carrier 
family 8 (sodium/calcium exchanger), member 1 (Slc8a1, NCX1), solute carrier family 17 (organic anion 
transporter), member 4 (Slc17a4; NPT-homologue) and solute carrier family 34 (type II sodium/phosphate 
co-transporter), member 2 (Slc34a2, NaPi-2b) was upregulated in the absences of PGC-1α (FIG 3F).  Since 
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several genes involved in renal ion transport were influenced by the ablation of PGC-1α, we investigated 
whether salt- and water homeostasis would be affected in PiNKO mice.  However, PiNKO mice displayed 
no alteration in either water intake or diuresis over a 24 hour period (FIG 3G-H), and there was no 
difference in food consumption between genotypes (FIG S1D).  PiNKO mice however displayed a mild 
increase in sodium excretion when normalized to urinary creatinine excretion (FIG 3I).  No significant 
difference could be detected for the urinary excretion of other ions, such as chloride, potassium and 
calcium (FIG 3I).  These data indicate that PiNKO mice display a largely normal regulation of water intake 
and urine concentration, but display a mild sodium-losing phenotype in the basal state. 
Young PiNKO mice can adapt their salt and water homeostasis to an altered dietary salt intake 
The small increase in sodium excretion in PiNKO mice could indicate a role for PGC-1α in maintenance of 
salt homeostasis.  To test this hypothesis, we exposed PiNKO mice to a dietary salt stress.  CTRL and PiNKO 
mice were administered a standardized diet supplemented with either 1% NaCl (normal salt diet, NSD), 
<0.02% NaCl (low salt diet, LSD) or 8% NaCl (high salt diet, HSD).  LSD-feeding did not alter water intake 
(FIG 4A) or diuresis (FIG 4B) in either genotype, however this diet resulted in a significantly reduced 
urine/water ratio only in CTRL mice (FIG 4C).  Conversely, HSD feeding increased both water intake (FIG 
4A), diuresis (FIG 4B) and urine/water ratio (FIG 4C), and did so to the same extent in both CTRL and PiNKO 
mice.  The administered diets did not alter food intake in any of the groups (FIG S1E). While urinary sodium 
excretion was slightly increased in PiNKO mice on a NSD (FIG 4D), PiNKO mice could efficiently adapt their 
urinary sodium and chloride excretion rates to both a decreased and an increased dietary sodium load (FIG 
4D-E).  Conclusively, these data indicate that young PiNKO mice display a mild salt losing phenotype in the 
basal state, but can efficiently adapt their salt- and water homeostasis to an altered dietary NaCl -load.  
Aging is associated with a reduced ability to adjust for alteration in urinary salt excretion [Schlanger et al. 
2010, Karam and Tuazon 2013].  Since young PiNKO mice displayed a mild salt losing phenotype in the 
basal state, we wanted to investigate whether this phenotype would be exacerbated as the mice aged.  
We therefore repeated the LSD-feeding in aged mice (15 months old).  In aged PiNKO mice, we could detect 
an increased loss of sodium in the urine compared to CTRL mice when fed an NSD (FIG 4F), corroborating 
our finding in young PiNKO mice (FIG 4D).  While there was no significant difference in urinary chloride 
excretion (FIG 4G) at this time-point, we could however detect a trend towards increased calcium excretion 
in the urine (FIG 4H).  Interestingly, although aged PiNKO mice could partially adapt to a reduced dietary 
salt load, they displayed increased urinary excretion of both sodium (FIG 4F) and calcium (FIG 4H) 
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compared to LSD-fed CTRL mice.  This ion losing phenotype also correlated with a significantly increased 
diuresis (FIG 4I) and urine/water ratio (FIG 4J) in PiNKO mice fed a LSD compared to CTRL mice.  
Collectively, these data indicate that young PiNKO mice can adapt to altered dietary salt intake, while this 
is progressively impaired as the mice age. 
 
HFD-feeding does not impact transcription of PGC-1α-regulated mitochondrial genes in kidney 
Analysis of the kidney transcriptome of PiNKO mice suggested an important role for PGC-1α in 
transcriptional regulation of several metabolic and mitochondrial processes (FIG 2A-B).  We were thus 
interested in whether PGC-1α was involved in renal adaptation to metabolic stress and more specifically, 
how the renal transcriptome would be affected by the ablation of PGC-1α in mice kept on a high fat diet 
(HFD).  To investigate this, we fed CTRL and PiNKO mice a HFD for five months.  After this period, CTRL and 
PiNKO mice were significantly heavier than their chow fed counterparts (CHOW) (FIG 5A). However, there 
was no significant difference in relative fat mass (FIG 5B) between HFD-fed CTRL and PiNKO mice.  
Moreover, both HFD-fed CTRL and PiNKO mice displayed significant hyperglycemia, characterized by 
increased fasting glucose levels (FIG 5C) compared to CHOW fed mice.  To investigate how the renal 
transcriptome is affected by the ablation of PGC-1α during HFD feeding, we performed a gene expression 
array on kidneys from HFD fed CTRL and PiNKO mice.  Using a cut-off of p<0.05 and a fold-change >1.2, we 
could find 418 genes that were significantly down-regulated, and 425 genes that were significantly up-
regulated in kidneys from HFD-fed PiNKO compared to HFD-fed CTRL mice (FIG S1F).  For the up-regulated 
genes, 38 out of 425 genes were associated with the GO-category response to external stimulus 
(GO:0009605).  However, none of the up-regulated genes in HFD-fed PiNKO compared to HFD-fed CTRL 
mice were associated with similar terms as those detected in chow fed PiNKO versus CTRL mice (FIG S1B).  
On the other hand, similar to the GO-analysis performed on kidneys from chow-fed mice (FIG 2A-B), 
metabolic and mitochondrial processes were overrepresented amongst the downregulated genes 
between HFD-fed CTRL and PiNKO mice (FIG 5E-F).  The GO-term oxidative phosphorylation (mmu00190) 
was amongst the highest ranking KEGG categories within the downregulated genes when comparing 
PiNKO and CTRL mice in both chow-fed (FIG 2B) and HFD-fed (FIG 5F) states.  Since diet-induced obesity 
has been associated with reduced mitochondrial transcription and reduced PGC-1α activity in several 
organs [Patti et al. 2003, Boudina et al. 2005, Sparks et al. 2005, Sivitz and Yorek 2010], we were 
interested in whether HFD-feeding would impact transcription of mitochondrial genes also in the kidney.  
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However, functional annotation of differentially regulated genes (p>0.05, fold change >1.2 or <-1.2) in 
kidney from HFD-fed CTRL mice compared to chow-fed CTRL mice did not reveal any significant enrichment 
of terms associated with mitochondrial structure or functions (unpublished observation).  To further 
investigate whether PGC-1α-regulated oxidative phosphorylation genes would be affected by HFD feeding, 
we selected genes that were down-regulated in PiNKO compared to CTRL mice and functionally annotated 
to the GO-category oxidative phosphorylation (mmu00190) (SI Table I).  We then cross-referenced this list 
with genes differentially regulated in HFD-fed CTRL mice compared to CHOW-fed CTRL mice.  Surprisingly, 
only 8 out of 42 PGC-1α-regulated genes associated with mitochondrial oxidative phosphorylation were 
significantly (p<0.05) altered with HFD feeding in CTRL mice in our microarray data.  However, validation 
of these genes with RT-PCR revealed that only expression of two of these predicted transcripts; NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (Ndufa4) and NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex 1 (Ndufa1) were significantly affected by HFD-feeding (FIG 5G).  The other positive hits 
from our microarray-data were accordingly unaltered in kidney of HFD-fed CTRL mice compared to chow-
fed CTRL mice when analyzed by RT-PCR using a large sample size (FIG 5G).  Considering that only a small 
number of these predicted genes changed their transcription with HFD feeding, we can conclude that HFD 
feeding did not alter expression of PGC-1α-regulated genes involved in renal mitochondrial oxidative 
phosphorylation.  In line with this, we did not detect any significant differences in PGC-1α transcript levels 
in the kidney after five months HFD feeding (FIG 5H).  Interestingly, transcript levels of PGC-1β and PRC 
displayed a slight but significant increase in kidney with HFD-feeding (FIG 5H), irrespective of genotype.  
Moreover, when we analyzed the expression of TFs involved in regulation of mitochondrial genes, we could 
detect a slight induction of NRF1 transcription, while expression levels of ERRα and TFAM were unaltered 
(FIG 5H).  Conclusively, five months of HFD feeding does not significantly alter transcription of 
mitochondrial genes in kidney. 
PGC-1α mediates induction of fatty acid metabolic genes in the kidney during HFD feeding 
Since we only detected minor differences in PGC-1α-regulated mitochondrial genes with HFD-feeding, we 
were next interested in whether loss of PGC-1α in kidney would affect the renal metabolic adaptations 
during HFD feeding.  GO-analysis of genes significantly (p<0.05, fold-change>1.2) altered in either CTRL 
mice (FIG 6A) or PiNKO mice (FIG 6B) with HFD feeding revealed an enrichment of down-regulated genes 
associated with the GO-term steroid biosynthesis (mmu00100) in both genotypes (FIG 6A-B).  This was 
associated with a significant down-regulation of genes involved in cholesterol biosynthesis, such as 
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squalene epoxidase (Sqle), farnesyl-diphosphate farnesyltransferase 1 (Fdft1) and 7-dehydrocholesterol 
reductase (Dhcr7) in kidneys from both HFD-fed CTRL and PiNKO mice (FIG 6C), indicating that the loss of 
PGC-1α does not affect transcriptional adaptation of renal cholesterol metabolism upon HFD feeding.  Next 
we focused on genes induced by HFD feeding, and could find the two related GO-terms; PPAR signaling 
pathway (mmu03320) and fatty acid degradation (mmu00071) significantly enriched amongst up-
regulated genes in CTRL mice (FIG 6A).  Interestingly, these GO-terms were not enriched amongst the up-
regulated processes in PiNKO mice (FIG 6B), which suggests that the induction of these processes could be 
dependent on PGC-1α.  To investigate this further, we measured transcript levels of PPARs in the kidney 
and detected an induction of PPARα, but not PPARβ/δ or PPARγ, in HFD fed mice (FIG 6D).  Importantly, 
the induction of PPARα with HFD feeding was blunted in PiNKO mice (FIG 6D), and a similar transcriptional 
pattern could be observed for several PPARα target genes involved in fatty acid metabolism (FIG 6E).  HFD 
feeding led to an increased transcription of acyl-CoA thioesterase 2 (Acot2), Acot3, solute carrier family 25 
(carnitine/acylcarnitine translocase) member 20 (SLC25A20), acyl-CoA dehydrogenase very long chain 
(Acadvl) and acyl-CoA dehydrogenase long chain (Acadl) in kidneys of CTRL mice, and this induction was 
diminished in the absence of PGC-1α (FIG 6E).  PGC-1α is a known transcriptional coactivator of PPARα in 
liver [Finck and Kelly 2006], and these data indicate an important role for PGC-1α in regulation of PPARα-
activity and fatty acid metabolism also in the kidney.  To confirm our findings, we selected genes, which 
were significantly induced in CTRL mice with HFD feeding (p<0.05, fold change>1.1) and which showed a 
blunted induction in HFD-fed PiNKO mice (p<0.05, fold change <1.1) compared to HFD-fed CTRL mice (SI 
Table II).  Using these cut-offs, out of the total number of genes induced in kidney with HFD feeding (1467 
genes), approximately one fifth of these (279 genes) were significantly reduced in PiNKO mice (FIG S1G).  
GO-analysis of this subset of genes revealed an enrichment of genes within the GO categories fatty acid 
degradation (mmu00071) (FIG S1H) and fatty acid metabolic process (GO:0006631) (FIG 6F), further 
supporting our finding that PGC-1α is important for the transcriptional induction of β-oxidation in kidneys 
from HFD-fed mice.  Moreover, within the GO category fatty acid metabolic process (GO:0006631), we 
could find several genes which are known target genes of PPARα, such as Acot3, Acaa2 and hydroxyacyl-
CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (Hadha) (FIG 6G).  Collectively, these 
data highlight an important role for PGC-1α in the induction of PPARα-target genes involved in fatty acid 
metabolism in kidney.  Impaired β-oxidation in kidney has been associated with increased lipotoxicity and 
increased renal inflammation during HFD-feeding [Tanaka et al. 2011].  Interestingly, several of the GO 
terms enriched amongst up-regulated genes in PiNKO mice with HFD-feeding were associated with 
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immune response, such as primary immunodeficiencies (mmu05340) and B cell receptor signaling pathway 
(mmu04664), or cancer; small cell lung cancer and pathways in cancer (mmu05222) (FIG 6B), while no such 
terms could be found in HFD fed CTRL mice (FIG 6A).  Importantly, motif activity response analysis of our 
gene expression array revealed that the activity of nuclear factor 'kappa-light-chain-enhancer' of activated 
B-cells (NF-κB)-activity (NFKB1_REL_RELA.p2) was predicted to be increased in HFD fed PiNKO mice 
compared to both chow-fed PiNKO mice and HFD-fed CTRL mice (FIG 6H).  Considering the role of NF-κB 
activation in the pathogenesis of renal inflammation [Sanz et al. 2010], this suggests a worsened renal 
phenotype in PiNKO mice upon HFD-feeding compared to CTRL mice.  Conclusively, these data highlight 
an important role of PGC-1α in the metabolic adaptation to HFD-feeding, through induction of PPARα-
target genes involved in renal fatty acid metabolism. 
Discussion 
The kidney has a high basal energy demand, and derives the majority of its energy from oxidative 
phosphorylation.  Renal mitochondrial activity is thus integral to the function of the kidney and for the 
maintenance of a constant rate of filtration and reabsorption along the nephron.  This is evident by the 
high mitochondrial density in nephron segments associated with a high basal transmembrane transport 
activity [Soltoff 1986] and the prevalence of renal dysfunction in patients suffering from hereditary 
mitochondrial disorders [Emma et al. 2011, Rahman and Hall 2013, Che et al. 2014].  PGC-1α is an 
important regulator of mitochondrial oxidative phosphorylation and oxidative metabolism in several 
organs [Liu and Lin 2011].  We were thus interested in elucidating the role of PGC-1α in the regulation of 
renal energy metabolism and function.  To this end, we have generated and characterized a nephron-
specific PGC-1α knockout mouse. 
We could demonstrate that PGC-1α plays an important role in the transcriptional regulation of 
genes involved in mitochondrial oxidative phosphorylation, TCA cycle and glycolysis in kidney.  These 
specific processes are known to be regulated by PGC-1α also in other metabolic organs, for instance in 
skeletal muscle [Perez-Schindler et al. 2012].  Our findings are thus in agreement with a global role of PGC-
1α in the regulation of mitochondrial and metabolic processes, which have been demonstrated also in 
BAT, heart and skeletal muscle [Liu and Lin 2011].  The transcriptional congruency between these tissues 
could result not only from high basal expression of PGC-1α in these organs, but also from a uniform 
expression of transcription factors relevant for mitochondrial transcription, such as NRF1, TFAM and ERRα.  
Indeed, renal expression of ERRα has been shown to equal that of both BAT and heart, and to exceed that 
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of skeletal muscle [Sladek et al. 1997, Ranhotra 2009].  Based on motif activity response analysis of our 
gene expression data, we predicted a significant blunting of ERRα transcriptional activity in our tubule-
specific PGC-1α knockout mice.  In line with this, we found that ERRα transcription was significantly 
reduced in PiNKO mice.  ERRα is not only a transcriptional partner of PGC-1α in the regulation of 
mitochondrial genes, but has also been shown to be important for the transcriptional regulation of genes 
involved in salt and water homeostasis and blood pressure regulation in kidney.  Global ERRα knockout 
mice are hypotensive and display a reduced sodium excretion in response to salt stress [Tremblay et al. 
2010].  Interestingly, despite reduced ERRα transcription and a predicted reduction in ERRα transcriptional 
activity, PiNKO mice displayed the opposite phenotype, characterized by a mild hypertension and a salt-
losing phenotype.  This discrepancy could be partially explained by an opposite regulation of several genes 
(i.e. Agt, Ptgds) important for blood pressure regulation and salt homeostasis in PiNKO compared to global 
ERRα knockout mice [Tremblay et al. 2010].  Renin transcription was however increased in both knockout 
models.  The effect on renin transcription is likely mediated through indirect effects, since PGC-1α has not 
been shown to function as a transcriptional corepressor.  The opposite regulation of several genes in PiNKO 
mice compared to ERRα knockout mice could originate from compensatory mechanisms due the global 
ablation of ERRα in this particular model [Tremblay et al. 2010].  Knockout of ERRγ on the other hand has 
been shown to lead to a reduced renal transcription of Klk1 in mice [Alaynick et al. 2010], similar to what 
we observed in PiNKO mice.  ERRγ transcription was however not altered in kidneys of PiNKO mice.  Despite 
the effect of PGC-1α ablation on the transcription of genes involved in mitochondrial energy metabolism, 
and regulation of salt- and water homeostasis, PiNKO mice display a very mild renal phenotype, and can 
adjust for both increased and decreased NaCl-load in the diet.  However, aged PiNKO mice displayed 
increasing difficulties to adjust their salt- and water balance, which was evident by the salt and water losing 
phenotype when fed a low NaCl-diet.  Importantly, aging is associated with a reduced ability to retain 
sodium during salt depletion also in humans [Schlanger et al. 2010, Karam and Tuazon 2013] and is 
associated with reduced renal PGC-1α levels in mice [Lim et al. 2012].  Aging is also connected to increased 
renal oxidative damage, resulting in exacerbated albuminuria [Kume et al. 2010], and has been linked to 
reduced renal mitochondrial number and function [de Cavanagh et al. 2003, Benigni et al. 2009].  
Conclusively, this points towards an important role for PGC-1α in maintaining renal tubular homeostasis 
with aging. 
Obesity and diabetes have been associated with reduced PGC-1α levels and impaired 
mitochondrial transcription in several organs [Patti et al. 2003, Boudina et al. 2005, Sparks et al. 2005, 
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Sivitz and Yorek 2010].  We were thus interested in how diet-induced obesity affects transcription of 
mitochondrial genes in the kidney, and the role of PGC-1α in this regulation.  After five months on a HFD, 
1467 genes were found to be significantly altered in kidneys from CTRL mice.  However, functional 
annotation of these genes did not reveal any association with GO-categories associated with mitochondrial 
structural components or oxidative function.  Moreover, only a small part of PGC-1α target genes involved 
in oxidative phosphorylation were found to be altered by HFD-feeding in CTRL mice.  Thus, HFD feeding 
does not lead to major alterations in mitochondrial transcription.  Our findings are supported by a study 
from Ruggiero et al. [Ruggiero et al. 2011], which demonstrates unchanged mitochondrial function in 
mouse kidney after 16 weeks HFD-feeding.  While mitochondrial transcription was unaltered with HFD-
feeding, we detected a significant induction of renal PPARα levels as well as several of its target genes 
involved in fatty acid metabolism.  Interestingly, induction of PPARα and its target genes with HFD-feeding 
was significantly blunted in the absence of renal PGC-1α.  It has been shown that ablation of PPARα in mice 
leads to an increased susceptibility to diabetic nephropathy [Park et al. 2006] and exacerbated free fatty 
acid-induced injury in the kidney [Kamijo et al. 2007].  Moreover, increased PPARα-activity in obese 
rodents has been shown to protect against renal lipotoxicity [Shin et al. 2009, Tanaka et al. 2011] and has 
been associated with increased levels of PGC-1α [Chung et al. 2012].  Our findings indicate that PGC-1α is 
necessary for the induction of renal PPARα expression in response to diet-induced obesity.  Hence, PGC-
1α might play an important role in protection against renal lipotoxicity. 
In conclusion, our results show that ablation of PGC-1α in renal tubular cells does not lead to any 
impairments in basal renal function, indicating that PGC-1α is dispensable for maintenance of basal renal 
physiology.  We can however demonstrate that PGC-1α is an important transcriptional regulator of 
mitochondrial and metabolic processes in the kidney, and would thus serve as a promising therapeutic 
target to ameliorate renal metabolic disorders.  In line with this, two recent studies have shown that 
treatment with the SIRT1-activator SRT1720 [Funk and Schnellmann 2013] or calorie restriction 
[Lempiainen et al. 2013], which both are linked to increased PGC-1α activation, could improve the renal 
mitochondrial phenotype and reduce ischemia/reperfusion injury in mice.  Moreover, proximal tubule-
specific ablation of PGC-1α has been shown to exacerbate endotoxemic acute kidney injury and 
overexpression of PGC-1α in cultured proximal tubule cells protected against both TNF- [Tran et al. 2011] 
and aldosterone-induced [Yuan et al. 2012] mitochondrial dysfunction.  Hence, increased PGC-1α activity 
could be a valid therapeutic strategy to ameliorate renal mitochondrial dysfunction in a broad spectrum 
of renal disorders.  
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Figure 1 – PiNKO mice display a renal-specific ablation of PGC-1α  
(A)  Representative recombination PCR for PGC-1α on DNA extracted from kidney, white adipose tissue 
(WAT), heart, liver and skeletal muscle.  (B)  Transcript levels of PGC-1α in kidney, WAT, heart, liver and 
skeletal muscle (SKM) normalized to eukaryotic elongation factor 2 (eEF2) mRNA levels (n=5-7).  (C)  
Transcript levels of indicated genes in whole kidney, normalized to eEF2 (n=7-8).  (D)  Absolute body weight 
of mice at 1, 15 and 24 months after doxycycline administration (n=5-11). (E)  Average kidney weight 
normalized to body weight at 1, 15 and 24 months after doxycycline administration (n=5-11).  Error bars 
represent mean ±SEM. Significant differences (p-value <0.05) between CTRL and PiNKO mice are indicated 
by an asterisk (*). 
 
4.  Manuscript 1: Transcriptional Regulation of Renal Function and Energy Metabolism 
by PGC-1α 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
64 
  
4.  Manuscript 1: Transcriptional Regulation of Renal Function and Energy Metabolism 
by PGC-1α 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
65 
Figure 2 – PGC-1α regulates transcription of metabolic and mitochondrial processes in kidney 
Top gene ontology (GO) terms enriched within the Biological processes (A) and KEGG (B) categories for 
down-regulated genes (p<0.05, fold change >1.2) in PiNKO compared to CTRL kidneys.  (C)  Heat maps 
generated using probe set intensities for the transcripts associated with the GO categories “Oxidative 
phosphorylation”, “TCA cycle” and “Glycolysis”.  (D)  Transcript levels of indicated genes in whole kidney, 
normalized to eEF2 (n=8).  (E)  Top transcription factor motifs exhibiting reduced activity in ISMARA 
analysis of microarray data for PiNKO compared to CTRL mice.  (F)  Transcript levels of indicated genes in 
whole kidney, normalized to eEF2 (n=8).  Error bars represent mean ±SEM. Significant differences (p value 
< 0.05) between CTRL and PiNKO mice are indicated by an asterisk (*). 
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Figure 3 – PiNKO mice display a mild hypertensive and salt-losing phenotype 
Systolic (A) and diastolic (B) blood pressure measured via tail-cuff photoplethysmography.  (C)   Transcript 
levels of indicated genes in whole kidney, normalized to eEF2 (n=8).  (D)  Top gene ontology (GO) terms 
enriched within the molecular function category for differentially regulated genes (p<0.05, fold change 
>1.2 or <-1.2) in PiNKO compared to CTRL kidneys.  (E)  Heat maps generated using probe-set intensities 
for transcripts belonging to the solute carrier (SLC) family or KCN-family of potassium transporters and 
associated with the GO category “Transmembrane transporter activity”.  (F)  Transcript levels of indicated 
genes in whole kidney, normalized to eEF2 (n=8).  (G)  Ad libitum water intake of mice measured over 24 
hours (n=9-11).  (H)  Urine excretion over 24 hours (n=9-11).  (I)  Urinary levels of sodium (Na+), chloride 
(Cl-), potassium (K+) and calcium (Ca2+) over 24 hours.  Values expressed relative to CTRL mice (n=8-9).  
Error bars represent mean ±SEM. Significant differences (p-value <0.05) between CTRL and PiNKO mice 
are indicated by an asterisk (*). 
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Figure 4 – Young PiNKO mice can adapt their salt and water homeostasis to an altered dietary 
salt intake 
(A)  Ad libitum water intake over 24 hours (n=8-9).  (B)  Urine excretion over 24 hours (n=8-9).  (C) Urine-
to-water ratio over 24 hours (n=8-9).  Urinary levels of (D) sodium and (E) chloride over 24 hours in mice 
fed a normal-salt diet (NSD), a low-salt diet (LSD) or a high-salt diet (HSD).  All values relative to NSD-fed 
CTRL mice (n=8-9).  Urinary levels of (F) sodium, (G) chloride and (H) calcium over 24 hours in aged mice 
fed a normal-salt diet (NSD) or a low-salt diet (LSD).  All values relative to NSD-fed CTRL mice (n=6-13).  (I) 
Urine excretion and (J) urine-to-water ratio over 24 hours in aged mice (n=6-13).  Error bars represent 
mean ±SEM. Significant differences (p value < 0.05) between CTRL and PiNKO mice are indicated by an 
asterisk (*), and between LSD/HSD-fed and NSD-fed groups are indicated by a number-sign (#). 
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Figure 5 – High fat diet (HFD)-feeding does not impact transcription of PGC-1α regulated 
mitochondrial genes in kidney 
(A)  Body weight of chow-fed (CHOW) and HFD-fed (HFD) mice after 20 weeks on their respective diets 
(n=10-15).  (B)  Relative fat mass expressed as % of total body weight (n=16).  (C)  Blood glucose measured 
in tail-vein blood after a 16 hour fast (n=8-15).  Top gene ontology (GO) terms enriched within the Biological 
processes (E) and KEGG (F) categories for down-regulated genes (p<0.05, fold change >1.2) in HFD-fed 
PiNKO compared to HFD-fed CTRL kidneys.  (G-H)  Transcript levels of indicated genes in whole kidney, 
normalized to eEF2 (n=7-8).  Error bars represent mean ±SEM. Significant differences (p-value <0.05) 
between CTRL and PiNKO mice are indicated by an asterisk (*), and between chow-fed and HFD-fed groups 
are indicated by a number-sign (#). 
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Figure 6 – PGC-1α mediates induction of fatty acid metabolic genes in the kidney during HFD 
feeding 
Top gene ontology (GO) terms enriched within the KEGG category for up- and down-regulated genes 
(p<0.05, fold change >1.2) in kidneys from (A) HFD-fed CTRL mice compared to chow-fed CTRL mice or in 
(B) HFD-fed PiNKO mice compared to chow-fed PiNKO mice.  (C-E)  Transcript levels of indicated genes in 
whole kidney, normalized to eEF2 (n=7-8).  (F)  Top GO-terms enriched within the biological processes 
category for genes significantly up-regulated (p<0.05, fold change >1.1) in HFD-fed CTRL mice compared 
to chow-fed CTRL mice, and significantly blunted (p<0.05) in HFD-fed PiNKO mice compared to HFD-fed 
CTRL mice.  (G)  Heat map generated using probe set intensities for transcripts associated with the GO-
category “Fatty acid metabolic process”.  Chow-fed CTRL mice (CWT), chow-fed PiNKO mice (CKO), HFD-
fed CTRL mice (HWT) and HFD-fed PiNKO mice (HKO).  (H)  Top transcription factor motifs exhibiting 
increased activity in ISMARA analysis of microarray data for HFD-fed compared to chow-fed PiNKO mice, 
and HFD-fed PiNKO compared to HFD-fed CTRL mice.  Error bars represent mean ±SEM. Significant 
differences (p value < 0.05) between CTRL and PiNKO mice are indicated by an asterisk (*), and between 
chow-fed and HFD-fed groups are indicated by a number-sign (#). 
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SI Figure 1 
(A)   Volcano-plot for probe intensities from gene expression array. P-values are plotted on the Y-axis and 
average log2 fold change is plotted on the X-axis.  Boxes represents cut-offs (p<0.05, fold change >1.2 or 
<-1.2) for up- and down-regulated genes in kidneys from chow-fed CTRL and PiNKO mice.  (B)  Top gene 
ontology (GO)-terms enriched within the Molecular functions category for genes significantly up-regulated 
(p<0.05, fold change >1.2) in chow-fed PiNKO mice compared to chow-fed CTRL mice.  (C)  Heart rate 
measured via tail-cuff photoplethysmography.  (D-E)  Food intake over 24 hours (n=8-9).  (F)  Volcano-plot 
for probe intensities from gene expression array. P-values are plotted on the Y-axis and average log2 fold 
change is plotted on the X-axis.  Boxes represents cut-offs (p<0.05, fold change >1.2 or <-1.2) for up- and 
down-regulated genes in kidneys from HFD-fed CTRL and PiNKO mice.  (G)  VENN diagram representing 
transcripts up-regulated in HFD-fed CTRL mice compared to chow-fed CTRL mice (blue) and the amount of 
these gene significantly blunted (p<0.05) in HFD-fed PiNKO compared to HFD-fed CTRL mice (yellow).  (H)  
GO-term enriched within the KEGG category for genes significantly up-regulated (p<0.05, fold change >1.1) 
in HFD-fed CTRL mice compared to chow-fed CTRL mice, and significantly blunted (p<0.05) in HFD-fed 
PiNKO mice compared to HFD-fed CTRL mice.  Significant differences (p value < 0.05) between CTRL and 
PiNKO mice are indicated by an asterisk (*).  
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SI Table I – Genes in this list are found to be significantly down-regulated (p<0.05, fold change < -1.2) in 
kidney between either chow-CTRL vs. chow-PiNKO or HFD-CTRL vs. HFD-PiNKO mice.  All genes were 
furthermore associated with the KEGG GO category oxidative phosphorylation (mmu00190). 
Gene Fold change - Chow-fed 
PiNKO Vs. Chow-fed CTRL 
mice 
p-value Fold change - High fat 
diet-fed PiNKO Vs. High 
fat diet-fed CTRL mice 
p-value 
Atp4a -1.25 0.030729 -1.21 0.059675 
Atp5c1 -1.20 0.001949 -1.22 0.001114 
Atp5d -1.23 0.002976 -1.12 0.078392 
Atp5e -1.33 2.30E-05 -1.20 0.001115 
Atp5f1 -1.22 0.000176 -1.21 0.00024 
Atp5g1 -1.08 0.536452 -1.49 0.005845 
Atp5g3 -1.32 3.69E-06 -1.23 5.84E-05 
Atp5h -1.21 3.19E-06 -1.21 2.45E-06 
Atp5k -1.18 0.00132 -1.24 0.000134 
Atp5l -1.26 0.002095 -1.15 0.03815 
Cox10 -1.41 7.36E-05 -1.36 0.000207 
Cox4i1 -1.30 0.000002 -1.19 0.000086 
Cox5a -1.31 0.000012 -1.36 0.000004 
Cox5b -1.24 0.088812 -1.37 0.019061 
Cox7a1 -3.31 0.000001 -3.06 0.000002 
Cox7a2 -1.25 0.000004 -1.24 0.000006 
Cox7b -1.24 0.027869 -1.03 0.727354 
Cyc1 -1.26 0.000012 -1.20 0.000087 
ND6 -1.40 0.002268 -1.16 0.123039 
Ndufa1 -1.25 0.006665 -1.23 0.009967 
Ndufa4 -1.26 0.000004 -1.24 0.000010 
Ndufa6 -1.22 0.000299 -1.20 0.000604 
Ndufa8 -1.28 0.000115 -1.30 0.000078 
Ndufa9 -1.25 0.000000 -1.22 0.000000 
Ndufb2 -1.21 0.004665 -1.09 0.131977 
Ndufb5 -1.21 0.000370 -1.17 0.002029 
Ndufb8 -1.25 0.002371 -1.18 0.014918 
Ndufc1 -1.32 0.000094 -1.29 0.000195 
Ndufs1 -1.31 0.000000 -1.14 0.000084 
Ndufs2 -1.21 0.000017 -1.18 0.000062 
Ndufs3 -1.22 0.000117 -1.25 0.000035 
Ndufs6 -1.21 0.000488 -1.18 0.001373 
Ndufs8 -1.24 0.000023 -1.23 0.000039 
Ndufv2 -1.25 0.000008 -1.17 0.000220 
Sdha -1.21 0.000003 -1.17 0.000019 
Sdhc -1.21 0.000143 -1.13 0.004467 
Sdhd -1.25 0.000007 -1.20 0.000054 
Uqcrb -1.20 0.002694 -1.18 0.004626 
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Uqcrc1 -1.26 0.000002 -1.25 0.000003 
Uqcrfs1 -1.33 0.000005 -1.25 0.000051 
Uqcrh -1.29 0.000103 -1.28 0.000115 
Uqcrq -1.24 0.000238 -1.23 0.000323 
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SI Table II – Genes within this table were significantly increased in kidney (p<0.05, fold change >1.1) from 
HFD-fed CTRL mice compared to chow-fed CTRL mice, and this induction was significantly blunted in HFD-
fed PiNKO mice compared to HFD-fed CTRL mice (p<0.05). 
0610038L08Rik BC018473 Faah Gm600 Mkl2 Slc22a5 
1110007C09Rik BC030499 Fadd Gm6086 Mpl Slc25a20 
1200014J11Rik C1s Fam171a1 Gm8234 Msi1 Slc25a22 
1700011F14Rik C2cd4a Fam18a Gm9442 Myl1 Slc35e4 
1700019E08Rik 
C330011F0
3 
Fam19a2 Gm9946 Myod1 Slc38a1 
1700067G17Rik 
C820005J03
Rik 
Fam5b Grin2d Ncapd2 Slc41a3 
1810012K16Rik Cadm4 Fam71f1 Gsto1 Ncr1 Slc6a5 
2300002M23Rik Ccdc146 Fancg Gucy1a2 Ndufs4 Slc6a8 
2310046A06Rik Ccl4 Fchsd1 Gucy2e Nfix Smyd1 
4632404H12Rik Ccnyl1 Fgf14 Hadha Nmur2 Snrpd2 
4732471J01Rik Cd80 Fgf16 Hbb-bh2 Olfr1100 Sowahb 
4921509C19Rik Cdh22 Fgfr4 Hck Olfr391-ps Spata21 
4921509C19Rik Cdkn1c Frmd5 Hddc3 Olfr479 Speer4e 
4921523A10Rik Cdkn2d G6pd2 Hepacam Olfr574 Ssxa1 
4921525B02Rik Chchd2 Gabbr2 Hexdc Olfr702 Ssxb1 
4930440C22Rik Chrm1 Gad2 Hlf Olfr884 Stfa2l1 
4930474M22Rik Cisd3 Gbe1 Hras1 Olfr951 Stmn3 
4930524N10Rik Cisd3 Glra1 Hsd17b4 Osbpl5 Stoml2 
4930583I09Rik Clic6 Gm10696 Ifitm6 Pcdhb7 Syne1 
4931403G20Rik Cnr1 Gm10839 Ikbke Pdk2 Taf7l 
4933422A05Rik Cox17 Gm10941 Il1rap Pex5l Tbx19 
4933434M16Rik Cox6b2 Gm11937 Il25 Pknox2 Tm6sf2 
5430421F17Rik Creb3l3 Gm12070 Inhbc Pla2g16 Tmem236 
5830473C10Rik Csmd1 Gm12070 Itih4 Plekha2 Tmem40 
A230077H06Rik Cyp2d13 Gm12356 Kif15 Plekhg6 Tmem79 
A430078I02Rik Cyp46a1 Gm12503 Kifc2 Plvap Tmem91 
Abcd3 D0H4S114 Gm12830 Kiss1r Ppcs Tmie 
Acaa2 
D630042P1
6Rik 
Gm13369 Klf4 Ppp1r32 Tspo 
Acad11 Dbil5 Gm13430 Klhl34 Ppp2r5c Tssk5 
Acadl Dcaf4 Gm13547 Klre1 Prickle1 Tyw1 
Acadvl Decr1 Gm13662 Krt42 Prl3a1 Ubac1 
Accn5 Dgkh Gm13941 Large Pstk Ube2d2b 
Acot11 Dhrs2 Gm14317 Ldlrad2 Pttg1 Uqcc 
Acot2 Dll1 Gm16701 LOC433944 Rab30 Vamp5 
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Acot3 Dmrt3 Gm17494 LOC434003 Rabep2 Vash1 
Adam6a Dnajb8 Gm17733 Lpin2 Rbpjl Vmn1r2 
Adcy2 Drd5 Gm17749 Lrrc39 Rcor3 Vmn1r212 
Agt Edil3 Gm19304 Lrrtm2 Rcvrn Vmn2r20 
Alyref2 Efcab4b Gm19462 Lypd3 Rdh8 Vmn2r93 
Apoa2 Eif4a3 Gm19747 Mettl21a Rhox4f Wnt8a 
Aqp9 Eno1 Gm20095 Mir184 Rubie Ypel4 
Arc Esp3 Gm20187 Mir1963 Sall4 Zbtb46 
As3mt Esrra Gm20279 Mir3473c Samsn1 Zeb2 
Atp2a1 Etfb Gm281 Mir466g Scarb2 Zfp146 
Atp5k Expi Gm4301 Mir5125 Siae Zfp319 
AW011738 F11 Gm5237 Mir744 Sla2 Zfp961 
AY358078 
F830002L21
Rik 
Gm5938 Mir92b Slc22a20 Zp4-ps 
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SI Table III – Sequences of primers used in this study 
Target gene Forward primer Reverse primer 
Acadl CCAGCTAATGCCTTACTTGGAGA GCAATTAAGAGCCTTTCCTGTGG 
Acadvl GTAGCCTCCATCCGAAGCTC CAGGCCCCCATTACTGATCC 
Acot2 AGTGCCTATGAAGGACTGAGG TCTTACGGCACTGGGGAATG 
Acot3 AGCTCTTGACCTTGTCTGTCTG GAGAAAGTTCAAGCAAACTGGG 
Agt GCAGGAGAGGAGGAACAGCCGA AGATGGCGAACAGGAAGGGGCT 
Atp5h GGGGGTCGGTGAAGTATCC AATTGCCTTCTGGTTTTGGGG 
Atp5k GCCAAGCGCTACAGTTACCTA GCCAGTTCTCTCTCAATCCGT 
Cox5a CCTGGGAATTGCGTAAAGGGA TAACCGTCTACATGCTCGCAA 
Cox7a1 TGTACAGACTGACCATGACGC GTGTCACTTCTTGTGGGGGAA 
Cpn1 AATTCCCCGACACCTGATGAC GGTGATGCCGTCTGGAAAGTA 
Cs CCCAGGATACGGTCATGCA GCAAACTCTCGCTGACAGGAA 
Dhcr7 AGGCTGGATCTCAAGGACAATG CAATGAATGGAGCGAAGAGCAG 
eEF2 ATACCTGCCTGTCAATGAGTCCTT CTGGCCGCCGGTGTT 
ERRα CGGTGTGGCATCCTGTGA CTCCCCTGGATGGTCCTCTT 
ERRβ CAGATCGGGAGCTTGTGTTC TGGTCCCCAAGTGTCAGACT 
ERRγ ACTTGGCTGACCGAGAGTTG GCAAGGGACAGTGTGGAGAA 
Fdft1 GTTCGTCAAGTGTCTAGGCCA GTGAGTCCTGGTCCATCTTGG 
Fh1 TGCTCTCAGTGCAAAATCCAA CGTGTGAGTTCGCCCAATT 
HkI ACAACGCCATCACTGGAATCT CAAGGAAACACCACTCCGACT 
Idh3a GCTGGTGGTGTTCAGACAGTAA CACTGAATAGGTGCTTTGGCAG 
Klk1 CAAGCTGGGGAGCACATGCCTA ACACTGGAGCTCATCTGGGTATTCA 
Lcad CCAGCTAATGCCTTACTTGGAGA GCAATTAAGAGCCTTTCCTGTGG 
Ldhb TAAGATGGTGGTGGACAGTGC GCATGGACTCGATGAGGTCAG 
Ndufa1 TCCACTGCGTACATCCACAAA CGTCTATCGCGTTCCATCAGA 
Ndufa4 AACCCAGAGCCATGGAACAAA AGTCTGGGCCTTCTTTCTTCAG 
Ndufb8 CAAGAAGTATAACATGCGAGTGGAA CCATACCCCATGCCATCATC 
Ndufs1 GTTTTGAGGGGTCAGGGAGAC TTCAACTTGCCCACTTCAACG 
Ndufs3 AAAGACTTTCCCCTCACTGGC AACTTGCGGAATTCTTGTGCC 
Nrf1 CTCTGCATCTCACCCTCCAAAC TCGCACCACATTCTCCAAAG 
Pfkm GGGGATCACCAATCTGTGTGT ATCATTCAGCAAGTCGCTCCA 
PGC-1α AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
PGC-1β CCATGCTGTTGATGTTCCAC GACGACTGACAGCACTTGGA 
PPARα ACAAGGCCTCAGGGTACCA GCCGAAAGAAGCCCTTACAG 
PPARβ/δ GCAAGCCCTTCAGTGACATCA CCAGCGCATTGAACTTGACA 
PPARγ CCCACCAACTTCGGAATCAG AATGCGAGTGGTCTTCCATCA 
PRC CACCCTGCCGGAGTGAAAT CGCATTGACTGCTGCTTGTC 
Ptgds GCTCCTTCTGCCCAGTTTTCC AGGAGGACCAAACCCATCCAC 
Ptges2 CCCAACGTGTACCGAACACCCG CTCCACAGCCCCAAACTTGCCC 
Ren1 AGGTAGCGACCCGCAGCATTAT ACCCCACAGACACCCCCTTCAT 
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Sdha GCTGGTGTGGATGTCACTAAGG CCCACCCATGTTGTAATGCA 
Slc12a7 (KCC4) GTACCACCTCAGGATCAGTGC ACCTCTGCTCCATCATTAGCG 
Slc17a4 (NPT1 Hom.) TGCAGAAAGCTGAGAAACCGA CTTCTTCTAAGGTCCAGCATCT 
Slc2a4 (GLUT4) GATGAGAAACGGAAGTTGGAGAGA GCACCACTGCGATGATCAGA 
Slc25a20 CTGCGCCCATCATTGGA CAGACCAAACCCAAAGAAGCA 
Slc34a2 (NaPi-2b) TCTACTTGTTCGTGTGCTCCC TTGTTGCTGAAGAACTGTCCG 
Slc43a2 (LAT4) CTCCTACCTGTGTACGAAGCC CATTCACCAGGCTCAACTCCT 
Slc8a1 (NCX1) GCATCTGCGTGTGTTCTTTGT CTTCCCAGACCTCCACAACTC 
Sqle TCTCCGTTTCTTCCCACTTCG ACTGGGGTTGACCAGAACAAG 
Tfam GGAATGTGGAGCGTGCTAAAA TGCTGGAAAAACACTTCGGAATA 
Uqcrfs1 CCTGAAGGGAAGAACATGGCT TAACTGGGACACTTCGACTGC 
Vegfa ATCATGCGGATCAAACCTCAC GGTCTGCATTCACATCTGCTG 
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5.1 - Discussion 
The kidneys are vital organs for the maintenance of systemic salt and water homeostasis, acid-base 
balance, blood pressure regulation and excretion of toxic substances and metabolic by-products.  This is 
achieved through an intricate system of plasma filtration and subsequent reabsorption of nutrients and 
ions along the renal nephron [Guyton and Hall 2000, Boron and Boulpaep 2003].  Trans-tubular transport 
is driven by a sodium gradient, generated by Na+-K+-ATPases in the basolateral membrane of the renal 
epithelium.  Transcellular transport in the kidney relies on ATP production through oxidative 
phosphorylation.  Hence, the kidney is one of the organs with the highest basal metabolic rate [Soltoff 
1986].  Mitochondrial dysfunction is appreciated as a central part of the etiology of several disorders 
affecting metabolic organs like skeletal muscle, liver and kidney [Pieczenik and Neustadt 2007].  
Mitochondrial cytopathies are closely associated with a reduced renal function, development of proximal 
tubulopathy and subsequent loss of both nutrients and ions in the urine [Niaudet 1998].  In recent years, 
several studies [Brooks et al. 2009, Tran et al. 2011, Funk and Schnellmann 2013, Lempiainen et al. 2013, 
Parikh 2013, Sharma et al. 2013] have demonstrated a strong association between mitochondrial 
dysfunction and renal disorders, such as diabetic nephropathy, sepsis and ischemia/reperfusion injury.  
Interestingly, treatments aimed at ameliorating disease progression in these disorders have been closely 
linked to a concurrent increase in renal mitochondrial function [Funk and Schnellmann 2013, Lempiainen 
et al. 2013].  Accordingly, these findings have sparked an interest in finding ways to ameliorate renal 
mitochondrial dysfunction associated with kidney pathologies.  In this context, PGC-1α might be a 
promising therapeutic target, considering its role as a master regulator of mitochondrial biogenesis and 
function [Liu and Lin 2011].  Additionally, this coactivator is highly expressed in the kidney [Puigserver et 
al. 1998, Larrouy et al. 1999] and its expression is reduced in several renal pathologies [Tran et al. 2011, 
Funk and Schnellmann 2013, Lempiainen et al. 2013].  Hence, PGC-1α might constitute a potential 
therapeutic candidate to ameliorate renal mitochondrial and metabolic disorders.  However, the role of 
PGC-1α in the kidney has not been conclusively investigated.  Thus, in the first part of this thesis we 
addressed this open question and accordingly studied the role of PGC-1α in the kidney and its impact on 
renal physiology.  Global- and tissue-specific knockout models for PGC-1α have been instrumental in 
elucidating the role of PGC-1α in various organs, such as heart [Arany et al. 2005], liver [Handschin et al. 
2005], skeletal muscle [Handschin et al. 2007a, Handschin et al. 2007b], brain [Ma et al. 2010], and white 
adipose tissue [Pardo et al. 2011].  Despite the high basal expression of PGC-1α and the oxidative 
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phenotype of the kidney, a renal-specific knockout model of PGC-1α has to this date not been published.  
One reason for this is likely due to technical reasons, since the heterogeneity of the renal cell population 
makes it difficult to target a transgene to all cells within the renal nephron.  However, in 2008, Traykova-
Brauch et al. published a study which provided an elegant solution to this problem [Traykova-Brauch et 
al. 2008].  The authors generated a transgenic mouse model, which expressed the reverse tetracycline-
dependent transactivator (rtTA) under the Pax8 promoter, thereby efficiently targeting it to all renal 
tubular cells [Traykova-Brauch et al. 2008].  When crossed with the transgenic LC1-Cre mouse line 
originally published by Schönig et al. [Schonig et al. 2002], this resulted in a mouse model with a 
doxycycline-inducible expression of Cre in all renal tubular cells.  We utilized this specific double-
transgenic mouse model to generate a nephron-specific, inducible PGC-1α knockout (PiNKO) mouse, with 
which we could study the role of PGC-1α in the kidney. 
After doxycycline induction, PiNKO mice were healthy and displayed no obvious aberrant systemic 
or renal phenotypes.  Transcriptome analysis of RNA extracted from whole kidney confirmed a significant 
reduction in PGC-1α-regulated metabolic gene programs, such as mitochondrial oxidative 
phosphorylation, TCA cycle and glycolysis.  These findings implicate an important role for PGC-1α in 
transcriptional regulation of mitochondrial processes in kidney, which is in agreement with the role of 
PGC-1α as a global transcriptional regulator of mitochondrial processes in other organs [Lin et al. 2004, 
Arany et al. 2005, Handschin et al. 2007b, Pardo et al. 2011].  Next, we investigated whether the 
reduction in renal mitochondrial biogenesis affected transcellular ion reabsorption.  This is a pertinent 
question, since inhibition of mitochondrial ATP-production has been shown to reduce transtubular 
transport activity in perfusion studies [Gullans et al. 1982].  Moreover, the loss of PGC-1α in PiNKO mice 
resulted in differential regulation of several mRNAs coding for transcellular transporters from both the 
solute carrier (SLC) and potassium transporter (KCN) families, which could further affect transtubular 
transport.  Intriguingly, PiNKO mice showed no major alterations in either salt or water handling, and only 
displayed a mild sodium-losing phenotype.  To challenge this aspect of renal physiology further, we 
decided to use two separate paradigms to stress the renal salt and water homeostasis in our mice; 
modulation of dietary salt intake and aging.  Altered dietary NaCl-intake leads to a drastic adaptation of 
renal tubular homeostasis and in extension increased tubular energy demand.  Indeed, low-NaCl diets 
have been suggested to boost renal energy metabolism to facilitate the increased transtubular transport 
activity needed to retain sufficient quantities of salts in the body [Siragy and Linden 1996, Klawitter et al. 
2012].  Interestingly, young PiNKO mice efficiently adapted to both reduced and increased dietary NaCl 
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loads.   Hence, despite a reduced mitochondrial transcription in PiNKO mice and an altered transcription 
of genes involved in transmembrane- and ion transport processes, PGC-1α is not necessary for 
maintaining renal ion and water homeostasis.  A reduced ability to adjust for altered dietary sodium intake 
is associated with aging in humans [Schlanger et al. 2010, Karam and Tuazon 2013].  Interestingly, in line 
with this, we detected a mild urinary sodium-loss in aged PiNKO mice and a concomitant impairment in 
the adaptation to a low-NaCl diet.  Hence, our data indicates that reduced expression of PGC-1α in the 
kidney during aging might result in a worsening of the renal phenotype as the mice age.  Importantly, PGC-
1α levels have been shown to be reduced in kidneys from aged mice [Lim et al. 2012].  Lim et al. 
demonstrated a significant reduction in renal PGC-1α levels at 24 month old mice compared to younger 
mice, and this was furthermore associated with a significant worsening of renal function and an increased 
renal damage [Lim et al. 2012].  Interestingly, it has been shown that calorie restriction or treatment with 
the PPARγ agonist Pioglitazone ameliorates renal injuries and improves mitochondrial function in aged 
mice [Yang et al. 2009, Kume et al. 2010].  Both calorie restriction and thiazolidinedione treatment are 
known to increase PGC-1α activity [Nisoli et al. 2005, Hondares et al. 2006] and elevated PGC-1α activity 
could therefore have a protective role in the kidney during aging.  Despite extensive research on the 
connection between PGC-1α and aging-related injuries such as sarcopenia in muscle and 
neurodegenerative disorders in brain [Wenz 2011, Dillon et al. 2012], little is known how PGC-1α 
influences aging-related dysfunctions in the kidney.  Hence, based on our findings that PGC-1α is a 
regulator of metabolic and mitochondrial processes in the kidney, an important future direction would be 
to elucidate the role of PGC-1α in aging-related renal dysfunction.  This could be achieved through a series 
of experiments designed to investigate the protective role of PGC-1α in aging-related renal dysfunction.  
The initial aim of such a study would be to map renal PGC-1α expression and oxidative function in aging 
mice and to correlate these parameters with aging-related alterations in blood pressure regulation, renal 
salt and water homeostasis as well as proteinuria and glomerular permselectivity.  This would be 
complemented with post mortem histological and molecular analysis of the kidneys.  A good age-span of 
the groups would be to use 3, 12 and 24 month old mice, which would represent young adult mice and 
two separate aging time points.  Since we detected a progressive impairment in the adaptation to altered 
dietary salt intake in PiNKO mice in our study, this indicates that loss of PGC-1α and the concomitant 
reduction in mitochondrial gene transcription could sensitize the kidneys to aging-related dysfunction.  
Hence, it would be imperative to perform the above-mentioned experiments in control and PiNKO mice.  
Such a setup would allow a closer examination of the relationship between mitochondrial dysfunction and 
renal impairment during aging and whether these pathological alterations are accelerated upon loss of 
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renal PGC-1α expression.  Ultimately, for a deeper mechanistic insight, it would be interesting to use the 
PiNKO model to examine whether PGC-1α is necessary to mediate the beneficial effects of calorie 
restriction and thiazolidinedione treatment on renal parameters in aged mice. 
The orphan nuclear receptor ERRα is an established transcriptional partner of PGC-1α [Mootha 
et al. 2004].  Importantly, in our microarray data, ERRα was predicted to be one of the top transcription 
factors with a reduced activity in kidneys from PiNKO mice compared to CTRL mice.  This indicates that 
ERRα is a transcriptional partner of PGC-1α in the kidney.  Interestingly, in a study by Tremblay et al. global 
deletion of ERRα was associated with altered transcriptional regulation of several genes involved in ion 
homeostasis and blood pressure regulation in kidney [Tremblay et al. 2010].  In this study, global ablation 
of ERRα led to a hypotensive phenotype associated with reduced urinary sodium excretion in mice 
[Tremblay et al. 2010].  Surprisingly, even though ERRα levels were also reduced in the kidney of PiNKO 
mice, these mice displayed an opposite phenotype as compared to ERRα knockout mice.  This dichotomy 
was also evident at the transcriptional level, since several differentially regulated genes in the global ERRα 
knockout mice (Ptgds, Agt, Slc34a2, and Slc22a4) [Tremblay et al. 2010] were regulated in an opposite 
direction in the kidney of PiNKO mice.  These differences could originate from ERRα-independent effects 
in PiNKO mice, or simply through compensatory mechanisms due to the systemic ablation of ERRα in the 
study by Tremblay et al.  An outstanding question would thus be to elucidate the transcriptional networks 
regulated by PGC-1α-ERRα interactions in renal tubular cells.  These experiments would preferably be 
done in an in vitro setup to avoid compensatory effects originating from other cell types within the kidney 
or other organs.  Considering the high expression of PGC-1α together with the high basal oxidative 
capacity of proximal tubule cells, this cell type would be the preferable model to use.  Overexpression of 
PGC-1α in proximal tubule cells would identify a transcriptional signature of PGC-1α-regulated genes in 
this cell type.  When combined with knockdown or pharmacological inhibition of ERRα, this would yield a 
subgroup of genes regulated by PGC-1α together with ERRα.  Transcriptome analysis of these two gene 
signatures and subsequent GO-analysis would reveal the functional annotations of PGC-1α/ERRα-
regulated genes in proximal tubule cells.  This would allow the identification of cell autonomous 
transcriptional networks of PGC-1α and ERRα in proximal tubule cells associated with energy metabolism, 
renal ion homeostasis and blood pressure regulation.  Importantly, such an approach can be extended to 
other renal cell types or transcriptional partners of PGC-1α.  Considering the complex organization of the 
kidney, in vitro approaches are essential to map the molecular mechanisms through which PGC-1α 
regulates renal transcription in a specific cell type.  Ultimately, these findings could be validated in an in 
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vivo setting, for example through the use of the PiNKO mouse model to specifically study the effect of 
PGC-1α deletion in a specific nephron segment.  Microdissection techniques could be used to excise 
specific regions of the nephron for molecular analysis and immunohistological and enzymatic stainings 
could be applied to whole kidney sections to study alteration induced by PGC-1α deletion.  There are also 
several nephron segment-specific drugs (i.e. loop diuretics, thiazides, amiloride) which modulate salt and 
water homeostasis in the kidney by acting only on certain parts of the nephron [Brenner and Stevens 
2013].  Hence, these diuretic drugs could be useful tools to modulate salt and water homeostasis only in 
specific nephron segments in PiNKO mice and would allow us to study the role of PGC-1α specifically on 
these localized processes. 
Obesity is associated with a reduced mitochondrial function in several organs [Patti et al. 2003, 
Boudina et al. 2005, Sparks et al. 2005, Sivitz and Yorek 2010]. However, this phenomenon has not been 
extensively studied in the kidney.  Hence, in the second part of this study we focused on metabolic 
adaptation in the kidney occurring during diet-induced obesity and how this is influenced by the loss of 
PGC-1α.  Five months of HFD-feeding did not lead to any major changes in renal mitochondrial 
transcription.  Despite a differential regulation (p<0.05, fold-change >1.2) of 1467 genes in kidney with 
HFD-feeding, none of these genes were primarily associated with GO-categories representing 
mitochondrial function or oxidative phosphorylation.  Furthermore, HFD-feeding led to a small decrease 
in PGC-1α levels in kidney and only a small number of PGC-1α-target genes associated with oxidative 
phosphorylation were affected by HFD-feeding in CTRL mice.  Hence, our data demonstrates that diet-
induced obesity does not affect transcription of mitochondrial genes in the kidney.  This finding is 
corroborated by a study from Ruggiero et al. from 2011, which shows that HFD-feeding does not alter 
mitochondrial oxidative function or biogenesis in kidney [Ruggiero et al. 2011].  However, the authors of 
this study detected increased oxidative stress and signs of renal dysfunction, such as fibrosis and 
glomerular hypertrophy with HFD-feeding.  Interestingly, in our study we detected a significant increase 
in glomerular hypertrophy in HFD-fed PiNKO mice compared to CTRL mice (Figure 1).  While, these 
alterations did not lead to an exacerbated proteinuria in PiNKO mice (unpublished data), this finding 
suggests that the overall renal health with HFD-feeding is significantly worsened in the absence of PGC-
1α.  A likely explanation for the worsened renal phenotype in HFD-fed PiNKO mice could be an increased 
susceptibility to renal lipotoxicity.  We demonstrated that renal PPARα-signaling and several known 
PPARα target genes involved in fatty acid oxidation were increased in kidneys of HFD-fed CTRL mice, which 
could represent an adaptive mechanism to cope with increased circulating levels of fatty acids.   
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Importantly, this induction was blunted in the absence of PGC-1α, which demonstrates a role for 
PGC-1α in the transcriptional regulation of renal PPARα-signaling and fatty acid metabolism.  This is in line 
with the known role of PGC-1α as a coactivator of PPARα-transcription [Vega et al. 2000].  Importantly, 
several recent studies using PPARα-knockout mice and/or pharmacological PPARα agonists [Park et al. 
2006, Kamijo et al. 2007, Shin et al. 2009, Tanaka et al. 2011] have shown that PPARα signaling is 
important for the protection against renal lipotoxicity and inflammation.  Hence, it will be of interest in 
future studies to elaborate on our current findings and further elucidate the importance of PGC-1α/PPARα 
signaling in protection against renal lipotoxicity.  This could be achieved through an experimental model 
of fatty acid-induced renal damage such as albumin overload [Kamijo et al. 2002].  Increased circulating 
levels of albumin lead to impaired glomerular permselectivity and thereby an increased urinary filtration 
of albumin.  Moreover, BSA-bound fatty acids have been demonstrated to elicit pathological alteration in 
proximal tubule cells, such as increased apoptosis and tubulointerstitial inflammation and fibrosis [Kamijo 
et al. 2002, Tanaka et al. 2011].  Importantly, pharmacological activation of PPARα has been shown to 
protect against both HFD- and BSA-induced renal lipotoxicity in mice [Tanaka et al. 2011].  Considering 
that several PPARα target genes displayed a blunted induction in HFD-fed PiNKO mice in our study, it 
would be interesting to perform a BSA-loading experiment in PiNKO mice.  We could thereby evaluate 
whether the loss of PGC-1α and hence a blunted induction of PPARα target genes would lead to 
exacerbated lipotoxic injury in the kidney.  This setup would provide a controlled and more potent 
lipotoxic stimuli than HFD feeding, especially since fatty acid-depleted BSA can be used as a control for 
these experiments.  Hence, this setup would allow us to characterize the direct effect of PGC-1α deletion 
Figure 1 - HFD-fed PiNKO mice 
display exacerbated glomerular 
hypertrophy 
Glomerular tuft area was quantified in 
periodic acid–schiff (PAS)-stained kidney 
cross-sections from chow- or HFD-fed 
CTRL and PiNKO mice.  Error bars 
represent mean ±SEM. Significant 
differences (p value < 0.05) between CTRL 
and PiNKO mice are indicted by an 
asterisk (*), and between chow-fed and 
HFD-fed groups are indicated by a 
number-sign (#). 
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on the sensitivity of the kidney to a lipotoxic stimuli.  In this context, CTRL and PiNKO mice would also be 
treated with the PPARα agonist fenofibrate, which has been demonstrated to ameliorate renal lipotoxicity 
[Tanaka et al. 2011].  This would help to provide mechanistic insight into how PGC-1α/PPARα signaling 
influences the protection against renal lipotoxicity.  These findings could eventually be applied to a more 
clinically relevant model of renal lipotoxicity, such as HFD-feeding and obesity, with the ultimate goal of 
developing therapeutic strategies to protect against fatty acid induced renal damage in obese and diabetic 
patients.  In our current study, we have focused mainly on functions associated with the renal tubular 
system.  However, another important component of basal renal function is the glomerulus, which largely 
consists of three distinct cell types, namely endothelial cells, mesangial cells and podocytes.  Podocytes 
are highly specialized cells found within kidney glomeruli and their foot processes play an integral role in 
the establishment and maintenance of the glomerular filtration barrier [Miner 2011].  This filtration 
barrier prevents loss of proteins and larger blood constituents into the urine.  Importantly, increased 
urinary protein excretion is a well-established prognostic risk factor for kidney disease progression in 
humans [Abbate et al. 2006].  Podocytes have a lower mitochondrial number compared to the 
surrounding proximal tubules and thus also express lower levels of PGC-1α (unpublished observation).  
However, despite its low basal expression, PGC-1α has been shown to play an important role in the 
response to podocyte injury.  Podocyte injury induced through experimental obesity/diabetes [Bao et al. 
2014] or through administration of adriamycin [Zhu et al. 2014] or aldosterone [Yuan et al. 2012a] has 
been associated with reduced PGC-1α levels and mitochondrial transcription in podocytes.  
Overexpression of PGC-1α in podocytes was furthermore sufficient to rescue mitochondrial function in 
response to both adriamycin- and aldosterone treatment in this cell-type [Yuan et al. 2012b, Zhu et al. 
2014].  These findings point towards an important therapeutic potential of increased PGC-1α-activity in 
podocytes.  However, PGC-1α has also been shown to mediate high-glucose induced apoptosis in cultured 
podocytes [Kim and Park 2013].  Therefore, in the context of using PGC-1α as a therapeutic target to 
ameliorate glomerular disorders, it is crucial to gain a full understanding of the role of PGC-1α in podocytes 
and glomerular function.  Hence, we were also interested in elucidating the role of PGC-1α in podocyte 
function and structural integrity.  To this end, we generated podocyte-specific PGC-1α knockout (PoPKO) 
mice by crossing mice expressing Cre under a podocyte-specific promoter (podocin; NHPS2-Cre) [Moeller 
et al. 2003] with mice harboring floxed PGC-1α alleles (PGC-1αfl/fl) [Lin et al. 2004].   
At 10 weeks of age, PoPKO mice did not display any significant differences in either body- or 
kidney weight (FIG 2A-B), and did not show any alterations in food intake, water intake or urine output 
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over 24 hours (FIG 2C).  To evaluate the function of the renal filtration barrier, we measured urinary 
protein excretion in PoPKO and CTRL mice.  Proteinuria is an important read-out of defects in glomerular 
permselectivity and increased urinary protein excretion is closely associated with early glomerular 
dysfunction in both rodents and humans [Miner 2011].  Intriguingly, we detected a strong trend towards 
increased absolute protein content in the urine of PoPKO mice compared to CTRL mice (FIG 2D).  This 
difference was still evident when protein levels were normalized to urinary creatinine levels (/crea) (FIG 
2D), indicating that this phenotype was not due to a general increase in urinary flow rate.  Next, we 
measured albumin and total protein levels in plasma and found no differences between PoPKO and CTRL 
mice (FIG 2E).  Consequently, these data point towards a mild defect in permselectivity in young PoPKO 
mice.  To stress podocyte function, we performed a BSA-loading experiment, where mice are injected with 
high levels of BSA which leads to acute glomerular and tubular damage [Yoshida et al. 2008].  
Interestingly, one day after BSA injection, PoPKO mice displayed reduced levels of both creatinine (FIG 2F) 
and total protein (FIG 2G) in the urine compared to CTRL mice.  These findings point towards a reduced 
glomerular filtration rate, which is a predictor of reduced glomerular function in PoPKO mice.  Next we 
performed adriamycin-injections in a small pilot group of CTRL and PoPKO mice.  Adriamycin-induced 
nephropathy is an established model of progressive glomerulosclerosis in mice [Okuda et al. 1986, Lee 
and Harris 2011].  Intriguingly, at 4 weeks post-injection, PoPKO mice displayed a strong trend towards 
reduced urinary creatinine and total protein levels (FIG 2H).  Moreover, both urinary uric acid and 
urea/blood urea nitrogen (BUN) levels were reduced in PoPKO mice, while they remained unchanged 
when normalized to urinary excretion of creatinine (FIG 2I).  Taken together, these data indicate that the 
ablation of PGC-1α in podocytes increases the susceptibility of podocytes to BSA-loading and adriamycin-
induced podocyte damage.  This is furthermore in line with the protective effect of PGC-1α overexpression 
in primary podocytes treated with adriamycin [Zhu et al. 2014] and could be linked to a protective effect 
of PGC-1α against the development of glomerulosclerosis.  Although preliminary, our findings regarding 
the role of PGC-1α in glomerular function are promising and this project is currently being pursued by 
another member of our lab.  Considering the reduced glomerular PGC-1α levels associated with several 
glomerular disease states [Yuan et al. 2012b, Bao et al. 2014, Zhu et al. 2014], our mouse model will 
provide an important tool to assess the causal link between reduced podocyte PGC-1α levels and 
glomerular dysfunction.  Further experiments are needed to expand upon the basal renal phenotype of 
the PoPKO mouse model.  We did not find any major alterations in renal function in young PoPKO mice 
(10 weeks).  However, glomerular function declines with age in both rodents and humans [Wiggins 2009] 
and it is thus imperative to study the function of the glomerular filtration barrier in old PoPKO mice.  
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Further experiments should preferably expand on our work on BSA- and adriamycin-induced 
nephropathy, especially considering the recent study by Zhu et al. were PGC-1α was shown to have a 
protective effect against adriamycin-induced damage in cultured podocytes [Zhu et al. 2014].  Hence, it 
would be interesting to induce glomerular damage in PoPKO mice through systemic administration of 
either adriamycin, puromycin aminonucleoside (PAN) or lipopolysaccharides (LPS).  This would be 
followed by analysis of urinary protein content, glomerular morphology and ultrastructure as well as an 
assessment of general pathological renal markers such as fibrosis and inflammation.  These experiments 
would indicate whether the loss of PGC-1α in podocytes sensitizes the glomerulus to these damaging 
stimuli and whether there is a causal link between reduced podocyte PGC-1α levels and glomerular 
dysfunction.  Another important issue would be to study the role of PGC-1α in the protection against 
podocyte lipotoxicity during HFD-feeding or during acute lipotoxicity such as encountered with BSA-
loading.  For these specific experiments, it would be interesting to monitor the maintenance of the 
glomerular filtration unit by measuring urinary protein content.  Subsequent molecular analysis would 
help to unravel whether loss of PGC-1α specifically in podocytes increases the susceptibility of the kidney 
to lipotoxic stimuli and thereby results in pathological alterations in glomerular and tubulointerstitial 
morphology and inflammation.  Further characterization of the PoPKO mouse model generated during 
the scope of this thesis will hopefully help to form a more comprehensive picture of the role of PGC-1α in 
podocytes.  These findings, together with the data generated from the PiNKO mouse model, will help to 
increase our understanding of the complex role of PGC-1α in renal physiology. 
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Figure 2 - Podocyte-specific PGC-1α knockout (PoPKO) mice display minor impairments in glomerular filtration 
(A)  Body weight of CTRL and PoPKO mice at 10 weeks (n=8-9).  (B)  Kidney weight normalized to body weight (n=3).  (C)  
Food intake, water intake and diuresis over 24 hours (n=8).  (D)  Urinary excretion of protein over 24 hours, absolute 
levels and total protein levels normalized to creatinine excretion (/crea) (n=8).  (E) Levels of albumin and total protein in 
plasma (n=8).  Urinary levels of (F) creatinine and (G) and total protein in CTRL and PoPKO mice before BSA injection (d0) 
and after BSA injection (d1) (n=4).  Urinary levels of (H) creatinine, total protein and (I) uric acid and urea/blood urea 
nitrogen (BUN) in CTRL and PoPKO mice 4 weeks after a single i.v. adriamycin injection (n=2).  Error bars represent mean 
±SEM. Significant differences (p-value <0.05) between CTRL and PoPKO mice are indicated by an asterisk (*). 
5.  The role of PGC-1α in kidney – Discussion and future perspectives 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
98    
5.2 – Future perspectives  
In the present study, we have generated and characterized a novel knockout model of PGC-1α in the 
kidney.  Transcriptome analysis confirmed that loss of PGC-1α in the kidney leads to a down-regulation of 
gene programs encoding mitochondrial and metabolic processes.  These findings are in agreement with 
the role of PGC-1α in other metabolic organs [Liu and Lin 2011], and underscores the importance of PGC-
1α as a global transcriptional regulator of mitochondrial metabolism.  Ablation of PGC-1α also led to an 
altered transcription of several genes belonging to the solute carrier (SLC) family, and the KCN-family of 
potassium transporters.  In addition, tubular reabsorption is a highly ATP-dependent process, and 
impaired mitochondrial ATP-production can inhibit transcellular transport [Gullans et al. 1982].  However, 
despite the ablation of PGC-1α in the kidney, PiNKO mice could efficiently correct their salt- and water 
reabsorption in response to either increased or decreased NaCl intake.  Hence, PGC-1α is not necessary 
for the regulation of renal salt and water homeostasis.  Further studies are needed to elucidate whether 
PGC-1α plays a regulatory role in other renal processes such as gluconeogenesis or vitamin D-
activation/calcium signaling.   
In our microarray data, ERRα was predicted to be one of the main transcription factors with a 
reduced activity in kidneys from PiNKO mice.  Our data furthermore shows that PGC-1α is necessary for 
the transcriptional induction of PPARα and PPARα-target genes in kidney during diet-induced obesity.  
ERRα and PPARα are established transcriptional partners of PGC-1α in the regulation of mitochondrial and 
metabolic processes [Vega et al. 2000, Huss et al. 2002].  However, both of these transcription factors 
have been shown to play an important role also in salt-handling and blood pressure regulation in the 
kidney [Obih and Oyekan 2008, Tremblay et al. 2010, Lee et al. 2011].  It would thus be of importance to 
elucidate the full transcriptional networks of both PGC-1α/ERRα and PGC-1α/PPARα in the kidney, to 
determine the functional outcome of these coactivator-transcription factor interactions.  Moreover, PGC-
1α is known to regulate gene programs in a tissue specific manner, through interactions with certain 
transcription factors.  One such example is the induction of hepatic gluconeogenesis through interaction 
with HNF4A [Yoon et al. 2001].  It would thus be interesting to investigate whether such tissue-specific 
PGC-1α-TF interactions might also exist in the kidney and which processes are accordingly regulated 
through these transcriptional networks.  One important aspect to consider for these experiments would 
be to differentiate between the different compartments of the nephron, in particular since it has been 
shown that the kidney displays a heterogeneous TF-expression pattern in different nephron segments 
[Krid et al. 2012].  Hence, the transcriptome analysis performed in our study provides a broad overview 
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of the transcriptional programs regulated by PGC-1α in the kidney and its impact on renal physiology.  
However, future studies would benefit from focusing on the transcriptional networks regulated by PGC-
1α in certain cell types or compartments of the nephron.  This could be achieved by performing microarray 
analysis of different microdissected nephron segments such as proximal tubules, loop of henle, distal 
tubules and collecting ducts.  For further molecular analysis and target validation, in vitro models of the 
specific cell types contained within these renal compartments could be utilized.  Transgenic mice with Cre-
expression targeted to a specific tubular cell type or compartment could also be utilized to knock out PGC-
1α in specific nephron segments.  While microdissection would still be needed to analyze the molecular 
events occurring in one specific subcompartment of the nephron, such mouse models would aid in 
interpreting the functional outcome of a PGC-1α deletion in a specific renal cell type.  
A causal link has been suggested between aberrant mitochondrial function and renal dysfunction 
[Niaudet 1998, Rahman and Hall 2013, Che et al. 2014].  This connection is underscored by the prevalence 
of renal tubular dysfunction in patients suffering from mitochondrial cytopathies [Emma et al. 2011].  
Moreover, sepsis-induced renal dysfunction has been associated with reduced mitochondrial function, 
and this phenotype was furthermore exacerbated in the absence of renal PGC-1α [Tran et al. 2011].  Our 
data demonstrate an essential role for PGC-1α in mitochondrial transcription and PGC-1α could therefore 
be an important therapeutic target to ameliorate renal disorders.  However, further studies are needed 
to elucidate the therapeutic potential of PGC-1α activation in a renal setting.  Generation of a transgenic 
mouse model overexpressing PGC-1α in the kidney would be an important tool to study the protective 
effects of PGC-1α in different renal disorders and in the context of aging.  Characterization of such a 
transgenic mouse model would also give a broader insight into which transcriptional programs and renal 
functions are directly regulated by PGC-1α in the kidney, especially when compared directly to the renal 
transcriptional profile of PiNKO mice generated in our current study.  While transgenic mouse models are 
important tools to elucidate the therapeutic potential of a protein, it is also essential to find ways to 
modulate these pathways through administration of pharmacological compounds or through dietary 
means.  The SIRT1-activating compounds resveratrol and SRT1720 have both been shown to elicit 
protective effects in renal disorders [Funk and Schnellmann 2013, Pan et al. 2014] and ketogenic diet 
feeding has also been reported to ameliorate diabetic nephropathy in mice [Poplawski et al. 2011].  These 
interventions have all been suggested to increase PGC-1α transcription and activity.  Treatment of PiNKO 
mice with either resveratrol or SRT1720 would allow to evaluate the specific requirement of tubular PGC-
1α for the protective effects of these compounds in association with experimental renal pathologies, such 
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as ischemia/reperfusion injury, endotoxemic injury or diabetic nephropathy, amongst others.  A similar 
setup could be used to test the requirements of PGC-1α in the protection against diabetic nephropathy 
elicited by ketogenic diet feeding.  These experiments will help to elucidate the role of PGC-1α as a 
molecular effector of these interventions and the eligibility of using PGC-1α as a therapeutic target to 
treat renal pathological alterations in human patients.   
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6.  Introduction to skeletal muscle physiology  
6.1 - Skeletal muscle and PGC-1α 
Skeletal muscle is the largest organ in the body (~40% of body weight) and in a sedentary state it accounts 
for 20-30% of the resting energy expenditure [Summermatter and Handschin 2012, Egan and Zierath 
2013].  Skeletal muscle thus contributes less to the resting energy expenditure than brain, kidney and 
heart [Muller et al. 2013].  However, during maximal physical activity, skeletal muscle can account for up 
to 90% of whole body energy expenditure [Zurlo et al. 1990], and ATP-turnover rates within the muscle 
can rise up to 100-fold over basal levels [Egan and Zierath 2013].  Skeletal muscle thus displays a high 
degree of metabolic plasticity, and exerts a significant impact on whole body metabolism in response to 
exercise. Hence, increased physical activity is acknowledged as an important approach to prevent and 
treat obesity and related metabolic disorders [Booth et al. 2012].  However, 30% of the global adult 
population are estimated to be physically inactive [Hallal et al. 2012] and a sedentary life-style is 
associated with a higher incidence of chronic non-communicable diseases such as cardiovascular diseases, 
diabetes and cancer [Booth et al. 2012, Egan and Zierath 2013]. 
 Skeletal muscle fibers are categorized as either oxidative/glycolytic or slow-twitch/fast-twitch 
based on their metabolic and contractile properties.  This is however an over-simplification considering 
the heterogeneous nature and plasticity of the mammalian skeletal muscle.  Human skeletal muscle 
contains 3 major fiber types; type I, type IIa and type IIx, while mouse skeletal muscle also contains a 
fourth sub-category, type IIb.  This categorization is based on the predominant expression pattern of 
myosin heavy-chains (MyHC)-I, MyHC-IIa, MyHC IIx or MyHC-IIb in the respective muscle fibers [Schiaffino 
and Reggiani 2011].  Type I fibers are generally found in postural muscles like the soleus, and are 
characterized as slow-twitch fatigue-resistant oxidative fibers, which are also often found in elite 
endurance athletes.  These fibers are red in appearance due to their high myoglobin content, and muscles 
rich in type I fibers display a high mitochondrial content and high basal expression of PGC-1α [Schiaffino 
and Reggiani 2011, Yan et al. 2011, Wilson et al. 2012].  Also type IIa fibers have a high mitochondrial 
content, however, these fibers are characterized as fast-twitch due to their contractile properties.  Type 
IIx and IIb fibers are considered to be glycolytic fast-twitch fibers, with a lower expression of PGC-1α, and 
a fatigue-prone phenotype compared to type I and IIa fibers [Lira et al. 2010, Schiaffino and Reggiani 
2011].  One debated aspect of skeletal muscle plasticity is the concept of true fiber-type switching [Booth 
et al. 2010, Wilson et al. 2012], which is the transformation of type II fibers into type I fibers in response 
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to exercise or other stimuli.  However, irrespective of any changes in MyHC composition, it is well 
established that skeletal muscle can attune its oxidative and functional capacity in response to different 
exercise modalities.  Endurance exercise is characterized by high-repetition, low-resistance muscle 
contractions, while resistance exercise denotes a low-repetition, high-resistance load on the muscle [Egan 
and Zierath 2013].  Resistance exercise elicits a shift from type IIb to IIa fibers, and results in a hypertrophic 
response characterized by increased protein synthesis rates, increased muscle fiber cross-sectional area 
and enhanced force generation [Booth and Thomason 1991, Fry 2004].  Endurance exercise on the other 
hand leads to a higher proportion of type IIa fibers in the muscle bed compared to type IIX/IIb fibers 
[Schiaffino and Reggiani 2011], and increases mitochondrial content, neovascularization and oxidative 
metabolism in the muscle without eliciting any significant hypertrophic effect on the muscle [van Wessel 
et al. 2010].  It is well known that repeated bouts of endurance exercise provokes an adaptive shift in 
skeletal muscle physiology towards a more oxidative, slow-twitch phenotype.  These exercise adaptation 
includes angiogenesis, mitochondrial biogenesis, improved lactate handling and a shift in substrate 
utilization, leading to a higher reliance of fat oxidation during submaximal exercise [Holloszy and Coyle 
1984, Hawley 2002].  Importantly, exercise training leads to increased PGC-1α expression and activity in 
skeletal muscle [Pérez-Schindler and Handschin 2013], and this is an important factor for the adaptive 
response of skeletal muscle to exercise. 
The versatile role of PGC-1α in skeletal muscle 
Perturbation of skeletal muscle homeostasis during a muscle contractions induces a range of 
mechanical, neurological, metabolic and endocrine signals, which elicit an adaptive response to exercise 
within the muscle, but also in other organs.    Importantly, many of these signaling pathways converge on 
PGC-1α (Figure 1A-B), making this coactivator an important transcriptional regulator of skeletal muscle 
adaptation [Svensson and Handschin 2014].  Induction of PGC-1α in skeletal muscle in response to 
exercise is postulated to depend on both exercise intensity and modality.  It was recently shown that 
resistance exercise leads to an induction of the truncated PGC-1α-isoform, PGC-1α4 in human skeletal 
muscle.  In addition, overexpression of PGC-1α4 in skeletal muscle elicits a hypertrophic response in 
transgenic mice [Ruas et al. 2012].  Contrariwise, full length PGC-1α does not influence the hypertrophic 
response in skeletal muscle [Perez-Schindler et al. 2013].  However, a recent study by Ydfors et al. could 
demonstrate that both PGC-1α4 and full length PGC-1α were induced in human skeletal muscle in 
response to an acute bout of either endurance or resistance exercise [Ydfors et al. 2013].  Hence, more 
research is needed to elucidate the exact contribution of the various PGC-1α isoforms and splice variants 
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to skeletal muscle adaptation during different exercise modalities.  Both resistance and endurance 
exercise elicits strong transcriptional responses in human skeletal muscle [Timmons et al. 2005, Stepto 
et al. 2009, Catoire et al. 2012].  Global expression profiling furthermore reveal an induction of gene 
programs coding for mitochondrial function and fat oxidation specifically in response to endurance 
exercise training [Stepto et al. 2009].  Importantly, both of these genetic programs are known to be 
activated by PGC-1α in skeletal muscle.  PGC-1α have been shown to be involved in the regulation of 
several gene programs involved in metabolic as well as functional adaptation of skeletal muscle.  
Overexpression of PGC-1α specifically in skeletal muscle leads to a shift towards an oxidative fiber type 
[Lin et al. 2002] and improved skeletal muscle refueling (Figure 1A) [Wende et al. 2007, Summermatter 
et al. 2010].  Moreover PGC-1α have been shown to regulate several processes important for exercise 
adaptation in skeletal muscle, such as angiogenesis [Arany et al. 2008], fatty acid transport and β-
oxidation [Gerhart-Hines et al. 2007, Summermatter et al. 2011], mitochondrial biogenesis and function 
[Lin et al. 2002, Handschin et al. 2007b], autophagy [Lira et al. 2013], calcium signaling [Summermatter 
et al. 2012], lactate metabolism [Summermatter et al. 2013a], neuromuscular junction reprogramming 
[Handschin et al. 2007c, Arnold et al. 2014], and myokines secretion [Bostrom et al. 2012, Rao et al. 
2014]. Activation of PGC-1α in the context of exercise is thus important for the transcriptional activation 
of several gene programs necessary for adaptation of skeletal muscle to endurance exercise training.  
Hence, it is important to understand how PGC-1α is activated in skeletal muscle in response to exercise. 
PGC-1α and exercise adaptation 
PGC-1α transcription in skeletal muscle is activated through similar signaling pathways 
responsible for PGC-1α-activation in other metabolic organs (as discussed in chapter 1).  One important 
signaling pathway responsible for induction of PGC-1α during muscle contractions is p38 MAPK signaling.  
Specifically, the p38γ MAPK isoform was shown to be important for the increased PGC-1α transcription 
and mitochondrial function in response to exercise [Pogozelski et al. 2009].  Constitutive activation of p38 
MAPK in skeletal muscle is associated with enhanced PGC-1α and mitochondrial protein levels, and ATF2 
was shown to be an important mediator of this effect [Akimoto et al. 2005].  P38 MAPK phosphorylates 
and activates ATF2 and MEF2 in response to exercise, thereby increasing PGC-1α transcription [Zhao et 
al. 1999, McGee and Hargreaves 2004, Akimoto et al. 2005].  Importantly, enhanced p38 MAPK activity 
in response to exercise is dependent on the generation of reactive oxygen species (ROS), since 
pharmacological inhibition of xanthine oxidase in rats blocked the activation of p38 MAPK in response to 
exercise [Gomez-Cabrera et al. 2005].  In line with this, antioxidant treatment in mice and humans was 
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sufficient to block induction of PGC-1α in skeletal muscle during exercise [Ristow et al. 2009, Meier et al. 
2013], and ROS-treatment in cultured myotubes led to an increased transcription of PGC-1α [Silveira et 
al. 2006].  ROS generation furthermore activates the TF; hypoxia-inducible factor 1 alpha (HIF-1α), which 
is also activated in response to reduced intracellular oxygen levels [Shoag and Arany 2010].  Once 
activated, HIF-1α binds to hypoxia response elements in the nucleus and regulates transcription of gene 
programs involved in angiogenesis and glycolysis. [Egan and Zierath 2013].  However, also PGC-1α 
regulates angiogenesis during exercise, and this was shown to occur through a HIF-1α-independent, ERRα-
dependent mechanism [Arany et al. 2008].  PGC-1α was also recently shown to regulate transcription of 
hypoxic response genes in muscle cells through the TF activator protein 1 (AP1) [Baresic et al. 2014]. 
During muscle contractions, oscillations in intracellular calcium levels are essential for myofibrillar 
contraction.  Calcium also activates PGC-1α transcription through activation of calcium/calmodulin-
dependent protein kinases (CaMK) and calcineurin A (CnA) signaling.  CnA activation enhances PGC-1α -
transcription through dephosphorylation and activation of MEF2 [Handschin et al. 2003], and 
Figure 1 - Upstream regulation of the PGC-
1α promoter, and biological processes 
regulated by PGC-1α in skeletal muscle 
(A) Downstream targets regulated by PGC-
1α in skeletal muscle and (B) signaling 
mechanisms responsible for activation of 
PGC-1α transcription in response to 
exercise. Adapted from (A) [Summermatter 
and Handschin 2012] and (B) [Egan et al. 
2010] 
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overexpression of CnA in skeletal muscle is associated with increased PGC-1α transcription [Ryder et al. 
2003].    Also overexpression of CaMKIV in skeletal muscle leads to an enhanced transcription of PGC-1α 
and mitochondrial genes [Wu et al. 2002].  However, neither inhibition of CnA activity nor knockout of 
CaMKIV influenced the induction of PGC-1α or mitochondrial proteins in response to exercise [Akimoto 
et al. 2004, Garcia-Roves et al. 2006], indicating that these proteins are not essential for exercise-induced 
PGC-1α transcription.  CaMKII is the predominant CaMK-isoform in skeletal muscle, and during exercise it 
is activated in an intensity-dependent manner [Egan and Zierath 2013].  CaMKII regulates PGC-1α 
transcription through modulation of transcriptional regulators such as HDACs, CREB and MEF2 [Egan et 
al. 2010].  In resting muscle, MEF2 transcriptional activity is repressed through interaction with HDACs.  
However, upon induction of CaMKII activation, this kinase phosphorylates HDAC4 which sequesters it in 
the cytoplasm, leading to transcriptional activation of the PGC-1α promoter by MEF2 (Figure 1B) [Liu et 
al. 2005, Egan et al. 2010].  Moreover, CaMKs phosphorylate and activate CREB, which enhances PGC-1α 
transcription by binding to CRE-elements in the PGC-1α promoter (Figure 1B) [Sun et al. 1994, Handschin 
et al. 2003, Egan et al. 2010].  Increased calcium signaling also activates ATF2-mediated transcription of 
PGC-1α in muscle cells through a CaMKII- and p38 MAPK-dependent mechanism [Wright et al. 2007].  This 
indicates a potential cross-talk between CaMK- and p38 MAPK-signaling in the activation of PGC-1α 
transcription in response to exercise.   
As mentioned earlier, exercise induces prominent changes in skeletal muscle metabolism, 
resulting in alteration in intracellular redox status and ATP/ADP ratio.  These alteration lead to activation 
of energy stress sensor such as AMPK and SIRT1 in skeletal muscle.  AMPK is activated in skeletal muscle 
in response to exercise [Wojtaszewski et al. 2000] and has been shown to influence PGC-1α activity 
through several mechanisms.  AMPK phosphorylates HDAC5 and CREB, thereby resulting in increased 
transcription of PGC-1α (Figure 1B) [Thomson et al. 2008, McGee et al. 2009].  Moreover, AMPK directly 
phosphorylates PGC-1α and increases its transcriptional activity [Jager et al. 2007].  In line with this, 
muscle-specific gain-of-function mutations of AMPK or treatment with the pharmacological AMPK-
activator; 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) leads to enhanced PGC-1α 
expression and increased mitochondrial biogenesis in skeletal muscle [Winder et al. 2000, Garcia-Roves 
et al. 2008, Narkar et al. 2008].  However, knockout of the AMPK subunits α1 or α2 did not prevent the 
induction of PGC-1α transcription in response to endurance exercise [Jorgensen et al. 2005].  Muscle 
specific ablation of the upstream AMPK-kinase; liver kinase B1 (LKB1) leads to reduced AMPK-activation 
and consequently reduced PGC-1α expression in skeletal muscle [Koh et al. 2006].  Interestingly, muscle-
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specific LKB1-knockout mice were not able to induce PGC-1α expression in response to an acute exercise 
bout [Tanner et al. 2013].  AMPK is furthermore important for the deacetylation of PGC-1α in response 
to exercise, since AMPK was shown to regulate the activity of the NAD+-sensitive protein deacetylase 
SIRT1 through modulation of the intracellular NAD+/NADH ratio (Figure 2) [Canto et al. 2009, Canto et al. 
2010].  Exercise modulates the intracellular redox status and leads to a shift in the NAD+/NADH ratio in 
muscle fibers [White and Schenk 2012].  NAD+ levels were shown to peak 3 hours post-exercise in mice, 
and coincide with a strong deacetylation of PGC-1α [Canto et al. 2009].  This has been postulated to be 
mediated by SIRT1, since PGC-1α is a known deacetylation target of SIRT1 [Rodgers et al. 2005].  However, 
a recent study could demonstrate enhanced deacetylation of PGC-1α in response to exercise, even in the 
absence of SIRT1 deacetylase activity [Philp et al. 2011]. Interestingly, the authors could detect a 
decreased interaction between PGC-1α and the acetyltransferase GCN5 in response to exercise [Philp et 
al. 2011], and this could potentially explain the altered PGC-1α acetylation status, since PGC-1α is a known 
acetylation-target for GCN5 [Lerin et al. 2006].  There are however questions being raised regarding the 
connection between SIRT1 and increased PGC-1α activity and mitochondrial function in vivo [Gurd et al. 
2012, White and Schenk 2012].  For example, mice with a muscle-specific overexpression of SIRT1 
displayed slightly reduced levels of PGC-1α in muscle [Gurd et al. 2009].  It was also recently shown that 
overexpression of SIRT1 in C2C12 myotubes led to a decreased PGC-1α activity and reduced mitochondrial 
protein levels [Higashida et al. 2013].  Hence, further research is needed to determine the exact 
Figure 2 - Reciprocal regulation of 
AMPK- and SIRT1-activity, and 
subsequent activation of PGC-1α 
Sequential activation of PGC-1α 
through concurrent deacetylation and 
phosphorylation of the PGC-1α 
protein by SIRT1 and AMPK 
respectively.  AMPK activates SIRT1 by 
increasing the intracellular 
NAD+/NADH ratio.  SIRT1 deacetylates 
the AMPK-kinase liver kinase B1 
(LKB1), resulting in increased 
activation of AMPK. 
Adapted from: [Svensson and 
Handschin 2014] 
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mechanism behind PGC-1α deacetylation in response to exercise, and to determine the role of SIRT1 in 
this process. 
Several exercise induced signals, both mechanical and metabolic, converge on PGC-1α to regulate 
its activity in skeletal muscle.  Moreover, PGC-1α is important for the regulation of several processes (vide 
supra) necessary for the adaptation to exercise in skeletal muscle.  A pertinent question is thus whether 
PGC-1α is necessary for the adaptation of skeletal muscle in response to endurance exercise.  Muscle-
specific PGC-1α knockout mice display an exercise intolerant phenotype [Handschin et al. 2007a], which 
is exacerbated when PGC-1β is concomitantly knocked-out [Zechner et al. 2010].  Moreover, PGC-1α was 
shown to be necessary for the increased angiogenesis and mitochondrial biogenesis in response to 
exercise [Chinsomboon et al. 2009, Geng et al. 2010].  Conversely, in a recent study utilizing muscle-
specific PGC-1α knockout animals, Rowe et al. could show that in response to 2 weeks of endurance 
exercise, transcription of mitochondrial proteins as well as total mitochondrial density were enhanced 
even in the absence of PGC-1α [Rowe et al. 2012].  PGC-1α was also shown to be dispensable for the type 
IIb-to-IIa fiber type transformation in response to exercise [Geng et al. 2010].  Interestingly, also in the 
PGC-1α/β double-knockout model published by Zechner et al. the authors claim that neither PGC-1α nor 
PGC-1β are necessary for fiber type determination in skeletal muscle [Zechner et al. 2010], while a type 
IIa-to-IIx/IIb fiber-type switch was demonstrated in the original muscle-specific PGC-1α knockout model 
published by Handschin et al. [Handschin et al. 2007a].  A recently published double-knockout model of 
PGC-1α/β by Rowe et al. [Rowe et al. 2013] could confirm the findings by Zechner et al, that ablation of 
both PGC-1-isoforms in muscle did not result in a fiber type switch.  However, in stark contrast to the 
findings by Zechner et al, the PGC-1α/β double-knockout mice published by Rowe et al. display no 
significant changes in either exercise performance or in the absolute mitochondrial content in skeletal 
muscle.  Both models however display a strong reduction in transcription of mitochondrial proteins and a 
reduced oxidative capacity in the absence of both PGC-1-isoforms [Zechner et al. 2010, Rowe et al. 2013].  
Hence, more research is needed to elucidate whether PGC-1α is really necessary for the adaptation of 
skeletal muscle to exercise, and accordingly which specific processes are PGC-1α-dependent.  
Nonetheless, regardless of the role of PGC-1α in the physiological adaptation to exercise, overexpression 
of PGC-1α in skeletal muscle has been demonstrated to elicit a range of beneficial effects in rodent models 
of metabolic and muscle-related disorders [Svensson and Handschin 2014].  Hence, activation of PGC-1α 
in skeletal muscle could be a promising therapeutic strategy to ameliorate metabolic and muscle-related 
disorders. 
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6.2 – PGC-1α activation and exercise mimetics 
Obesity and diabetes in human patients is associated with mitochondrial impairments, glucose 
intolerance and exacerbated intramuscular lipid accumulation [Roden 2005].  Conversely, exercise is 
associated with increased mitochondrial biogenesis in skeletal muscle [Holloszy 1967], improved glucose 
uptake [Richter and Hargreaves 2013] and enhanced capacity for fat oxidation [Holloszy and Coyle 1984].  
Hence, increased physical activity is acknowledged as an important therapeutic strategy to prevent and 
treat metabolic dysfunction associated with obesity and diabetes in human patients [Perseghin et al. 
1996, Knowler et al. 2002, Strasser 2013].  Physical inactivity is a widespread across the global population 
[Hallal et al. 2012] and a sedentary lifestyle is closely linked to a higher incidence of chronic diseases such 
as diabetes, cancer and neurodegenerative disorders [Handschin and Spiegelman 2008, Booth et al. 
2012].  Physical inactivity in bed rest patients has been shown to induce a shift towards glycolytic type IIx 
fibers, to reduce the capacity for fat oxidation in muscle and to result in an increased intramuscular lipid 
content [Bergouignan et al. 2011].  While the cause for metabolic dysfunction in obese and diabetic 
patients is multifactorial, skeletal muscle plays an important role in the etiology of these diseases due to 
its central role in regulating systemic metabolic rate and glucose uptake.  Obesity and diabetes is 
associated with impaired mitochondrial and metabolic function in skeletal muscle.  This is illustrated by 
the reduced number of oxidative type I fibers [Hickey et al. 1995] in obese diabetic patients, and a reduced 
expression of PGC-1α-responsive genes in muscle [Mootha et al. 2003].  Moreover, reduced PGC-1α 
expression has been associated with increased incidence of type 2 diabetes and an increased BMI in 
diabetes-prone humans [Benton et al. 2008].  Intriguingly, diet-induced obesity in both mice and humans 
is associated with reduced levels of PGC-1α in skeletal muscle and concurrent mitochondrial dysfunction 
[Sparks et al. 2005].  Considering the many beneficial effects of PGC-1α on mitochondrial and metabolic 
processes in muscle, elevation of PGC-1α levels in skeletal muscle has been suggested as a potential 
therapeutic strategy to ameliorate metabolic dysfunction in obese and diabetic patients.  However, 
overexpression of PGC-1α in skeletal muscle was shown to have a detrimental effect on insulin-stimulated 
glucose uptake in sedentary mice fed a HFD [Choi et al. 2008].  This was suggested to occur in response 
to an increased fatty acid uptake and de novo lipogenesis, leading to exacerbated intramyocellular lipid 
accumulation in these mice.  While this phenotype could be ameliorated by concomitant exercise training 
[Summermatter et al. 2013b], these findings indicate that activation of PGC-1α as a monotherapy in 
sedentary obese patients could lead to potentially detrimental effects.  On the other hand, 
overexpression/activation of PGC-1α in skeletal muscle has been demonstrated to elicit several beneficial 
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effects in rodent models of various muscle-related pathologies such as cancer-associated cachexia, 
Duchenne muscular dystrophy, amyotrophic lateral sclerosis and disuse atrophy, to name a few [Svensson 
and Handschin 2014].  The positive effects of exercise or PGC-1α activation in metabolic and muscle-
related disorders have sparked an interest in developing pharmacological compounds that activate 
signaling pathways normally induced in skeletal muscle during exercise. These compounds are postulated 
to ameliorate metabolic dysfunction in obese patients or to mimic the beneficial effects of exercise in 
patients suffering from muscle-related disorders.  In line with the postulated use of these compounds, 
they have aptly been termed “exercise-mimetics” and are suggested work either as a monotherapy or as 
an adjuvant treatment in combination with exercise [Fan et al. 2013].  The term “exercise-mimetic” has 
emerged during the last decade [Booth and Laye 2009] and the discovery of a potential exercise-mimetic 
drug is by some considered to be the long-elusive goal of exercise science [Narkar et al. 2008, Fan et al. 
2013].  However, the concept of mimicking exercise through the administration of a single drug has been 
extensively critiqued [Goodyear 2008, Warden and Fuchs 2008, Booth and Laye 2009, Carey and Kingwell 
2009, Hawley and Holloszy 2009].  The systemic adaptations of physical exercise are polygenic and 
depend on integration of endocrine, neuronal, mechanical and metabolic stimuli.  Moreover, exercise 
adaptation is the result of a concurrent activation of several distinct pathways during muscle contraction, 
which are unlikely to be mimicked by a monotherapeutic approach [Booth and Laye 2009, Hawley and 
Holloszy 2009].  The true therapeutic potential of exercise mimetic compounds probably lies somewhere 
in between these two extreme standpoints.  While exercise mimetics might not be useful as a proxy for 
physical activity, these compounds could potentially be combined to elicit activation of complementary 
signaling pathways in muscle and act as adjuvant therapies to augment the beneficial effects of physical 
exercise. 
Several studies have investigated the therapeutic potential of different pharmacological 
compounds on skeletal muscle metabolism and function, as well as their impact on whole body 
metabolism.  Amongst these we find the well-known SIRT1-activating compounds RSV and SRT1720.  
However, also other compounds known to modulate the activity of PPARβ/δ, ERRβ/γ, AMPK and REV-
ERBα/β have been suggested as potential exercise mimetic compounds [Fan et al. 2013], and in this 
paragraph we will take a closer look at these postulated exercise mimetics.  PPARβ/δ is highly expressed 
in skeletal muscle, and has been shown to be able to directly regulate PGC-1α expression [Schuler et al. 
2006, Hondares et al. 2007].  PGC-1α in turn has been demonstrated to act as a coactivator of PPARβ/δ 
in muscle cells [Dressel et al. 2003].  In line with this, mice with a muscle-specific overexpression of 
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PPARβ/δ display a similar phenotype to PGC-1α transgenic mice, mainly characterized by an enhanced 
oxidative capacity in skeletal muscle [Lin et al. 2002, Wang et al. 2004].  Several aspects of the phenotype 
of PPARβ/δ muscle-transgenic mice was also mimicked through treatment of mice with the isoform-
selective PPARβ/δ agonist GW501516 [Wang et al. 2004].  These findings were expanded upon in a study 
by Narkar et al. from 2008, were the authors demonstrated that GW501516 treatment enhanced exercise 
performance and augmented exercise-induced mitochondrial biogenesis in skeletal muscle [Narkar et al. 
2008].  Intriguingly, the authors showed that concurrent administration of GW501516 and the AMPK-
agonist AICAR led to synergistic effects on skeletal muscle transcription that partially overlapped with the 
transcriptional profile of GW501516 in combination with exercise [Narkar et al. 2008].  Hence, these data 
illustrate the potential benefits of using PPARβ/δ agonists in combination with other pharmacological 
activators, or as an adjuvant therapy together with physical activity.  Interestingly, Narkar et al. also 
showed that administration of AICAR was sufficient to enhance exercise performance in mice and to 
induce PGC-1α expression in myotubes in a PPARβ/δ-dependent fashion [Narkar et al. 2008].  
Additionally, GW501516 treatment has been show to increase fatty acid oxidation in human skeletal 
muscle cells [Kramer et al. 2007] and to enhance whole body fat oxidation in human subjects [Riserus et 
al. 2008].  These findings indicate that GW501516 could have a therapeutic potential in obese humans.  
Other potential exercise mimetic compounds that have been suggested are the ERRβ/γ-agonist GSK4716 
and the REV-ERBα/β agonists SR9009 and SR9011 [Fan et al. 2013].  Treatment with GSK4716 led to an 
induction of PGC-1α/β and all ERR isoforms in primary mouse myotubes, together with an increase of 
several mitochondrial genes [Rangwala et al. 2010].  However, further studies are needed to evaluate the 
efficiency of this agonist in an in vivo setting.  On the other hand, treatment of mice with the REV-ERBα/β 
agonist SR9009 has been shown to enhance exercise performance in mice and to increase mitochondrial 
biogenesis in C2C12 cells [Woldt et al. 2013].  Both GSK4716 and SR9009/9011 elicit beneficial effects in 
skeletal muscle, however, further research is needed to evaluate their efficiency as potential exercise 
mimetic compounds in rodents, and more importantly, in human subjects.  The efficiency of a compound 
to elicit beneficial effects in obese subjects is not only connected to the effects of these compounds in 
skeletal muscle, but their effects on all major metabolic organs in the body.  Two compounds which have 
demonstrated pleiotropic beneficial metabolic effects in obese rodents are the calorie restriction 
(CR)/exercise mimetics RSV and SRT1720. 
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Resveratrol and SRT1720 
RSV was initially identified in the 1940s as a plant polyphenol in the roots of white hellebore [Baur and 
Sinclair 2006].  However, not until a connection was made between the RSV content in red wine, and the 
lipid lowering effects of red wine consumption in 1992  [Siemann and Creasy 1992] did the interest in the 
therapeutic potential of RSV take off (Figure 3A).  Over the years, many studies have investigated the 
therapeutic potential of RSV, however due to the pleiotropic nature of this compound, several open 
questions still remain regarding its mode of action.  Initially, this compound was shown to have beneficial 
effects for a range of disease states such as cancer as well as cardiovascular and inflammatory disorders 
[Baur and Sinclair 2006].  The mechanisms responsible for the pleiotropic effects of RSV are debated. 
Intriguingly, RSV has been shown to be an inhibitor of several enzymes such as phosphoinositide 3-kinase 
(PI3K) [Frojdo et al. 2007], cyclo- and lipooxygenase (COX, LOX), mitogen-activated protein kinases 
(MAPK) [Pirola and Frojdo 2008] and phosphodiesterases (PDE) [Park et al. 2012].  The best studied 
aspect of RSV function is however its ability to activate the enzymes SIRT1 [Howitz et al. 2003] and AMPK 
[Pirola and Frojdo 2008].  Whether RSV directly activates SIRT1 is debated.  Several studies have 
postulated that SIRT1-activation by RSV is an in vitro artefact [Kaeberlein et al. 2005, Beher et al. 2009, 
Pacholec et al. 2010] while a more recent study could demonstrate a direct allosteric activation of SIRT1 
by RSV [Hubbard et al. 2013].  Nonetheless, RSV undoubtedly displays pleiotropic effects in vivo, and has 
been shown to act as a PDE-inhibitor, thereby increasing AMPK and SIRT1 activation downstream of cyclic 
AMP (cAMP) and exchange protein directly activated by cAMP 1 (epac1) signaling [Park et al. 2012].   
Figure 3 – Timeline of research related to resveratrol / Effects of resveratrol administration on 
lifespan of model organisms. 
(A)  Timeline of resveratrol-related research as a function of number of resveratrol citations over time 
(1940 – 2006).  (B)  Mean and maximum lifespan extension with resveratrol-treatment in S.cerevisae, 
C.elegans, D.melanogaster, N.furzeri and in mammals.  Adapted from: [Baur and Sinclair 2006]. 
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Moreover, RSV can also act as an inhibitor of mitochondrial respiration [Zini et al. 1999], which has been 
demonstrated to lead to reduced ATP-production and consequently AMPK activation in skeletal muscle 
cells [Price et al. 2012].  Interestingly, RSV failed to protect AMPK-null mice against HFD-induced obesity 
[Um et al. 2010], which implies a role for AMPK in mediating the effects of RSV.  RSV was furthermore 
shown to increase the NAD+-to-NADH ratio in an AMPK-dependent manner [Um et al. 2010] and SIRT1 
has been demonstrated to deacetylate the AMPK-kinase liver kinase B1 (LKB1) [Lan et al. 2008], thereby 
forming a reciprocal link between AMPK- and SIRT1 activation (Figure 2). 
 The role of RSV as a SIRT1 activator was initially shown in yeast, and was connected to an 
extension of the life-span of S.cerevisae [Howitz et al. 2003].  The effect of RSV on organismal life-span 
was later demonstrated also in C.elegans [Wood et al. 2004], D.melanogaster [Bauer et al. 2004] and 
N.furzeri [Valenzano et al. 2006] (Figure 3B).  However, this extension of life-span could not be replicated 
in other studies using a similar setup [Kaeberlein et al. 2005, Bass et al. 2007] and has not been 
demonstrated in mammalian models [Mercken et al. 2012].  Nonetheless, RSV mimics the effects of CR 
at least on the transcriptional level in several organs [Barger et al. 2008, Pearson et al. 2008] and was 
shown to extend life-span of mice fed a HFD [Pearson et al. 2008].  Treatment with RSV is associated with 
several beneficial effects in obese mice such as an improved glucose tolerance, enhance energy 
expenditure, increased weight loss and ameliorated dyslipidemia [Baur et al. 2006, Lagouge et al. 2006, 
Milne et al. 2007, Um et al. 2010], which could explain the enhanced life-span in these mice [Pearson et 
al. 2008].  While the beneficial effects of RSV treatment in obese mice are well established, clinical trials 
have demonstrated potential caveats of using RSV as a monodrug therapy in humans [Tome-Carneiro et 
al. 2013].  This includes a low bioavailability of RSV in humans and potentially harmful synergism with our 
drugs due to inhibition of hepatic drug-metabolism by RSV [Smoliga et al. 2011, Tome-Carneiro et al. 
2013]. Moreover, in a recent clinical trial in patients with multiple myeloma, several study participants 
developed nephrotoxicity in response to SRT501 (formulated RSV) treatment [Popat et al. 2013].  Despite 
this, beneficial effects of RSV treatment have been demonstrated in clinical studies, such as a reduced 
metabolic rate, decreased inflammatory markers and reduced hepatic steatosis in obese men [Timmers 
et al. 2011].  These effect could however not be replicated in a related clinical study, using a longer 
treatment time and higher dose of RSV [Poulsen et al. 2013].  Intriguingly, RSV administration in obese 
humans leads to alteration in the transcriptional profile of both skeletal muscle and adipose tissue 
[Timmers et al. 2011, Konings et al. 2014].  Especially in skeletal muscle, RSV treatment was associated 
with increased PGC-1α levels, and an enhanced transcription of mitochondrial genes [Timmers et al. 
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2011], mirroring the effects of RSV treatment in mice [Lagouge et al. 2006].  The activation of PGC-1α in 
skeletal muscle and the concomitant increase in mitochondrial biogenesis with RSV treatment has led to 
the hypothesis that PGC-1α is a major downstream mediator of the effects of RSV.  This has however not 
been conclusively evaluated.  Considering the concurrent activation of AMPK, SIRT1 and PGC-1α in skeletal 
muscle during RSV treatment [Lagouge et al. 2006, Timmers et al. 2011], this compound has been 
considered as a potential exercise mimetic drug.  In keeping with this, several recent studies have focused 
on the potential additive effects of RSV administration and physical exercise in both mice and humans.  In 
rodents, RSV administration enhanced endurance capacity and muscle force production [Lagouge et al. 
2006, Murase et al. 2009, Um et al. 2010, Dolinsky et al. 2012, Wu et al. 2013] and acted synergistically 
with exercise training to enhance skeletal muscle cytochrome c oxidase protein content and enzymatic 
activity [Menzies et al. 2013].  Two recent studies from the group of Henriette Pilegaard focus on the 
potential synergism between RSV administration and lifelong exercise training on aging-related 
parameters.  The authors could however detect no additive or synergistic effects of RSV supplementation 
on exercise-mediated mitochondrial biogenesis or reduction in systemic inflammatory parameters 
[Olesen et al. 2013, Ringholm et al. 2013].  In human studies, RSV administration is not associated with 
any improvement in exercise performance [Voduc et al. 2014].  Interestingly, a recent study by Gliemann 
et al. showed that concomitant RSV administration actually blunted oxygen uptake during exercise in aged 
men [Gliemann et al. 2013].  The interpretations of these data have however caused controversy and 
debate within the scientific community [Smoliga and Blanchard 2013, Buford and Anton 2014, Hartmann 
and Forbes 2014].  However, the discrepancy between the effects of RSV in rodents and humans indicate 
that further studies are needed to elucidate the potential role of RSV as an adjuvant therapy to endurance 
exercise training. 
 
 
 
 
Figure 4 – SIRT1-activators 
Chemical structures of resveratrol and the novel SIRT1-activators SRT1460, SRT1720 and SRT2183. 
Adapted from: [Milne et al. 2007]. 
6.  Introduction to skeletal muscle physiology 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
122 
In order to develop more potent SIRT1-activating compounds than RSV, Milne et al. identified and 
characterized several SIRT1-activating compounds, structurally distinct from RSV, namely SRT1460, 
SRT1720 and SRT2183 (Figure 4).  Out of these compounds, SRT1720 was shown to possess the strongest 
ability to activate SIRT1, approximately a 1000-fold more potent than RSV in an in vitro assay [Milne et al. 
2007].  SRT1720 was further demonstrated to improve glucose tolerance, enhance exercise performance 
and reduce hepatic steatosis in obese rodent models [Milne et al. 2007, Feige et al. 2008, Minor et al. 
2011].  In line with the beneficial effects of SRT1720 on systemic metabolism, this compound was also 
shown to increase the lifespan of both HFD-fed and chow-fed mice [Minor et al. 2011, Mitchell et al. 
2014].  In C.elegans however, the lifespan-extending effect of RSV could not be replicated by SRT1720-
administration [Zarse et al. 2010], indicating a difference in the effects elicited by these compounds.  
Similar to RSV, the ability of SRT1720 to activate SIRT1 in vivo has been questioned [Pacholec et al. 2010].  
Moreover, the ability of this compound to elicit deacetylation of the SIRT1-substrate p53 have been 
attributed to the ability of SRT1720 to inhibit p300 histone acetyltransferase activity, rather than any 
direct effect on SIRT1 [Huber et al. 2010].  SRT1720 treatment has however been shown to induced AMPK 
activity and lead to deacetylation of SIRT1-substrates such as p53 and PGC-1α in vivo [Feige et al. 2008].  
Nevertheless, little is known regarding which would be the direct target(s) of this compound in vivo.  
Similar to RSV, it is important for the future use of these compounds in a clinical setting to elucidate which 
are the main targets of these compounds in vivo, and which of these targets are responsible for eliciting 
the beneficial effects of RSV and SRT1720.  In this context, PGC-1α is postulated to be an important 
downstream mediator of the effects of both RSV and SRT1720, in particular since increased PGC-1α 
transcription and activity have been detected in obese mice treated with RSV or SRT1720 and this was 
associated with an enhanced transcription of mitochondrial genes in skeletal muscle [Lagouge et al. 2006, 
Feige et al. 2008]. 
 
6.3 - Ketone body metabolism 
In order to fully understand the complexity of skeletal muscle function and metabolism, it is essential to 
understand how fuel metabolism is regulated in this organ, both in the context of exercise, but also in the 
transition from a fed to a fasted state.  During prolonged starvation, the body has developed an intricate 
system to cope with a reduced nutrient availability, while maintaining normal function of vital organs such 
as brain, kidney, heart and skeletal muscle.  During prolonged starvation, the body readily mobilizes its 
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endogenous energy stores such as glycogen, triacylglycerols and eventually, muscle proteins to maintain 
energy homeostasis.  The liver is an important organ in the adaptation to a fasted state, since this organ 
maintains blood glucose levels during fasting, initially through glycogenolysis and subsequently through 
gluconeogenesis using either glycerol, lactate, pyruvate, TCA-cycle intermediates or gluconeogenic amino 
acids as substrate (Figure 5A) [Nuttall et al. 2008].  
During continuous starvation, lipolysis in white adipose tissue depots is increased as a result of 
reduced circulating insulin levels.  Fatty acids are used as a metabolic fuel in organs such as heart and 
skeletal muscle, but they are also efficiently oxidized within the liver.  However, while the TCA-cycle 
intermediate oxaloacetate is diverted into hepatic gluconeogenesis, TCA-cycle activity is reduced, and 
acetyl-CoA accumulates in hepatocytes.  At this point, acetyl-CoA is shunted into hepatic ketone body 
production and contributes to the production of ketone bodies, which are released into the bloodstream 
and utilized as alternative energy substrates in extra-hepatic organs [Hashim and Vanitallie 2014].  
Accordingly, as glucose and insulin levels diminish during long-term fasting, concentrations of ketone 
bodies, beta-hydroxybutyrate (βOHB), acetoacetate (AcAc) and acetone rise in the circulation, resulting 
Figure 5 – Alterations of glucose, fatty acid and ketone body levels with prolonged starvation 
(A)  Glucose utilization is reduced in humans during prolonged starvation.  Glucose originates mainly 
from gluconeogenesis after 24 hours starvation. Adapted from: [Cahill 2006].  (B)  Concentrations 
of free fatty acids (FFA), acetone, beta-Hydroxybutyrate (b-OHB) and acetoacetate (AcAc) in blood 
of humans fasted for 40 days. Adapted from: [Longo and Mattson 2014]. 
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in a state of ketosis (Figure 5B).  Ketone body production, termed ketogenesis, is driven by increased 
delivery of fatty acids to liver during fasting, coupled to an enhanced gluconeogenesis.  Moreover, hepatic 
ketogenesis is regulated by hormonal mechanisms as well as the intracellular redox status.  Ketogenesis 
is catalyzed by three distinct enzymes, namely 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), 3-
hydroxymethyl-3-methylglutaryl-CoA lyase (HMGCL) and 3-hydroxybutyrate dehydrogenase, type 1 
(BDH1) (Figure 6).  HMGCS2 is a rate-limiting enzyme for hepatic ketogenesis, and its expression is 
regulated by two important nutrient sensing pathways.  Insulin signaling inhibits HMGCS2-transcription 
through inhibition of forkhead box protein A2 (FOXA2) [Wolfrum et al. 2003], while glucagon on the other 
hand increases FOXA2 transcriptional activity via acetylation by p300 [von Meyenn et al. 2013].  
Moreover, mammalian target of rapamycin complex 1 (mTORC1) represses ketogenesis by increasing the 
activity of NCoR1 as a transcriptional repressor towards PPARα, thereby reducing hepatic ketogenesis 
[Sengupta et al. 2010].  HMGCS2 activity is furthermore regulated through direct acetylation as well as 
succinylation.  BDH1 activity is also known to be regulated through the intracellular redox status 
(NAD+/NADH-ratio) (Figure 6) [Newman and Verdin 2014].   
Figure 6 – Outline of ketone body metabolism. 
Ketone bodies (acetoacetate, βOHB) are exclusively produced in the liver from an acetyl-CoA 
backbone, through the enzymes HMGCS2, HMGCL and BDH1.  In extra-hepatic organs, ketone 
bodies are taken up through ketone body transporters MCT1/MCT2 and oxidized to acetyl-
CoA, which subsequently enters the TCA-cycle to generate ATP.  Adapted from: [Newman 
and Verdin 2014] 
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While the regulation of ketone body production in liver is well studied, the control of ketone body 
oxidation in target organs is not yet fully understood.  Ketone body oxidation occurs in all extra-hepatic 
organs in a concentration-dependent manner.  Ketolysis is catalyzed by three important enzymes localized 
to the mitochondrial matrix, namely BDH1, 3-oxoacid CoA-transferase (OXCT1) and acetyl-CoA 
acetyltransferase 1 (ACAT1) (Figure 6) [Newman and Verdin 2014].  These enzymes oxidize βOHB and 
AcAc into acetyl-CoA, which subsequently enters the TCA-cycle for terminal oxidation.  OXCT1 is the rate-
limiting ketolytic enzyme and its expression is an important determinant of the ketolytic capacity of an 
organ.  While OXCT1 is not expressed in liver, it is highly expressed in oxidative organs such as kidney, 
heart, brain and skeletal muscle.  Global ablation of OXCT1 in mice is lethal within 48 hours after birth 
[Cotter et al. 2011].  Mice with either muscle-, neuron- or heart-specific deletion of OXCT1 are viable, but 
display a maladapted fasting response characterized by fasting-induced hyperketonemia [Cotter et al. 
2013].  Despite the apparent importance of ketone body oxidation, relatively little is known about how 
ketone body oxidation is regulated.  In diabetic rodents, skeletal muscle uptake of βOHB is impaired [Ikeda 
et al. 1991, Okuda et al. 1991] and OXCT1 and ACAT1 activity is furthermore reduced in heart of diabetic 
rats [Grinblat et al. 1986, Turko et al. 2001].  Contrariwise, endurance exercise training enhances the 
activity of ketolytic enzymes in skeletal muscle [Winder et al. 1974, Askew et al. 1975].  Hence, ketolytic 
capacity in skeletal muscle is influenced by both pathological and physiological signals.  Enhanced ketolytic 
capacity in skeletal muscle is furthermore suggested to be responsible for the reduced post-exercise 
ketosis in exercise trained rodents and humans [Johnson et al. 1969, Adams and Koeslag 1988].  Heart, 
kidney and brain have a higher basal OXCT1-activity than skeletal muscle and normalized to organ weight, 
the heart has the highest ketolytic capacity in the body (20-fold higher than skeletal muscle) [Fukao et al. 
2004].  However, due to the size of skeletal muscle, this organ still has a large impact on the systemic 
ketolytic capacity. In line with this, ablation of ketolytic capacity specifically in skeletal muscle leads to 
fasting-induced hyperketonemia [Cotter et al. 2013], indicating that this organ constitutes a large part of 
the systemic ketolytic capacity.  Intriguingly, administration of ketone bodies to a working heart has been 
shown to increase heart work efficiency by 25% (work/O2 consumed) [Kashiwaya et al. 1994] and has 
been suggested to improve exercise performance of both rodents and humans [Hashim and Vanitallie 
2014].  Hence, ketone bodies seem to have a positive effect on muscle function and energy metabolism. 
Ketone body oxidation is an important process to maintain energy homeostasis in the brain during 
prolonged starvation, since this organ cannot efficiently utilize long-chain fatty acids as an energy 
substrate [Schonfeld and Reiser 2013].  Hence, during prolonged starvation in humans, ketone bodies 
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account for up to 60% of the energy consumed in brain tissue [Cahill 2006].  Interestingly, ketone bodies 
have also been suggested to have therapeutic effects in the context of neurological disorders, such as 
Alzheimer’s disease, Parkinson’s disease and epilepsy [Paoli et al. 2013, Hashim and Vanitallie 2014].  
While the exact mechanism behind the beneficial effects of ketonemia in these disorders is still unknown, 
there are several hypotheses how this could be achieved.  For instance, it has been suggested that while 
glucose uptake and oxidation are impaired in several neurological disorders, ketone body uptake is 
unaltered and inducing of a state of ketosis could thus be used to rescue the metabolic dysfunction 
associated with diseases such as Alzheimer’s disease [Hashim and Vanitallie 2014].  On the contrary, 
several types of cancers have been shown to possess ketolytic deficiencies and a chronic state of ketosis 
could thus be used to induce metabolic deficiencies specifically in cancer cells [Seyfried et al. 2014].  
Ketogenic diets have been used as anticonvulsant therapies since 1920 and is together with drug therapy 
considered an established method to reduce epileptic seizures.  However, the exact mechanism behind 
these effects is still unknown [Paoli et al. 2013].  A prolonged state of ketosis has been suggested to induce 
mitochondrial biogenesis in the hypothalamus, thus enhancing ATP-production leading to stabilization of 
the resting membrane potential [Bough et al. 2006].  Intriguingly, enhanced mitochondrial protein levels 
have also been detected in BAT in response to ketogenic diet feeding [Srivastava et al. 2013].  A 
connection between chronic ketosis and improved mitochondrial function have also been demonstrated 
in the context of mitochondrial dysfunction.  Ketogenic diet feeding was able to ameliorate mitochondrial 
protein levels and function in both heart and skeletal muscle of mice with mitochondrial myopathies 
[Ahola-Erkkila et al. 2010, Krebs et al. 2011].  This effect was associated with a normalization of PGC-1α 
levels in the heart, which was suggested to be a mechanism how a ketogenic diet could increase 
mitochondrial transcription [Krebs et al. 2011, Benit and Rustin 2012].  Nevertheless, the exact 
mechanism how a ketogenic diet affects PGC-1α transcription and mitochondrial function is still unknown.  
Intriguingly, a recent study by Shimazu et al. demonstrated that βOHB acts as an HDAC inhibitor in vivo, 
and was thus able to inhibit the activity of HDAC1, HDAC3 and HDAC4 [Shimazu et al. 2013].   Importantly, 
treatment of mice with HDAC1-specific inhibitors was also recently demonstrated to increase PGC-1α 
transcription and mitochondrial biogenesis in skeletal muscle and BAT [Galmozzi et al. 2013].  However, 
the role of βOHB as an HDAC inhibitor in skeletal muscle and BAT is so far not investigated and future 
studies are needed to elucidate whether this effect of βOHB could account for the increased 
mitochondrial biogenesis in response to ketogenic diet feeding.  While the therapeutic role of a ketogenic 
diet in the context of diabetes, cancer and neurodegenerative disease is currently being explored [Paoli 
et al. 2013, Hashim and Vanitallie 2014], little is known about how a chronic state of ketosis affects 
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skeletal muscle biology.  Atrophic stimuli such as fasting, uremia, diabetes and cancer cachexia have been 
associated with reduced expression of the main ketolytic enzyme OXCT1 in rodent skeletal muscle [Lecker 
et al. 2004].  Intriguingly, patients suffering from Duchenne muscular dystrophy have been shown to 
exhibit hyperketonemia, which could indicate a reduced ketolytic capacity in muscle [Honke et al. 1997].  
While ketone bodies are important for skeletal muscle health and metabolism, more research is needed 
to elucidate the exact link between ketone body oxidation, and skeletal muscle function, both in 
physiological and pathophysiological states.  
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6.4 - The role of PGC-1α in skeletal muscle – Aims  
It is well established that obesity and metabolic dysfunction are closely associated with a sedentary 
lifestyle and an excess of calorie intake.  Hence, exercise and CR would be efficient ways to ameliorate 
metabolic dysfunction in humans.  However, it is not easy to maintain these diet- and exercise regimens.  
Thus, it has been suggested that administration of compounds, which could mimic the effects of either 
exercise or CR would have a great therapeutic potential.  RSV and SRT1720 are two such compounds which 
have been shown to activate cAMP-Epac1 signaling, AMPK and SIRT1 as well as PGC-1α in obese rodent 
models.  This is furthermore associated with an improved metabolic phenotype in obese mice treated 
with these compounds.  We were thus interested in whether PGC-1α is the molecular effector of the 
beneficial effects of resveratrol and SRT1720 in skeletal muscle and on whole body metabolism in obese 
mice.  Moreover, we were interested in whether the structurally distinct compounds resveratrol and 
SRT1720 would elicit analogous or differential effects in major metabolic organs such as skeletal muscle, 
liver and WAT.  These finding are presented in chapter 7/manuscript 2 of this thesis, and can be 
summarized with these two aims: 
1. Define the role of skeletal muscle PGC-1α as a potential mediator of the beneficial effects 
of resveratrol and SRT1720 in skeletal muscle, as well as on systemic metabolic parameters. 
 
2. Compare the effects elicited by resveratrol and SRT1720 treatment in diet-induced obese 
mice; are the effects on organ-specific and systemic metabolic parameters analogous? 
PGC-1α is an important regulator of mitochondrial and metabolic pathways and modulates several 
metabolic processes involved in glucose and fatty acid oxidation in skeletal muscle.  Another important 
metabolic fuel in skeletal muscle, especially in nutrient-deprived states, are ketone bodies. However, 
despite the high basal ketolytic capacity of oxidative muscles, the role of PGC-1α in the regulation of 
ketone body oxidation has to our knowledge so far not been investigated.  Our findings regarding the role 
of PGC-1α in the regulation of ketone body oxidation will be presented in chapter 8/manuscript 3 of this 
current thesis.  The fourth aim of this thesis can thus be summarized: 
3. Investigate the role of PGC-1α in the regulation of skeletal muscle ketone body oxidation 
and its impact on systemic ketone body metabolism. 
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Abstract 
Resveratrol (RSV) and SRT1720 (SRT) elicit metabolic effects similar to caloric restriction in mice, and are 
postulated to ameliorate obesity and related metabolic complications in humans. While the primary 
target for these compounds remains controversial, peroxisome proliferator-activated receptor γ co-
activator 1α (PGC-1α) has emerged as a major downstream effector responsible for metabolic 
remodeling of muscle and other metabolic tissues in response to RSV or SRT treatment. However, the 
requirement of intact PGC-1α in skeletal muscle for the effects of these compounds on systemic 
metabolism has so far not been demonstrated. Using muscle-specific PGC-1α knockout mice, we show 
that PGC-1α is necessary for transcriptional induction of mitochondrial genes in muscle with both RSV 
and SRT treatment. Nevertheless, the beneficial effects of these compounds on body composition and 
glucose homeostasis occur even in the absence of muscle PGC-1α. We furthermore investigated whether 
RSV- and SRT-treatment would induce comparable metabolic effects in target organs. Intriguingly, RSV 
and SRT treatment lead to several analogous but also differential effects on lipid metabolism and 
mitochondrial biogenesis in skeletal muscle, liver and white adipose tissue. Our results provide 
important insights into the mechanism, effects and organ specificity of caloric restriction mimetics such 
as RSV and SRT. These findings will prove important for the design of future therapeutic interventions 
aimed at ameliorating obesity and obesity-related metabolic dysfunction in patients. 
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Introduction 
In moderation, caloric restriction (CR) elicits various beneficial metabolic effects in humans [Speakman 
and Mitchell 2011]. Thus, inducing a similar metabolic state through pharmacological interventions has 
been proposed as an approach to ameliorate obesity, type 2 diabetes and other metabolic complications 
in patients. Resveratrol (RSV) is a naturally occurring compound which mimics both metabolic and 
transcriptional effects of CR in mice [Pearson et al. 2008, Smith et al. 2009]. Moreover, RSV improves 
metabolic dysfunction and prolongs lifespan in high fat diet (HFD) fed rodents [Baur et al. 2006, Lagouge 
et al. 2006]. The exact molecular mechanism how RSV promotes these effects is not fully elucidated. 
AMP-activated protein kinase (AMPK) [Um et al. 2010], sirtuin 1 (SIRT1) [Price et al. 2012] and cAMP-
degrading phosphodiesterases (PDEs) [Park et al. 2012] are all proposed to be primary targets for this 
polyphenolic compound. It is however known that besides activation of these targets, RSV has additional 
properties and can act as an antioxidant, a phytoestrogen and as an anti-inflammatory agent [Baur 
2010]. Thus, in search for new, more specific pharmacological activators of SIRT1, several synthetic 
compounds have been identified, including SRT1720 (SRT) [Milne et al. 2007]. SRT shows a higher 
efficacy and selectivity for activating SIRT1 compared to RSV [Milne et al. 2007], and mimics many of the 
transcriptional changes observed during both CR and RSV treatment in mice [Smith et al. 2009]. SRT 
treatment can furthermore ameliorate metabolic defects in both HFD-fed [Feige et al. 2008] and aged 
mice [Minor et al. 2011], but as for RSV, it is controversial whether SRT directly activates SIRT1 to 
mediate these metabolic changes [Pacholec et al. 2010]. For both compounds however, peroxisome 
proliferator-activated receptor γ co-activator 1α (PGC-1α) has been proposed as the common 
downstream effector in control of metabolic plasticity [Lagouge et al. 2006, Feige et al. 2008, Martin-
Montalvo and de Cabo 2013]. This is regardless of the putative direct target of these compounds, since 
PGC-1α is activated by AMPK-mediated phosphorylation, SIRT1-induced deacetylation as well as 
increased cAMP levels [Herzig et al. 2001, Rodgers et al. 2005, Jager et al. 2007]. In metabolic organs, 
PGC-1α is an important transcriptional co-activator that controls several integrated metabolic programs 
such as mitochondrial biogenesis, oxidative phosphorylation (OXPHOS) and fatty acid (FA) β-oxidation 
[Handschin 2009]. These processes are furthermore postulated to be induced by CR [Martin-Montalvo 
and de Cabo 2013] and upon administration of RSV and SRT in mice [Lagouge et al. 2006, Feige et al. 
2008].  Accordingly, RSV and SRT treatment have been reported to activate PGC-1α and lead to 
metabolic remodeling in several organs, especially in skeletal muscle (SKM) [Lagouge et al. 2006, Feige 
et al. 2008]. However, the requirement for PGC-1α in mediating the effects of RSV and SRT in vivo has so 
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far not been conclusively validated. Using mice with a SKM-specific deletion of PGC-1α, we now 
demonstrate that while functional PGC-1α is required for transcriptional induction of mitochondrial 
genes in muscle, this co-activator in muscle is dispensable for the systemic metabolic effects of both RSV- 
and SRT-treatment. Another important question is whether structurally distinct compounds such as RSV 
and SRT would be able to induce similar effects in major metabolic organs. To answer this, we performed 
a comparative analysis of these two CR-mimetic compounds on metabolic processes in SKM, liver and 
white adipose tissue (WAT), and could reveal several important analogous but also differential effects 
between RSV and SRT on lipid metabolism and mitochondrial biogenesis. 
 
Material and methods 
Animals and diets - PGC-1α muscle-specific knockout (MKO) mice were generated by crossing PGC-
1αloxP/loxP mice with HSA-Cre transgenic mice, as previously described [Perez-Schindler et al. 2013]. Mice 
were housed in a conventional facility with a 12-h light/12-h dark cycle with free access to food and 
water. All experiments were performed in accordance with federal guidelines and were approved by the 
Kantonales Veterinäramt of Kanton Basel-Stadt. The high fat diet (HFD) used for this study contains 60 
kcal% fat derived mainly from lard (D12492, Research Diets Inc.), and either RSV (4 g/kg diet; Cayman 
Chemicals) or SRT1720 (1 g/kg diet; Sanofi Aventis) was added to the diet during production. Initially, 
mice were fed a HFD for two weeks, and then half of the groups were switched to a diet containing 
either RSV for a period of 4 weeks (RSV-S), RSV for 13 weeks (RSV-L), or SRT1720 for 4 weeks (SRT). The 
respective control groups received a similar HFD without any additions for the remainder of the study. 
Metabolic measurements - Body composition was measured using an EchoMRI-100™ analyzer (EchoMRI 
Medical Systems). Intraperitoneal glucose tolerance test (GTT) was performed in overnight (16h) fasted 
mice. Mice were injected with a bolus of 2 g glucose/kg body weight, and blood glucose was measured in 
tail vein blood at 0, 15, 30, 45, 60, 90, 120 and 180 minutes after injection using a handheld glucose 
meter (Accu-Chek, Roche). To assess whole body metabolism through indirect calorimetry, mice were 
individually housed in metabolic chambers (CLAMS, Columbus instruments) over a time period of 48 h 
after an initial acclimatization period. During the measurement period, oxygen consumption, food intake 
and spontaneous activity was measured in 30 minute intervals.  
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Blood analysis - Blood glucose was measured in a tail vein blood sample from ad libitum fed and 
overnight (16h) fasted mice using a handheld glucose meter (Accu-Chek, Roche). Whole tail-vein blood 
was collected in Microvette tubes (Sarstedt) and plasma was isolated. Levels of cholesterol, high-density 
lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) in plasma were 
determined using an automated biochemical analyzer (Cobas c 111 analyzer; Roche). Free fatty acids in 
plasma were determined using a colorimetric commercial test (HR Series NEFA-HR(2); Wako Diagnostics) 
according to manufacturer’s instructions . 
Microscopy - NADH and SDH staining were performed on 10 µm cryo-sections from tibialis anterior (TA) 
by exposing the sections to either NADH (Sigma) or SDH (Sigma) in the presence of nitroblue tetrazolium 
(Sigma). Staining intensity was quantified using Image-J software on pictures taken from the same region 
of the muscle for all groups. Liver specimens were snap-frozen in 2-methyl butane pre-cooled in liquid 
nitrogen. Tissues were cut into 5 μm thick cryo-sections and stained with Oil Red O (ORO, Sigma) for lipid 
content. Oil Red O staining was evaluated by an expert pathologist. For studies of mitochondrial number, 
pieces of TA muscle were fixed in 3% paraformaldehyde/ 0.5% glutaraldehyde, further fixed in 1% 
osmiumtetroxid and embedded in epon. 60-70 nm sections were cut and pictures were taken with a 
Morgagni 268(D) TEM (FEI). Number of mitochondria in these pictures were quantified using Image-J 
software. 
RNA extraction and RT-PCR - Snap-frozen gastrocnemius, liver or white adipose tissue was homogenized 
and total RNA was extracted using TRIzol reagent (Invitrogen). RNA concentration was adjusted and 1 µg 
of total RNA was used for cDNA synthesis. Semi-quantitative Real-time PCR analysis was performed using 
Power SYBR Green master mix (Applied Biosystems) on a StepOnePlus Real-Time PCR System (Applied 
Biosystems). Relative expression levels for each gene of interest were calculated with the ΔΔCt method, 
using PolR2A, HPRT or RPL0 as normalization control. 
Nuclear isolation and immunoprecipitation - For nuclear isolation, liver was homogenized in hypotonic 
lysis buffer (HLB) (10 mM NaCL, 1.5 mM MgCl2, 20 mM HEPES pH 7.4, 20% glycerol, 0.1% Triton-X, 1 mM 
DTT) supplemented with protease inhibitors (C0mplete, Roche), phosphatase inhibitors (Sigma), 10 mM 
Nicotinamide A (Sigma) and 10 mM Trichostatin A (Sigma), using a Dounce homogenizer. Intact nuclei 
were isolated through differential centrifugation at 880g for 3 minutes, and nuclear pellet was washed 3 
times in HLB. Isolated nuclei were lysed using RIPA buffer supplemented with protease inhibitors 
(C0mplete, Roche), phosphatase inhibitors (Sigma), 10 mM Nicotinamide A (Sigma) and 10 mM 
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Trichostatin A (Sigma). For immunoprecipitation, 500 µg nuclear proteins were pre-cleared with protein-
A beads (Protein A –Sepharose 4B, Invitrogen). Pre-cleared supernatant was incubated with 2 µg pan-
Acetyl antibody (sc8649; Santa Cruz Biotechnology) for 2 hours, followed by overnight incubation with 50 
µL 50% slurry of protein-A beads. Immunoprecipitated proteins were denatured in 2x Laemmli sample 
buffer (Sigma), and prepared for immunoblotting. 
Immunoblotting - Tissues were homogenized in RIPA buffer supplemented with protease inhibitors 
(C0mplete, Roche), phosphatase inhibitors (Sigma), 10 mM Nicotinamide A (Sigma) and 10 mM 
Trichostatin A (Sigma). Equal amounts of proteins were separated on SDS-PAGE under reducing 
conditions, and transferred to a nitrocellulose membrane (Whatman). Proteins of interest were detected 
using the following antibodies: Mitoprofile (MS604; MitoSciences), AMPKα (2532; Cell signaling), p-
AMPKα T172 (2531; Cell signaling), eEF2 (2332; Cell signaling), Creb (9197; Cell signaling), p-Creb S133 
(9196; Cell signaling), Insulin receptor β (IRβ) (3025; Cell signaling), p-IRβ Y1146 (3021; Cell signaling), Akt 
(9271; Cell signaling), p-Akt S473 (9271; Cell signaling), p-Akt T308 (4056; Cell signaling), GSK3β (9315; 
Cell signaling), p-GSK3β (5558P; Cell signaling), PGC-1 (AB3242; Millipore), Polyclonal Swine Anti-Rabbit 
Immunoglobulin/HRP (P0399, Dako), Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP (P0260, Dako). 
Densitometric analysis of immunoblots was performed on 6-7 individual samples using Image-J software, 
and a representative selection is presented in each figure. 
Hepatic lipid extraction - Liver tissue was homogenized in 1 mL of 2:1 chloroform:methanol mixture, and 
transferred to a glass tube together with 1 mL distilled water. The sample was then vigorously mixed and 
centrifuged 10 minutes at 2000 rpm. The upper aqueous phase was removed and the lower organic 
phase was transferred to a new glass tube, and dried under N2 at 50°C. The sample was then 
resuspended in chloroform and added to a solid-phase extraction column (UPTI-CLEAN NH2-S 
100mg/1mL SPE Columns, Interchim). Samples were eluted with chloroform, dried under N2 at 50°C, and 
subsequently resuspended in chloroform containing 1% Triton-X. Triglycerides were measured using a 
commercial enzymatic kit (TG PAP 150, BioMérieux), and normalized to the initial weight of the tissue 
used for extraction. 
Statistical analysis - All data are presented as means ± SEM. Unpaired student two-tailed t test was used 
to determine differences between groups.  
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Results 
To investigate the requirement for SKM PGC-1α in the metabolic effects of RSV and SRT, we used mice 
carrying a muscle-specific knockout of PGC-1α (MKO) [Perez-Schindler et al. 2013] and their floxed 
littermates with intact PGC-1α expression as control group (CTRL). These mice were fed a HFD for two 
weeks and subsequently switched to a diet containing RSV either for four weeks (short-term treatment; 
RSV-S), or for thirteen weeks (long-term treatment; RSV-L). A third group received a HFD for two weeks, 
and was then switched to a diet containing SRT1720 (SRT) for four weeks. Control groups were fed a HFD 
for a total of 6 weeks (RSV-S and SRT) or 15 weeks (RSV-L).  
In line with the suggested role of RSV as a CR-mimetic [Pearson et al. 2008], RSV-treated mice 
displayed a reduced body weight (Fig. 1A) and fat mass (Fig. 1B) at the end of the treatment compared to 
HFD fed control mice. In contrast to the RSV-mediated effects, SRT treatment affected neither body 
weight (Fig. 1A) nor relative fat mass (Fig. 1B). The reduction in fat mass in RSV treated mice could not be 
attributed to any changes in either food intake (Suppl. Fig. S1A) or spontaneous activity (Suppl. Fig. S1B). 
The lean phenotype in the RSV groups could however be due to increased basal energy expenditure. We 
thus assessed oxygen consumption in our mice as a measure of energy expenditure, and could indeed 
detect an increased metabolic rate with RSV-treatment at both time-points (Fig. 1C). Interestingly, SRT-
treated mice also exhibited an enhanced metabolic rate based on their increased oxygen consumption 
(Fig. 1C), which however did not correlate with a reduction in fat mass (Fig. 1B). Surprisingly, none of 
these parameters where affected by the ablation of PGC-1α in muscle, since PGC-1α MKO mice displayed 
an equivalent change in body weight (Fig. 1A), fat mass (Fig. 1B) and energy expenditure (Fig. 1C) 
compared to CTRL mice upon RSV- and SRT-treatment. Hence, these data demonstrate that SKM PGC-1α 
is dispensable for the effect of RSV and SRT on body composition and whole body energy expenditure. 
SKM is the major site for insulin-induced glucose uptake, and therefore an important organ in the 
regulation of whole body glucose homeostasis. Moreover, both RSV and SRT have been shown to 
improve glucose homeostasis in obese mice [Baur et al. 2006, Lagouge et al. 2006, Milne et al. 2007, 
Feige et al. 2008, Smith et al. 2009, Minor et al. 2011] and we wanted to investigate whether this effect 
was mediated through SKM PGC-1α. Through an intraperitoneal glucose tolerance test we could confirm 
that RSV- and SRT-treatment led to improved glucose excursion rates in HFD fed mice (Fig. 1D, Fig. 1E). 
This correlated with a reduction in both fed and fasted blood glucose levels in SRT treated mice, which 
could not be observed with RSV treatment (Suppl. Fig. S1C, Fig. 1F). Ablation of SKM PGC-1α led to an 
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improvement in glucose excursion rates (Fig. 1D, Fig. 1E) as well as reduced fasted blood glucose levels 
(Fig. 1F) compared to CTRL mice after 15 weeks of HFD feeding. However, ablation of PGC-1α in muscle 
did not prevent the effects of either RSV or SRT treatment on glucose homeostasis in HFD fed mice (Fig. 
1D-F, Suppl. Fig. S1C). Taken together, these data indicate that SKM PGC-1α is dispensable for the effects 
of RSV and SRT on whole body glucose homeostasis. 
PGC-1α is required for induction of mitochondrial gene transcription, but not for enhanced oxidative 
capacity in skeletal muscle of RSV- or SRT-treated mice 
Since the systemic effects of RSV and SRT were unaffected by the ablation of PGC-1α in muscle, we were 
interested in how these compounds would affect SKM metabolism in our mice. We focused on the 
aspect of mitochondrial function and biogenesis since RSV and SRT have been postulated to affect these 
parameters via activation of PGC-1α [Martin-Montalvo and de Cabo 2013]. As previously shown 
[Handschin et al. 2007], ablation of PGC-1α led to an impaired oxidative phenotype in SKM. This was 
evident in our mice by the reduced transcript levels of several mitochondrial genes, namely cytochrome 
c (Cytc), cytochrome c oxidase subunit 5b (Cox5b), citrate synthase (Cs) and NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 8 (Ndufb8) in SKM (Fig. 2A). PGC-1α MKO mice furthermore displayed 
reduced levels of proteins involved in mitochondrial OXPHOS (Fig. 2B). In the RSV-S group, RSV treatment 
induced no changes in mRNA expression of mitochondrial genes (Fig. 2A), OXPHOS protein content (Fig. 
2B), or staining intensity for oxidative function (Fig. 2C, Suppl. Fig. S2A and S2B) in SKM. In the RSV-L 
group however, we detected a trend towards increased PGC-1α gene transcription (Fig. 2A), and a 
concomitant mild induction of some mitochondrial PGC-1α target genes (CytC, Cox5b, Cs) (Fig. 2A). 
Importantly, these transcriptional effects were dependent on PGC-1α, since the effect of RSV treatment 
on these genes was abolished in PGC-1α MKO mice (Fig. 2A). Surprisingly, RSV treatment affected 
neither OXPHOS protein levels (Fig. 2B) nor oxidative enzymatic staining in the muscle (Fig. 2C, Suppl. Fig. 
S2A and S2B). SRT treatment led to an increased mRNA (Fig. 2A) and protein level (Fig. 2B) of Ndfub8 in 
skeletal muscle. Apart from Ndufb8, no other mitochondrial gene tested was found to be induced by SRT 
treatment (Fig. 2A, Suppl. Fig. S2C). Importantly, the effect on Ndufb8 transcription was dependent on 
PGC-1α, as both induction of mRNA (Fig. 2A) and protein levels (Fig. 2B) of Ndufb8 with SRT treatment 
were blunted in PGC-1α MKO mice. Despite the mild effect on mitochondrial gene transcription, SRT 
treatment resulted in a more intense NADH (Fig. 2B, Suppl. Fig. S2A) and SDH (Suppl. Fig. S2B) staining in 
SKM, indicating an enhanced oxidative capacity in this tissue. Surprisingly, this effect occurred to a 
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certain extent also in PGC-1α MKO mice (Fig. 2C, Suppl. Fig. S2A and S2B) implying that this effect of SRT 
treatment was independent of SKM PGC-1α. Increased oxidative capacity with SRT treatment could be a 
consequence of a higher mitochondrial number in skeletal muscle. We therefore quantified 
mitochondria in electron microscopy pictures from SKM, and could detect an increased number of 
intramyofibrillar mitochondria with SRT treatment in both genotypes, although it did not reach statistical 
significance for PGC-1α MKO mice (Fig. 2D). Thus, the increase in oxidative capacity with SRT treatment 
might be a consequence of a higher mitochondrial number in skeletal muscle.  
RSV- and SRT-treatment can affect transcription of several processes in SKM besides 
mitochondrial function, for example glycolysis, β-oxidation and myosin heavy chain isoforms [Lagouge et 
al. 2006, Feige et al. 2008]. In our experimental cohorts however, RSV-S mice displayed no difference in 
the mRNA levels of genes involved in glucose uptake/glycolysis (Fig. 3A) or myosin heavy chain (MHC) 
subtypes in SKM (Fig. 3B). Intriguingly, we observed a PGC-1α-independent induction of uncoupling 
protein 3 (UCP3) mRNA expression (Fig. 3C) in RSV-S mice, while other genes involved in FA β-oxidation 
such as medium-chain acyl-CoA dehydrogenase (MCAD), carnitine palmitoyltransferase 1B (Cpt1b) and 
pyruvate dehydrogenase kinase isozyme 4 (PDK4) were unchanged (Fig. 3C). Interestingly, the increase in 
UCP3 expression with RSV treatment was transient, since this effect was no longer present in the RSV-L 
group (Fig. 3C). In contrast, a mild, PGC-1α-dependent induction of MHCIIA and MHCIIB mRNA 
expression was observed in RSV-L mice (Fig. 3B), which was not present in RSV-S animals. SRT treatment 
promoted an induction of both hexokinase 2 (HK2) (Fig. 3A) and MCAD (Fig. 3C), while the mRNA 
expression of other genes involved in glycolysis, FA β-oxidation and MHC subtypes was unchanged (Fig. 
3A-C). In the PGC-1α MKO group, induction of HK2 and MCAD by SRT did not reach statistical significance 
(Fig. 3A and Fig. 3C). Due to the mild effects of RSV on gene expression in SKM, we assessed AMPK 
phosphorylation as readout of RSV-induced signaling in SKM. In line with the mild transcriptional effects 
of RSV treatment in SKM, we could detect no significant induction of AMPK phosphorylation (T172) (Fig. 
3D) for either the RSV-S or RSV-L groups. 
SRT induces transcription of PGC-1α target genes in liver 
Since PGC-1α MKO mice displayed a similar systemic response to both RSV- and SRT-treatment as CTRL 
mice, this suggests only a minor role of skeletal muscle PGC-1α in the regulation of systemic metabolism 
by these compounds. We therefore continued to analyze the effects of RSV- and SRT-treatment in other 
major metabolic organs, such as liver and white adipose tissue (WAT). To avoid confounding metabolic 
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crosstalk due to ablation of PGC-1α in muscle, the following experiments were performed in mice with 
intact SKM PGC-1α expression. In contrast to the mild effects seen in SKM, SRT treatment boosted the 
transcription of several mitochondrial genes (Cox5b, CytC, CS, ubiquinol-cytochrome c reductase core 
protein 2 Uqcrc2) in liver (Fig. 4A), along with a small but significant increase in protein levels of Uqcrc2 
and ATP synthase subunit alpha 5 (ATP5A) (Fig. 4B). SRT treatment furthermore led to a minor elevation 
in PGC-1α protein levels (Fig. 4B), as well as to the transcriptional induction of genes involved in 
ketogenesis (acetyl-coenzyme A acetyltransferase 1 Acat1, 3-hydroxymethyl-3-methylglutaryl-CoA lyase 
Hmgcl, 3-hydroxy-3-methylglutaryl-CoA synthase 2 Hmgcs2) and gluconeogenesis (phosphoenolpyruvate 
carboxykinase PEPCK, glucose-6-phosphatase G6pc) (Fig. 4C). All of these metabolic processes are 
regulated by hepatic PGC-1α [Rhee et al. 2003]. Our results therefore indicate that SRT treatment results 
in an increased transcriptional activity of PGC-1α in liver. Since SRT is an activator of SIRT1 [Milne et al. 
2007], which can deacetylates and thereby activates PGC-1α [Rodgers et al. 2005], we determined the 
acetylation status of PGC-1α in the livers of CTRL and SRT-treated animals on a HFD. In these animals, no 
difference in PGC-1α acetylation status between HFD-fed CTRL and SRT-treated mice could be detected 
(Fig. 4D). In contrast, we observed a strong trend towards increased hepatic AMPK phosphorylation with 
SRT treatment (Fig. 4E, Suppl. Fig. S3A), correlating with an increased phosphorylation of the AMPK-
sensitive phosphorylation site (S79) on acetyl-CoA-carboxylase (ACC) (Fig. 4E, Suppl. Fig. S3A). Since 
AMPK phosphorylates and thereby increases the transcriptional activity of PGC-1α [Jager et al. 2007], 
AMPK activation upon SRT treatment could account for the increased hepatic PGC-1α activity in SRT-
treated mice. These animals accordingly displayed an induction of several PGC-1α target genes involved 
in mitochondrial FA β-oxidation (MCAD, long-chain acyl-CoA dehydrogenase LCAD), mitochondrial FA 
import (Cpt1b, carnitine-acylcarnitine translocase CACT) and FA uptake (lipoprotein lipase LPL, cluster of 
differentiation 36 CD36) in the liver (Fig. 4F). Importantly, altered transcriptional activation of PGC-1α-
regulated processes in liver was exclusively found in SRT-, but not in RSV-treated animals. In fact, 
administration of RSV even reduced transcript levels of hepatic PGC-1α (Fig. 4A, Suppl. Fig. S3B) at both 
time-points and did not alter transcription of mitochondrial (Fig. 4A, Suppl. Fig. S3B), ketogenic or 
gluconeogenic genes (Fig. 4C, Suppl. Fig. S3C). Likewise in contrast to SRT-treated mice, RSV 
administration resulted in no transcriptional changes on either FA β-oxidation or mitochondrial FA 
import (Fig. 4F, Suppl. Fig. S3D) apart from an induction of Cpt1b in the RSV-S group (Fig. 4F). 
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RSV and SRT differentially regulate hepatic lipogenesis 
Due to the observed metabolic remodeling of the liver by SRT, we also measured the expression of genes 
important for hepatic lipogenesis in the SRT cohort. SRT treatment resulted in an induction of the 
lipogenic transcription factor sterol regulatory element binding protein-1c (Srebp1c), as well as its target 
genes involved in lipogenesis (acetyl-CoA carboxylase 2 ACC2, Stearoyl-CoA desaturase-1 SCD1, FA 
synthase Fasn) and FA re-esterification (glycerophosphate acyltransferase GPAT) (Fig. 4G). Since insulin is 
a known regulator of Srebp1c transcription and processing [Horton et al. 2002], we determined whether 
increased hepatic insulin signaling could account for the increased lipogenic gene transcription upon SRT 
treatment. In the SRT group, we detected an elevated phosphorylation of AKT (T308), while auto-
phosphorylation of insulin receptor β (IRβ) (Y1146) as well as phosphorylation of the AKT-target glycogen 
synthase kinase 3 beta (GSK3β) (S9) were reduced (Suppl. Fig. S3E). This would indicate reduced insulin 
signaling in liver with SRT treatment, and could therefore not account for the increased transcriptional 
activation of lipogenesis seen with this compound. Interestingly, RSV treatment resulted in a significant 
reduction of genes involved in lipogenesis (ACC2, SCD1, Fasn) and FA re-esterification (GPAT), as well as a 
statistically non-significant trend (RSV-S p=0.061 / RSV-L p=0.062) towards reduced Srebp1c transcription 
(Fig. 4G, Suppl. Fig. S3F), thereby showing an opposite regulation of hepatic lipogenesis compared to SRT 
treatment. We next investigated whether these strikingly opposite transcriptional responses to RSV and 
SRT treatment would affect hepatic triglyceride (TG) content. In the RSV-S group, a trend (p=0.056) 
towards reduced TG content was observed (Fig. 4H, Suppl. Fig S3H). Surprisingly, this effect was not 
present in the RSV-L group (Suppl. Fig. S3G, Suppl. Fig S3H), even though lipogenic gene transcription 
was still reduced at this time-point (Suppl. Fig. S3F). SRT treatment did not affect hepatic TG content (Fig. 
4H, Suppl. Fig S3H). Next, we also studied the effect of these two compounds on hepatic cholesterol 
biosynthesis. In line with the increased transcription of anabolic processes, such as hepatic lipid and 
ketone body production, SRT treatment also increased the transcription of genes involved in cholesterol 
biosynthesis (acetyl-CoA acetyltransferase 2 Acat2, farnesyl-diphosphate farnesyltransferase 1 Fdft1, 7-
dehydrocholesterol reductase Dhcr7) in the liver (Fig. 4I). Consequently, we could detect increased levels 
of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in plasma 
from SRT treated mice (Fig. 4J). In contrast, RSV-treatment did not affect the transcription of genes 
involved in cholesterol synthesis (Fig. 4I, Suppl. Fig. S3I). Nevertheless, RSV-S mice exhibited reduced 
levels of LDL-C in the blood (Fig. 4J), while HDL-C (Fig. 4J) levels remained unaltered. Moreover, the 
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reduction in circulating LDL-C levels is most likely a transient effect of RSV treatment, since no 
differences in either LDL or HDL cholesterol was observed in the RSV-L group (Suppl. Fig. S3J).  
Long-term RSV treatment leads to an induction of genes involved in lipogenesis and lipolysis in white 
adipose tissue 
Our data demonstrate a high selectivity for SRT over RSV to affect liver metabolism. We therefore 
assessed the consequence of SRT and RSV administration on WAT metabolism to investigate whether 
this tissue can account for the metabolic remodeling promoted by RSV. In contrast to the effects in liver, 
neither SRT nor RSV-S groups displayed any alterations in lipogenic gene transcription, with the 
exception of a down-regulation of Fasn transcript levels in the RSV-S mice (Fig. 5A). RSV-L mice however 
displayed a robust induction of a number of lipogenic genes (Srebp1c, ACC1, Scd1, Fasn) as well as genes 
involved in FA re-esterification (GPAT, diglyceride acyltransferase 1, 2 DGAT1, DGAT2) in WAT (Fig. 5A). 
Interestingly, these lipogenic genes were down-regulated with RSV treatment in liver at the same time-
point (Fig. 4G, Suppl. Fig S3F), indicating that RSV exerts opposing effects on lipogenic gene transcription 
in WAT compared to liver. In contrast, SRT did not influence lipogenesis in WAT whereas a strong effect 
was observed in hepatic tissue. To elucidate the mechanism behind the induction of lipogenic genes in 
WAT with long-term RSV treatment, we analyzed the insulin signaling pathway in WAT from these mice. 
Protein levels of IRβ, AKT and GSK3β were all increased in WAT from the RSV-L group, together with 
increased auto-phosphorylation of IRβ (Y1146), as well as an increased phosphorylation of both AKT 
(S473) and GSK3β (S9) (Fig. 5B). Since enhanced insulin signaling in adipocytes is linked to increased 
lipogenesis [Kersten 2001], the upregulation of IRβ protein levels and increased AKT (S473) 
phosphorylation in WAT from RSV-L mice could provide an explanation for the increased transcription of 
lipogenic genes observed in this group. Increased lipogenesis and FA re-esterification is indicative of an 
increased adipogenesis in WAT. However, diametrically opposite to the elevation of lipogenic gene 
expression, short- and long-term RSV treatment led to a reduced fat mass in our mice (Fig. 1B). Hence, 
we speculated that not only lipogenesis, but also other aspects of triglyceride handling might be affected 
in WAT of RSV-treated animals. Indeed, in addition to the transcriptional activation of lipogenic 
processes in the RSV-L group, we also found an induction of genes involved in lipolysis (adipose 
triglyceride lipase ATGL, hormone-sensitive lipase HSL) (Fig. 5C). However, despite the induction of 
lipolytic genes with RSV-treatment, no alterations in plasma non-esterified FA levels in the RSV-L group 
were observed (Suppl. Fig. S4A). These data, together with the concurrent induction of lipolysis and FA 
7.  Manuscript 2: Modulation of Fat and Liver Metabolism Mediates Systemic Effects of 
Resveratrol and SRT1720 Independently of Skeletal Muscle PGC-1α 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
159 
re-esterification, would point towards an increased FA recycling in the RSV-L mice. Since the availability 
of glycerol-3-phosphate (G3P) is essential for FA re-esterification, we investigated transcriptional 
regulation of genes involved in G3P synthesis. Interestingly, we could observe an induction of genes 
involved in two processes important for G3P generation, namely glucose uptake/glycolysis (glucose 
transporter type 4 GLUT4, HK2) and glyceroneogenesis (PEPCK) in the RSV-L group (Fig. 5C). No 
differences in these genes could be detected for the RSV-S and SRT groups, apart from a significant 
upregulation of HKII in SRT treated mice (Fig. 5C). 
RSV improves mitochondrial biogenesis and reduces inflammation in white adipose tissue 
Since SRT treatment affected transcription of mitochondrial genes in liver, we also investigated this 
aspect in adipose tissue. In contrast to the effects in liver, SRT treatment only resulted in a trend towards 
increased PGC-1α transcription in WAT (Fig. 6A), but had no further effect on mitochondrial transcript 
(Fig. 6A) or protein levels (Fig. 6B, Suppl. Fig. S4B). In contrast, RSV-S mice had significantly increased 
PGC-1α transcript levels in WAT (Fig. 6A). RSV-L mice showed no significant induction of PGC-1α mRNA 
levels (Fig. 6A), while PGC-1α protein levels for this time-point were significantly induced (Fig. 6B, Suppl. 
Fig. S4B). In line with the induction of PGC-1α, RSV treatment resulted in a significant induction of 
mitochondrial genes (Uqcrc2, succinate dehydrogenase complex, subunit A SDHA) at both time-points 
(Fig. 6A), while only RSV-L mice displayed enhanced mitochondrial protein levels of SDHB (Fig. 6B, Suppl. 
Fig. S4B). To determine whether the transcriptional induction of mitochondrial genes in WAT could be 
mediated by increased AMPK activity, we determined AMPK phosphorylation (T172) in RSV-S and RSV-L 
mice. In the RSV-S group, relative AMPK phosphorylation displayed a trend towards being up-regulated 
(p=0.07) (Suppl. Fig. S4C). In RSV-L mice however, both AMPK protein levels and relative phosphorylation 
of AMPK (T172) were unchanged (Suppl. Fig. S4C). These data suggest that increased AMPK activity 
might not be the main mechanism by which RSV-treatment increases mitochondrial transcript and 
protein levels in WAT. Another possible explanation for the increased mitochondrial gene transcription is 
through down-regulation of activating transcription factor 3 (ATF3), a transcriptional repressor that 
reduces transcription of PGC-1α and mitochondrial genes in WAT [Jang et al. 2013]. Interestingly, we 
could detect a significant reduction in ATF3 transcript levels in WAT of RSV-L mice, and a strong trend 
(p=0.06) towards diminished ATF3 transcription in RSV-S mice (Fig. 6C). To substantiate these findings, 
we also studied the expression of adiponectin (Adipoq), a gene known to be repressed by ATF3 in 
adipocytes [Kim et al. 2006]. In line with the reduced ATF3 mRNA levels, expression of adiponectin was 
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significantly increased specifically in RSV-treated mice (Fig. 6C), indicating a reduced transcriptional 
repression by ATF3. In SRT treated mice however, no alterations in either ATF3 or adiponectin expression 
were found (Fig. 6C). This finding correlates well with the unchanged mitochondrial gene transcription 
with SRT treatment (Fig. 6A), and suggests that repression of ATF3 is an RSV-specific effect. To gain more 
insight into the mechanisms that underlie the repression of ATF3 expression by RSV, we assessed the 
activity of cAMP response element-binding protein (CREB) since increased CREB-activity has been 
associated with increased ATF3 transcription in WAT in obese conditions [Qi et al. 2009]. In line with the 
lower transcript levels of ATF3 in RSV-treated mice, we could also detect reduced levels of CREB 
phosphorylation (S133) (Fig. 6D, Suppl. Fig. S4D), correlating with a reduced activity of this transcription 
factor. Besides various beneficial systemic effects of adiponectin on whole body metabolism, this 
hormone also possesses anti-inflammatory properties in fat tissue [Tilg and Wolf 2005]. We therefore 
measured gene expression of inflammatory markers in WAT of our mice. In line with the repression of 
ATF3 and induction of adiponectin, inflammatory gene transcription (tumor necrosis factor α TNF, 
monocyte chemotactic protein-1 MCP-1, cluster of differentiation 68 CD68) was decreased in RSV 
treated mice (Fig. 6E). However, SRT treatment did not result in any changes in pro-inflammatory gene 
expression similar to the lack of effect of SRT on mitochondrial OXPHOS gene transcription, adiponectin 
levels or CREB activity in WAT. 
 
Discussion 
Caloric restriction (CR) mediates several beneficial metabolic effects in organisms ranging from yeast to 
rodents and humans [Speakman and Mitchell 2011] and has even been linked to an increased life- and 
healthspan. Therefore, it is not surprising that the concept of using pharmacological CR-mimetics, 
including RSV and SRT, to ameliorate metabolic disorders has received a lot of attention in recent years 
[Ingram et al. 2006, Speakman and Mitchell 2011]. In agreement with other studies [Baur et al. 2006, 
Lagouge et al. 2006, Milne et al. 2007, Feige et al. 2008, Smith et al. 2009, Minor et al. 2011], we 
demonstrate that both RSV and SRT exert beneficial metabolic effects in HFD-fed mice in vivo, such as an 
increased metabolic rate, improved glucose homeostasis, and at least for RSV-treated mice, reduced 
adiposity. However, in contrast to previous hypotheses implying muscle PGC-1α as the common 
molecular effector of these CR mimetics, we now show that SKM PGC-1α is dispensable for the whole-
body metabolic effects of RSV and SRT in vivo, since metabolic changes occurred to the same extent in 
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CTRL as in PGC-1α MKO mice. Importantly, PGC-1α was required for the transcriptional effects on 
mitochondrial genes induced by RSV and SRT treatment in SKM. In contrast to the regulation of gene 
expression, muscle PGC-1α was dispensable for non-transcriptional changes in SKM with SRT treatment, 
such as enhanced oxidative capacity, which could explain why whole body oxygen consumption was 
unaffected by the genetic ablation of SKM PGC-1α. Interestingly, a similar observation was made in a 
study by Finley et al. in regard to the requirement for muscle PGC-1α to induce the systemic effects of CR 
[Finley et al. 2012]. Analogous to our data, this study showed that during CR, PGC-1α was required for 
the enhanced transcription of mitochondrial genes in SKM, while basal oxygen consumption increased to 
the same extent even in the absence of SKM PGC-1α [Finley et al. 2012]. These data and our findings 
collectively indicate that enhanced oxidative capacity in SKM during CR, or during treatment with CR-
mimetic compounds, seems to be dissociated from the induction of mitochondrial genes seen in this 
context, and would therefore be independent of muscle PGC-1α. However, all of these results were 
obtained in sedentary animals and thus do not preclude a more prominent role for muscle PGC-1α in the 
regulation of the metabolic phenotype of physically active mice in which muscle contributes much more 
significantly to the global metabolic rate.  
Despite the structural difference between RSV and SRT, the effects of these compounds are 
considered to be analogous and ultimately mediated through the same signaling pathways. For example, 
the transcriptional response to these two compounds overlaps in the liver [Minor et al. 2011] and is 
similar to the hepatic transcriptional profile during CR [Pearson et al. 2008, Smith et al. 2009]. 
Importantly however, this overlap is small in comparison to the total number of regulated genes [Minor 
et al. 2011] suggesting that many effects of these two postulated CR-mimetic compounds on metabolic 
processes in the liver are in fact unique. In line with this, we identified several metabolic processes in this 
organ that were activated by SRT administration, but not altered with RSV treatment, including 
cholesterol metabolism, β-oxidation, ketogenesis and gluconeogenesis. Intriguingly, we also found that 
RSV and SRT differentially regulate the transcription of lipogenic genes in liver. In agreement with other 
studies [Baur et al. 2006, Gomez-Zorita et al. 2012, Jin et al. 2013], we observed that RSV treatment 
leads to a reduction in hepatic lipogenic gene transcription, and that this results in a mild protection 
against hepatic steatosis. Importantly, this effect also occurs in humans that receive RSV treatment 
[Timmers et al. 2011]. Conversely, SRT treatment led to an enhanced transcription of lipogenic genes in 
liver, and in contrast to other studies [Feige et al. 2008, Yamazaki et al. 2009, Minor et al. 2011], SRT 
administration did not protect against hepatic steatosis. At least in one of these studies [Feige et al. 
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2008], the SRT-linked reduction in hepatic lipid accumulation was only observed at a dose that was five 
times higher than that used in our study. Importantly, this high dose of SRT completely abrogated any 
weight gain in the HFD-fed mice [Feige et al. 2008] and the reduced hepatic lipid accumulation could 
therefore be interpreted as an extension of the lean phenotype of these mice rather than a direct 
hepatic effect of SRT. Importantly, in the mice receiving a similar dose of SRT (100 mg/kg/day) as that 
used in our study, Feige et al. [Feige et al. 2008] could not detect any protective effect of SRT against 
hepatic steatosis. Taken together, the effect of SRT on hepatic gene expression and modulation of 
metabolic pathways in our setup was much stronger than that of RSV. For example, SRT promoted a 
transcriptional induction of cholesterol biosynthesis genes in the liver. This correlated with increased 
circulating levels of HDL and LDL cholesterol, which might constitute a caveat for using this compound as 
a treatment for obesity in patients. In contrast, RSV has a more beneficial effect on whole body lipid 
parameters in our mice, since we could demonstrate a trend towards reduced hepatic lipid accumulation 
as well as significantly lower LDL-cholesterol levels in the RSV-S group. Importantly, this reduction in LDL 
cholesterol levels with RSV treatment has also been reported in human patients [Bhatt et al. 2012, 
Tome-Carneiro et al. 2012]. 
Another important difference we could observe between SRT and RSV is the reduction in 
adiposity seen only with RSV administration. This reduction in fat mass in RSV-, but not SRT-treated mice 
was associated with robust transcriptional effects in WAT in the former cohort. The resulting gene 
expression profile indicates improved adipose tissue health, for example due to increased mitochondrial 
function, enhanced adiponectin expression and reduced adipose tissue inflammation upon RSV 
treatment. These effects have further been corroborated by other studies using RSV in both rodents 
[Rivera et al. 2009, Beaudoin et al. 2013, Gomez-Zorita et al. 2013] and non-human primates [Jimenez-
Gomez et al. 2013]. In search for a mechanism how RSV mediates these effects in WAT, we could 
demonstrate that RSV leads to a reduction in the transcriptional repressor ATF3, a negative regulator of 
mitochondrial metabolism [Jang et al. 2013], GLUT4 [Qi et al. 2009], as well as of adiponectin expression 
[Kim et al. 2006]. CREB is a positive transcriptional regulator of ATF3 during obesity [Qi et al. 2009]. In 
line with this, we found that RSV treatment resulted in reduced phosphorylation of CREB in WAT, 
indicating a reduced activity of this transcription factor. Importantly, mice expressing a dominant 
negative form of CREB in WAT [Qi et al. 2009] display similar phenotypic changes as seen with RSV 
treatment in our study, including reduced inflammation, improved GLUT4 expression and improved 
whole body glucose tolerance. Moreover, in a transcription factor analysis performed in WAT from 
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humans receiving RSV treatment, CREB1-activity was predicted to be inhibited by RSV. This is in 
agreement with our findings, and gives credence that the repression of CREB-ATF3 axis by RSV treatment 
in WAT is also relevant in humans [Konings et al. 2013].  
The efficacy of CR on longevity in different species is somewhat controversial, and the extent of 
the effect of RSV in particular has been questioned in recent studies [Higashida et al. 2013]. Similarly, we 
could not observe an increase in mitochondrial oxidative capacity that was reported in the study by 
Lagouge et al. [Lagouge et al. 2006] even though the same dose of RSV (4 g/kg diet) was used. In 
contrast, two recent studies found no effect of RSV treatment (4 g/kg diet) on oxidative protein content 
[Higashida et al. 2013, Ringholm et al. 2013] and mitochondrial DNA content [Ringholm et al. 2013] in 
SKM, similar to our results. One important difference between the Lagouge and our study is the choice of 
HFD. The diet our mice received (D12492, Research diet) is mainly composed of lard, and thus contains a 
high percentage of long-chain FAs (LCFA). The HFD used by Lagouge et al. (D12327, Research diets) 
contains mainly coconut oil, which in comparison to lard primarily consists of medium-chain FAs (MCFA). 
HFDs rich in LCFAs have a more detrimental effect on adiposity and glucose tolerance in mice than 
MCFA-based diets [Montgomery et al. 2013]. In addition, MCFA-rich diets might even induce 
mitochondrial metabolism and oxidative capacity in SKM [Turner et al. 2009, Montgomery et al. 2013]. 
Thus, the different composition of FAs in the HFDs used by us and by Lagouge et al. might have 
differentially influenced the basal metabolic state of SKM and as a consequence, the response to RSV.  
Higashida et al. [Higashida et al. 2013] speculate that the lack of effect of RSV treatment in their study 
could be due to the low bioavailability of the compound in blood. However, using the same dose of RSV, 
we and others could clearly demonstrate systemic metabolic effects in mice, metabolic adaptation of 
SKM as well as modulation of signaling pathways in both liver and WAT. Taken together, these findings 
indicate that the effects of RSV on SKM metabolism and function seem to be complex and highly 
dependent on the specific experimental context. 
In summary, we show that PGC-1α is required for the transcriptional effects of both RSV and SRT 
on mitochondrial gene expression in SKM, while muscle PGC-1α is dispensable for the systemic 
metabolic effects mediated by RSV and SRT. However, our findings suggest PGC-1α to be a potential 
mediator of RSV- and SRT-treatment in other tissues such as liver and WAT. Importantly, at least in 
sedentary, HFD-fed mice, treatment with RSV and SRT resulted in more prominent metabolic changes in 
WAT and liver as compared to SKM. It might therefore be of importance to adapt a broader, less muscle-
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centric view on the metabolic effects of RSV- and SRT-treatment, in particular in the context of a 
potential therapy of sedentary, obese patients. Furthermore, the comparison of short- and long-term 
administration of RSV highlights some potential caveats for the design of such a therapy: for example, 
increased lipogenesis in WAT of the long-term RSV-treated animals could indicate that administration of 
this compound in patients should be time-limited. Intriguingly, despite the apparently similar systemic 
effects of RSV and SRT, these compounds exert differential effects on key metabolic organs including 
SKM, liver and WAT (Fig. 6F). Hence, our findings reveal important insights into the specific effects of 
these structurally distinct compounds. Importantly, this indicates that increased hepatic lipogenesis and 
LDL levels should be considered when designing SRT-based therapeutic approaches. It is currently 
unclear whether these differences between RSV and SRT are caused by variable bioavailability in these 
tissues, activation of different molecular targets and signaling pathways or due to non-SIRT1-mediated 
effects of RSV, e.g. its phytoestrogenic, anti-inflammatory or antioxidant properties. In either case, it is of 
importance to consider the differential effects of RSV and SRT treatment for future study design, and 
even more significantly for the use of these compounds in a clinical context. 
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Figure 1 - Systemic effects of RSV and SRT are independent of skeletal muscle PGC-1α 
CTRL and PGC-1α MKO mice were fed a high fat diet (HFD) for 2 weeks, followed by resveratrol (RSV) 
treatment (4 g/kg diet) for 4 weeks (RSV-S), 13 weeks (RSV-L) or SRT1720 administration (1 g/kg diet) for 
4 weeks (SRT). (A) Body weight at the end of the treatment period (n= 8-15 per group). (B) Fat mass 
expressed as percentage of total body weight at the end of the treatment period (n= 5-9 per group). (C) 
Basal energy expenditure as measured by 24 hour average oxygen consumption (vO2) (n= 5-9 per group). 
(D) Intraperitoneal glucose tolerance test. Mice were injected with a bolus of 2 g glucose/kg body weight 
after a 16 hours fasting period (n= 8-10 per group). (E) Area under curve for intraperitoneal glucose 
tolerance test (n= 8-10 per group). (F) Blood glucose levels measured in tail vein blood after a 16 hours 
fasting period (n= 8-10 per group). Error bars represent mean ±SEM. Significant differences (p value < 
0.05) between CTRL and PGC-1α MKO mice are indicated by a number sign (#) and between untreated 
and treated groups by an asterisk (*). 
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Figure 2 - PGC-1α is required for the transcriptional induction of mitochondrial genes in skeletal 
muscle 
(A) mRNA levels of PGC-1α and mitochondrial genes in skeletal muscle (SKM) relative to PolR2A (RSV-S, 
RSV-L) or HPRT (SRT) (n= 5-8 per group). (B) Representative immunoblots of mitochondrial proteins in 
SKM (n= 6 per group). (C) Representative pictures of nicotinamide adenine dinucleotide (NADH) stainings 
of SKM sections (n= 3 per group). (D) Representative electron micrographs from SKM. Bar graph shows 
average mitochondrial number per image normalized to HFD CTRL, and expressed in arbitrary units (a.u.) 
(n= 3 per group). Error bars represent mean ±SEM. Significant differences (p value < 0.05) between CTRL 
and PGC-1α MKO mice are indicated by a number sign (#) and between untreated and treated groups by 
an asterisk (*). Abbreviations not mentioned earlier: ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1 ATP5A; ubiquinol cytochrome c reductase core protein 2 Uqcrc2; succinate 
dehydrogenase complex, subunit B SDHB; eukaryotic elongation factor 2 eEF2. 
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Figure 3 - RSV and SRT treatment lead to minor transcriptional effects in skeletal muscle 
(A-C) mRNA levels of genes involved in (A) glucose uptake and glycolysis, (B) myosin heavy chain (MHC) 
subtypes and (C) fatty acid (FA) β-oxidation in skeletal muscle (SKM) relative to PolR2A (RSV-S, RSV-L) or 
HPRT (SRT) (n= 5-8 per group). (D) Representative immunoblots of AMPK total protein and AMPK 
phosphorylation (T172) in SKM. Bar graphs show quantification of AMPK phosphorylation relative to 
total AMPK protein content (n= 6 per group). Error bars represent mean ±SEM. Significant differences (p 
value < 0.05) between CTRL and PGC-1α MKO mice are indicated by a number sign (#) and between 
untreated and treated groups by an asterisk (*). Abbreviations not mentioned earlier: pyruvate kinase 
muscle isozyme 1 PKM1. 
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Figure 4 - RSV and SRT treatment promote differential effects on metabolic processes in the liver 
(A) mRNA levels of PGC-1α/β and mitochondrial genes in liver, relative to RPL0 (RSV-S) or PolR2A (SRT) 
(n= 5-8 per group). (B) Representative immunoblots of PGC-1α and mitochondrial proteins in liver. Bar 
graphs show quantification of PGC-1α and mitochondrial protein content relative to eEF2 (n=6 per 
group). (C) mRNA levels of genes involved in ketogenesis and gluconeogenesis in liver, relative to RPL0 
(RSV-S) or PolR2A (SRT) (n= 5-8 per group). (D) Immunoprecipitation of acetylated lysines from hepatic 
nuclear extracts, followed by immunoblotting against PGC-1α. For the input, an immunoblot against 
PGC-1α from hepatic nuclear extracts is shown (n= 3 per group). (E) Representative immunoblot of AMPK 
total protein and AMPK phosphorylation (T172), as well as ACC total protein and ACC phosphorylation 
(S79) in liver (n=6 per group). (F-G) mRNA levels of genes involved in (F) fatty acid β-oxidation, fatty acid 
uptake and (G) lipogenesis in liver, relative to RPL0 (RSV-S) or PolR2A (SRT) (n= 5-8 per group). (H) 
Triglyceride content in liver expressed in arbitrary units (a.u.), relative to high fat diet (HFD) fed groups 
(n= 5-8 per group). (I) mRNA levels of genes involved in cholesterol biogenesis in liver, relative to RPL0 
(RSV-S) or PolR2A (SRT) (n= 5-8 per group). (J) LDL- and HDL cholesterol levels measured in plasma (n=8-
10 per group). Error bars represent mean ±SEM. Significant differences (p value < 0.05) between 
untreated and treated groups are indicated by an asterisk (*). 
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Figure 5 - Long-term RSV treatment induces genes involved in lipogenesis and lipolysis in white 
adipose tissue 
(A) mRNA levels of genes involved in lipogenesis in white adipose tissue (WAT), relative to PolR2A (RSV-S, 
RSV-L) or HPRT (SRT) (n= 5-8 per group).  (B) Representative immunoblots of IRβ, Akt and GSK3β as well 
as their respective phosphorylations in WAT. Bar graphs to the right represents quantification of IRβ, Akt 
and GSK3β protein levels as well as their respective phosphorylations relative to eEF2, as well as 
phosphorylation relative to total protein level  in white adipose tissue (WAT) (n=6 per group). (C) mRNA 
levels of genes involved in lipolysis and glycerol-3-phosphate generation in WAT, relative to PolR2A (RSV-
S, RSV-L) or HPRT (SRT) (n= 5-8 per group). Error bars represent mean ±SEM. Significant differences (p 
value < 0.05) between untreated and treated groups are indicated by an asterisk (*). 
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Figure 6 - RSV improves mitochondrial biogenesis and reduces inflammation in white adipose tissue 
 (A) mRNA levels of PGC-1α/β and mitochondrial genes in white adipose tissue (WAT), relative to PolR2A 
(RSV-S, RSV-L) or HPRT (SRT) (n= 5-8 per group). (B) Representative immunoblots of PGC-1α and 
mitochondrial proteins in WAT (n=6 per group). (C) mRNA levels of ATF3 and Adipoq in WAT, relative to 
PolR2A (RSV-S, RSV-L) or HPRT (SRT) (n= 5-8 per group). (D) Representative immunoblots of CREB total 
protein and CREB phosphorylation (S133) in WAT (n=6 per group). (E) mRNA levels of genes associated 
with inflammation in WAT, relative to PolR2A (RSV-S, RSV-L) or HPRT (SRT) (n= 5-8 per group). Error bars 
represent mean ±SEM. Significant differences (p value < 0.05) between untreated and treated groups are 
indicated by an asterisk (*). (F) Schematic representation of the effects of resveratrol and SRT1720 on 
whole body level, as well as relevant gene programs affected in skeletal muscle, liver and white adipose 
tissue. Abbreviations not mentioned earlier: ATP synthase F0 subunit 6 ATP6. 
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SI Figure 1 
CTRL and PGC-1α MKO mice were fed a high fat diet (HFD) for 2 weeks, followed by resveratrol (RSV) 
treatment (4 g/kg diet) for 4 weeks (RSV-S), 13 weeks (RSV-L) or SRT1720 administration (1 g/kg diet) for 
4 weeks (SRT). Average (A) food intake and (B) spontaneous ambulatory activity over 24 hours (n=5-9 per 
group). (C) Blood glucose measured in tail vein blood from ad libitum fed mice (n=8-10 per group). Error 
bars represent mean ±SEM. Significant differences (p value < 0.05) between CTRL and PGC-1α MKO mice 
are indicated by a number sign (#) and between untreated and treated groups by an asterisk (*). 
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SI Figure 2 
(A) Quantification of nicotinamide adenine dinucleotide (NADH) stainings of skeletal muscle (SKM) 
sections, expressed in arbitrary units (a.u.) normalized to HFD fed CTRL mice (n=3 per group). (B) 
Representative pictures of enzymatic succinic dehydrogenase (SDH) stainings of SKM sections. Bar 
graphs show quantification of SDH staining, expressed in arbitrary units (a.u.) normalized to HFD fed 
CTRL mice (n=3 per group).  (C) mRNA levels of mitochondrial genes in SKM relative to HPRT (n=5-8 per 
group). Error bars represent mean ±SEM. Significant differences (p value < 0.05) between CTRL and PGC-
1α MKO mice are indicated by a number sign (#) and between untreated and treated groups by an 
asterisk (*). Abbreviations not mentioned earlier: NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 5 Ndufa5; NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 3 Ndufb3; NADH 
Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 9 Ndufb9; NADH Dehydrogenase (Ubiquinone) 
Flavoprotein 1 Ndufv1. 
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SI Figure 3 
(A) Quantification of immunoblots of AMPK and ACC and their respective phosphorylations relative to 
eEF2, as well as phosphorylation relative to total protein level of AMPK and ACC in liver (n=6 per group). 
(B) mRNA levels of PGC-1α/β and mitochondrial genes in liver, relative to PolR2A (n=8 per group). (C) 
mRNA levels of genes involved in ketogenesis and gluconeogenesis in liver, relative to PolR2A (n=8 per 
group). (D) mRNA levels of genes involved in fatty acid β-oxidation and fatty acid uptake in liver, relative 
to PolR2A (n=8 per group). (E) Representative immunoblot of IRβ, Akt and GSK3β as well as their 
respective phosphorylations. Bar graphs show quantification of total protein level and phosphorylation 
relative to eEF2, as well as phosphorylation relative to total protein level of IRβ, Akt and GSK3β (n=6 per 
group). (F) mRNA levels of genes involved in  de novo lipogenesis in liver relative to PolR2A (n=8 per 
group). (G) Triglyceride content in liver expressed in arbitrary units (a.u.), relative to high fat diet (HFD) 
fed group (n=8 per group). (H) Representative pictures of Oil Red O staining in liver sections (n=5 per 
group). (I) mRNA levels of genes involved in cholesterol biogenesis in liver, relative to PolR2A (n=8 per 
group). (J) LDL- and HDL cholesterol levels measured in plasma (n=8 per group). Error bars represent 
mean ±SEM. Significant differences (p value < 0.05) between untreated and treated groups are indicated 
by an asterisk (*). 
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SI Figure 4 
(A) Fasted and fed non-esterified fatty acid (NEFA) levels in plasma (n=8 per group). (B) Quantification of 
PGC-1α and mitochondrial protein content relative to eEF2 in immunoblots from white adipose tissue 
(WAT) (n=6 per group). (C) Representative immunoblots of AMPK total protein and AMPK 
phosphorylation (T172) in WAT. Bar graphs show quantification of AMPK protein levels and AMPK 
phosphorylation (T172) relative to eEF2, as well as AMPK phosphorylation relative to total AMPK protein 
content in WAT (n=6 per group). (D) Quantification of CREB and CREB phosphorylation (S133) relative to 
eEF2, as well as CREB phosphorylation relative to total CREB protein content in WAT (n=6 per group). 
Error bars represent mean ±SEM. Significant differences (p value < 0.05) between untreated and treated 
groups are indicated by an asterisk (*). 
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Table S1 - qPCR primer sequences 
 
Target gene Forward primer Reverse primer 
ACAT1 GTGAAGGAAGTCTACATGGGCA TGTGGTGCATGGAGTGGAAATA 
ACAT2 ATTCAAAACATGGGGATTCGGC TCAATGGGAAACCGAGAGACAG 
ACC1 AAGGCTATGTGAAGGATG CTGTCTGAAGAGGTTAGG 
ACC2 CTTGCTTCTCTTTCTGACTTG GGCTTCCACCTTACTGTTG 
ADIPOQ AAGAAGGACAAGGCCGTTCTC GCTATGGGTAGTTGCAGTCAG 
ATF3 CTGGCTTCCTGTGCACTTCTA GGTCAATGCAGTAGGTCACCA 
ATGL CACTTTAGCTCCAAGGATGA TGGTTCAGTAGGCCATTCCT 
ATP6 ACTATGAGCTGGAGCCGTAATTACA TGGAAGGAAGTGGGCAAGTG 
CACT CTGCGCCCATCATTGGA CAGACCAAACCCAAAGAAGCA 
CD36 GGCAAAGAACAGCAGCAAAAT TGGCTAGATAACGAACTCTGTATGTGT 
CD68 CAGCTCCAAGCCCAAATTCAAA GATATGCCCCAAGCCCTCTTTA 
COX5B CTTCAGGCACCAAGGAAGAC TTCACAGATGCAGCCCACTA 
CPT1B ATCATGTATCGCCGCAAACT CCATCTGGTAGGAGCACATGG 
CS CCCAGGATACGGTCATGCA GCAAACTCTCGCTGACAGGAA 
CYTC AAATCTCCACGGTCTGTTCG TATCCTCTCCCCAGGTGATG 
DGAT1 TGGTGTGTGGTGATGCTGATC GCCAGGCGCTTCTCAA 
DHCR7 AGGCTGGATCTCAAGGACAATG CAATGAATGGAGCGAAGAGCAG 
FASN GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
FDFT1 GTTCGTCAAGTGTCTAGGCCA GTGAGTCCTGGTCCATCTTGG 
G6PC GTGCTTGCATTCCTGTATGGTA TAGGCTGAGGAGGAGAAAACTG 
GLUT4 CATGGCTGTCGCTGGTTTC AAACCCATGCCGACAATGA 
GPAT TGACAGTTGGCACAATAGAC CGGCTCATAAGGCTCTCC 
HK2 AAAACCAAGTGCAGAAGGTTGAC GAACCGCCTAGAAATCTCCAGAA 
HMGCL CCAGCTTTGTTTCTCCCAAGTG GATGCCGGGAAACTTCTGAATG 
HMGCS2 CCACAAGGTGAACTTCTCTCCA TGCATCTCATCCACTCGTTCAA 
HPRT ATGCCGAGGATTTGGAAAAAGTG TGACATCTCGAGCAAGTCTTTCA 
HSL CACAGACCTCTAAATCCCACGAG AGGGAGTAGTCGATGGAGAAGAT 
LCAD CCAGCTAATGCCTTACTTGGAGA GCAATTAAGAGCCTTTCCTGTGG 
LPL AAGCAGCAAGATGTACCTGAAGA CATCCTCAGTCCCAGAAAAGTGA 
MCAD AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
MCP-1 AGGTGTCCCAAAGAAGCTGTAG TGTCTGGACCCATTCCTTCTTG 
MHC I CCTCCTCACATCTTCTCCATCTCT TGGACTGATTCTCCCGATCTG 
MHCIIa CAACCTCAAAGAGCGTTATGCA AGGGTTGACGGTGACACAGAA 
MHCIIb CAACCCATATGACTTTGCTTACGT TCCCAGGATATCAACAGCAGTGT 
MHCIIx GGCCCCACCCCACATC CTCCCGATCTGTCAGCATGA 
NDUF5A ACATGCAGCCTATAGAAAATACACAGA TCCGCCTTGACCATATCCA 
NDUFB3 TAC CAC AAA CGC AGC AAA CC AAG GGA CGC CAT TAG AAA CG 
NDUFB8 CAAGAAGTATAACATGCGAGTGGAA CCATACCCCATGCCATCATC 
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NDUFB9 CATGGTGTATCCACAGGGACAA GCTGGGTAGCCCTCATCATATC 
NDUFV1 CTTCCCCACTGGCCTCAAG CCAAAACCCAGTGATCCAGC 
PDK4 AAAATTTCCAGGCCAACCAA CGAAGAGCATGTGGTGAAGGT 
PEPCK CTTCTCTGCCAAGGTCATCC TTTTGGGGATGGGCAC 
PGC-1α AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
PGC-1β CCATGCTGTTGATGTTCCAC GACGACTGACAGCACTTGGA 
PKM1 CATTATCGTGCTCACCAAGTCTG GATTTCGAGTCACGGCAATGATA 
POLR2A AATCCGCATCATGAACAGTG CAGCATGTTGGACTCAATGC 
RPL0 CTGCTGAACATGCTGAACATCTC CTTCAGGGTTATAAATGCTGCCG 
SCD1 GTCAGGAGGGCAGGTTTC GAGCGTGGACTTCGGTTC 
SDHA GCTGGTGTGGATGTCACTAAGG CCCACCCATGTTGTAATGCA 
SDHB TGACGTCAGGAGCCAAAATGG CCTCGACAGGCCTGAAACTG 
SDHC AGTTCAAACCGTCCTCTGTCTC CCTCCACTCAAGGCTATTCCAG 
SDHD TTCTCTTAAAGCTGGGCGTTCT GAAATGCTGACACATAAGCGGG 
SREBP1C GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
TNF GCCTATGTCTCAGCCTCTTCTC TGGGAACTTCTCATCCCTTTGG 
UCP3 TTTTGCGGACCTCCTCACTT TGGATCTGCAGACGGACCTT 
UQCRC2 CCCATCTTGCTTTGCTGTCTG AATAAAATCTCGAGAAGGACCCG 
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Abstract 
In response to a reduced nutrient intake, the body readily mobilizes its energy stores to maintain systemic 
energy homeostasis.  In a low-carbohydrate environment, such as during fasting or adherence to a high-
fat/low-carbohydrate diet, ketone bodies become an important energy substrate in extra-hepatic organs.  
This is especially pertinent in organs with a high energy demand such as brain, kidney, heart and skeletal 
muscle.  Here we show that the transcriptional coactivator peroxisome proliferator-activated receptor 
gamma coactivator 1 alpha (PGC-1α) is an important transcriptional regulator of ketolytic enzymes in 
these organs.  Consequently, overexpression or knockout of PGC-1α specifically in skeletal muscle is 
sufficient to modulate systemic ketone body homeostasis in response to fasting, high-fat/low-
carbohydrate diet feeding and exercise. PGC-1α is furthermore necessary for the transcriptional induction 
of ketolytic enzymes and improved ketolytic capacity in response to endurance exercise training. 
Importantly, overexpression of PGC-1α was sufficient to ameliorate diabetic hyperketonemia in mice.  
These results demonstrate a novel role of skeletal muscle PGC-1α as a transcriptional regulator of systemic 
ketolytic capacity, and a potential therapeutic target to ameliorate diabetic ketoacidosis. 
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Introduction 
To maintain energy homeostasis, the body has developed several mechanisms to adjust for variations in 
nutrient availability.  During nutrient-deprivation, such as fasting, the body can mobilize endogenous 
energy stores to compensate for a reduced energy intake.  Moreover, this is accompanied by a switch in 
fuel-preference in many organs.  During prolonged starvation, ketone bodies become an important 
alternative fuel to help maintain energy homeostasis. [Cahill 2006].  This is especially important in tissues 
with a high energy demand, such as kidney, heart, brain and skeletal muscle [Robinson and Williamson 
1980, Newman and Verdin 2014].  The collective term ketone body encompasses β-hydroxybutyrate 
(βOHB), acetoacetate (AcAc) and acetone.  βOHB and AcAc are short-chain derivatives of acetyl-CoA, 
almost exclusively produced in the liver through oxidation of fatty acids and subsequent ketogenesis, 
while acetone is formed through spontaneous degradation of AcAc [Robinson and Williamson 1980, 
Newman and Verdin 2014].  Hepatic ketogenesis is induced during states of reduced carbohydrate intake, 
such as fasting [Cahill 2006] and low-carbohydrate ketogenic diets (LCKD) [Wheless 2008] but also after 
exercise [Johnson et al. 1969].  The ketogenic rate of the liver is dictated by the availability of circulating 
fatty acids and the intracellular redox status, but also through direct hormonal control by insulin and 
glucagon [Laffel 1999, Newman and Verdin 2014].  In extra-hepatic organs, βOHB and AcAc are oxidized 
to acetyl-CoA through an enzymatic process termed ketolysis, and subsequently oxidized in the TCA-cycle.  
Ketolysis occurs in the mitochondrial matrix and is catalyzed by 3-hydroxybutyrate dehydrogenase, type 
1 (BDH1), succinyl-CoA:3-ketoacid-coenzyme A transferase 1 (SCOT; OXCT1) and acetyl-CoA 
acetyltransferase 1 (ACAT1)  [Robinson and Williamson 1980, Newman and Verdin 2014].  Mutations 
within genes encoding these enzymes are associated with exacerbated ketosis during starvation in 
humans [Saudubray et al. 1987, Fukao et al. 2011] and whole-body knockout of the rate-limiting enzyme 
OXCT1 leads to severe hyperketonemia and lethality in mice [Cotter et al. 2011].  Hyperketonemia is also 
a common complication in diabetic patients and can lead to severe and possibly lethal ketoacidosis [Laffel 
1999].  Diabetic ketoacidosis has been attributed to an exacerbated lipolysis, coupled to increased hepatic 
ketogenesis [McGarry and Foster 1980, Laffel 1999]. However, there is also evidence for reduced ketone 
body uptake [Ikeda et al. 1991, Okuda et al. 1991] and impaired OXCT1 activity [Grinblat et al. 1986, 
Turko et al. 2001] in heart and skeletal muscle of diabetic rodents. These data suggest a possible 
involvement of impaired ketolysis in the etiology of diabetic ketoacidosis.  However, relatively little is 
known about how ketolytic enzymes are regulated [Newman and Verdin 2014].  An important metabolic 
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regulator in oxidative organs is the transcriptional coactivator peroxisome proliferator-activated receptor 
gamma coactivator 1 alpha (PGC-1α) [Lin et al. 2005].  PGC-1α is known to control several gene programs 
associated with mitochondrial and metabolic processes in oxidative organs [Lin et al. 2005].  Moreover, 
PGC-1α has also been shown to regulate transcription of the main lactate and ketone body transporter 
monocarboxylate transporter 1 (MCT1) in skeletal muscle [Summermatter et al. 2013a].  Interestingly, 
exercise training, a stimulus known to increase PGC-1α activity in muscle [Baar et al. 2002, Pilegaard et 
al. 2003, Mathai et al. 2008], enhances ketolytic capacity in skeletal muscle of both healthy and diabetic 
rodents [Adams and Koeslag 1988, El Midaoui et al. 2005].  PGC-1α might therefore be involved in the 
regulation of ketone body oxidation.  In this study, we demonstrate that PGC-1α is an important 
transcriptional regulator of ketolytic enzymes.  Moreover, we show that modulation of PGC-1α in skeletal 
muscle affects systemic ketosis in response to various stimuli such as fasting, LCKD feeding and exercise.  
In line with this, muscle-specific overexpression of PGC-1α was sufficient to reduce hyperketonemia in 
diabetic mice, and would thus constitute a novel therapeutic target to ameliorate diabetic ketoacidosis. 
 
Material and methods 
Animals and diets - Animals were housed in a conventional facility with a 12-h light/12-h dark cycle with 
free access to food and water. All experiments were performed in accordance with federal guidelines and 
were approved by the Kantonales Veterinäramt of Kanton Basel-Stadt. PGC-1α muscle specific knockout 
mice (mKO), PGC-1α muscle specific transgenic mice (mTG) and whole-body PGC-1α-knockout mice (gKO) 
used in this study have been described elsewhere [Lin et al. 2002, Lin et al. 2004, Perez-Schindler et al. 
2013]. The diets used for this study were either a chow diet (CHOW) (AIN-93G, Provimi Kliba Nafag AG) 
containing 7% fat, 58.5% carbohydrates and 18% proteins, or a low-carbohydrate ketogenic diet (LCKD) 
(XL75:XP10, Provimi Kliba Nafag AG), containing 74.4% fat, 3% carbohydrates and 9.9% proteins.  
Blood analysis - Blood glucose and blood βOHB were measured in a tail vein blood sample using either a 
handheld glucose meter (Accu-Chek, Roche) or βOHB-meter (Precision Xtra, Abbott). For non-esterified 
fatty acid (NEFA) levels, whole tail-vein blood was collected in Microvette tubes (Sarstedt) and plasma 
was isolated. NEFA levels in plasma were determined using a colorimetric commercial test (HR Series 
NEFA-HR(2); Wako Diagnostics) according to manufacturer’s instructions.  Plasma acetoacetate (AcAc) 
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levels were determined using a colorimetric commercial test (Acetoacetate Assay Kit; Abcam) according 
to manufacturer’s instructions. 
βOHB tolerance test - Animals were fasted for 5 hours in the morning, and then received a bolus 
intraperitoneal (I.P.) injection of 1.5 g/kg bodyweight Na-βOHB (Sigma). Blood βOHB levels were 
consecutively measured in tail vein blood at 0, 15, 30, 45, 60 and 90 minutes after injection. 
Acute and chronic exercise - Chronic exercise training was performed by allowing mice free access to 
running wheels (Columbus instruments) in their home cages, starting from the age of 10-12 weeks, and 
lasting for a total of 8 weeks.  Sedentary control groups were housed under similar conditions in cages 
without running wheels.  Twenty hours prior to sacrifice, mice were moved from their wheel cages to 
cages without running wheels.  For post-exercise ketosis tests, animals were acclimatized to treadmill 
running 2 days before the start of the experiment, for 5 minutes at 8 meters/minute (m/m) followed by 5 
minutes at 10 m/m, at an incline of 5°. For the actual experiment, treadmill (Columbus instruments) was 
kept at an incline of 5°. The program started at 5 m/m for 5 minutes, followed by 8 m/m for 10 minutes.  
The speed of the treadmill was then increased by 2 m/m every 15 minutes.  Before the run, basal blood 
βOHB and glucose of the mice was assessed in a tail-vein blood sample.  Mice were removed from the 
treadmill after 80 minutes of running, before any of the mice reached terminal exhaustion.  Blood βOHB 
and glucose levels were consecutively measured in tail vein blood at 0, 30 and 180 minutes after 
termination of treadmill running.  
Streptozotocin-administration – Mice were fasted for 10 hours previous to injection, and subsequently 
injected with Streptozotocin (STZ) (Sigma) I.P. at a dose of 150 mg/kg. 10% sucrose was administered to 
the mice during the first 24 hours after injection.  Successful induction of hyperglycemia was confirmed 
at 3 days after injection.  Blood βOHB and glucose levels were measured in tail vein blood at day 5, and 
mice were sacrificed for organ collection. 
In vitro experiments - C2C12 myoblasts were grown to confluence in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (P/S).  Confluent myoblasts 
were differentiated into myotubes through addition of DMEM containing 2% horse serum and 1% P/S.  All 
subsequent experiments were conducted on myotubes that were differentiated for 4 days.  For 
overexpression of PGC-1α, myoblasts were transduced with adenovirus containing either GFP-PGC-1α or 
GFP (control).  After 24 hours, virus was removed, and fresh differentiation medium was added. 48 hours 
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after initial infection, cells were washed with PBS and harvested on ice. For inhibition of ERRα, myotubes 
were co-incubated with 10 µM XCT-790 (Sigma) or 0.2% DMSO (vehicle) for 48 hours.  Three independent 
experiments were performed in triplicates. 
RNA extraction and qRT-PCR - Frozen tissue or cells were homogenized and total RNA was extracted using 
TRIzol reagent (Invitrogen). RNA concentration was adjusted and cDNA synthesis was performed using 1 
ug of total RNA. Semi-quantitative Real-time PCR analysis was performed using Fast SYBR Green master 
mix (Applied Biosystems) on a StepOnePlus Real-Time PCR System (Applied Biosystems). Relative 
expression levels for each gene of interest were calculated with the ΔΔCt method, using 18s as 
normalization control.  
Immunoblotting - Tissues were homogenized in RIPA buffer, and equal amounts of proteins were 
separated on SDS-PAGE under reducing conditions, and transferred to a nitrocellulose membrane 
(Whatman). Proteins of interest were detected using the following antibodies: OXCT1 (ab105320; Abcam), 
ACAT1 (HPA004428; Sigma), eEF2 (2332; Cell signaling), Polyclonal Swine Anti-Rabbit 
Immunoglobulins/HRP (P0399, Dako), Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP (P0260, 
Dako). Densitometric analysis of immunoblots was performed on 6 – 7 individual samples using Image-J 
software, and a representative selection from this group is presented in each figure. 
Statistical analysis - All data are presented as means ± SEM.  Unpaired student two-tailed t test or one-
way ANOVA with Bonferroni’s post-hoc test was used to determine differences between groups.  
Significance was considered with p<0.05.  
 
Results 
To study the role of PGC-1α in systemic ketone body homeostasis, we used mice with a whole body 
knockout of PGC-1α (global KO; gKO) and measured circulating βOHB levels after 24 hours of fasting.  
Fasting induced a state of ketosis in CTRL mice, as indicated by the increased levels of βOHB in blood (FIG 
1A).  Interestingly, gKO mice displayed a significant hyperketonemia compared to CTRL mice in response 
to fasting (FIG 1A).  To investigate whether this phenotype could be explained by an increased ketone 
body production, we measured mRNA levels of genes involved in hepatic ketogenesis.  We could detect a 
complete ablation of PGC-1α mRNA in liver in gKO mice (FIG 1B).  However, the loss of PGC-1α in liver did 
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not impair the induction of ketogenic genes, such as Acat1, 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(Hmgcs2) and 3-Hydroxymethyl-3-Methylglutaryl-CoA lyase (Hmgcl) with fasting (FIG 1B).  This finding is 
surprising considering the supposed role of PGC-1α as a transcriptional coactivator of hepatic ketogenic 
genes [Rhee et al. 2003, Tabata et al. 2014] but could be connected to the aberrant systemic metabolic 
phenotype of global PGC-1α knockout mice [Lin et al. 2004, Leone et al. 2005].  Nonetheless, changes in 
hepatic ketogenesis are not likely to explain the fasting-induced hyperketonemia in gKO mice.  
Interestingly, mice with a global reduction in ketolytic capacity such as whole-body OXCT1 knockout mice 
[Cotter et al. 2011] display increased circulating ketone body levels due to impaired extra-hepatic ketone 
body oxidation.  We therefore hypothesized that impaired ketolysis could account for the fasting-induced 
hyperketonemia in gKO mice.  Hence, we measured expression of PGC-1α and genes important for ketone 
body oxidation in major ketolytic organs such as kidney (FIG 1C), brain (FIG 1D), heart (FIG 1E) and skeletal 
muscle (FIG 1F).  As observed in liver, gKO mice displayed a complete ablation of PGC-1α mRNA in all 
ketolytic organs investigated (FIG 1C-F).  Interestingly, this was associated with a reduced transcription of 
the ketolytic genes Bdh1, Oxct1 and Acat1 in kidney, brain and heart (FIG 1C-E).  Hence, PGC-1α is a global 
transcriptional regulator of ketolytic enzymes.  Surprisingly, only Oxct1 transcription was affected in 
skeletal muscle of gKO mice, while no significant differences could be detected for Bdh1 and Acat1 (FIG 
1F). 
PGC-1α knockout in skeletal muscle leads to reduced transcription of ketolytic genes 
Since skeletal muscle has been demonstrated to contribute significantly to the removal of ketone bodies 
from the blood after fasting [Cotter et al. 2013], and since Oxct1 transcription was significantly reduced 
in skeletal muscle from gKO mice (FIG 1F), we decided to further investigate the role of PGC-1α in the 
regulation of skeletal muscle ketone body oxidation.  We thus utilized muscle-specific PGC-1α knockout 
(mKO) mice, which allows us to circumvent the aberrant metabolic phenotype associated with global 
deletion of PGC-1α.  PGC-1α mKO mice displayed an ablation of PGC-1α in skeletal muscle (FIG 1G-H) and 
in contrast to gKO mice (FIG 1F), this was accompanied by reduced transcription of all ketolytic genes 
(Bdh1, Oxct1, and Acat1) (FIG 1G-H).  Importantly, in line with the reduced Oxct1 and Acat1 mRNA levels, 
also protein levels of both OXCT1 and ACAT1 were reduced in gastrocnemius muscle of mKO mice (FIG 
1I).  Moreover, mRNA levels of the main ketone body transporter Mct1, together with mRNA levels of TCA 
cycle enzymes such as citrate synthase (Cs), aconitase 2 (Aco2) and isocitrate dehydrogenase [NAD] 
subunit alpha (Idh3a) were decreased in muscle from mKO mice (FIG 1J).  Collectively, these data 
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demonstrate that PGC-1α is important for the transcriptional regulation of ketone body transporters, 
ketolytic enzymes as well as TCA-cycle enzymes.  PGC-1α thus affects transcriptional regulation of the 
components necessary for terminal oxidation of ketone bodies in skeletal muscle. 
PGC-1α muscle-specific knockout mice display fasting-induced hyperketonemia 
To investigate whether muscle-specific ablation of PGC-1α could recapitulate the hyperketonemia seen 
with global ablation of PGC-1α, we fasted the mice for 24 hours and measured circulating βOHB levels in 
blood.  PGC-1α mKO mice displayed a significant hyperketonemia with increased circulating levels of 
βOHB (FIG 2A) and AcAc (FIG 2B) compared to CTRL mice.  To confirm that the increased ketosis in mKO 
mice was not due to an altered fasting response in liver, we measured transcription of genes important 
for hepatic ketogenesis.  There was no difference between CTRL and mKO mice in the induction of genes 
involved in hepatic fatty acid uptake (cluster of differentiation 36, CD36) β-oxidation (carnitine 
palmitoyltransferase 1B, Cpt1b; long-chain acyl-CoA dehydrogenase, Lcad) (FIG 2C) or ketogenesis (Acat1, 
Hmgcl, Bdh1) (FIG 2D) with fasting.  Moreover, circulating levels of non-esterified fatty acids (NEFA) in 
blood were comparable between CTRL and mKO mice upon fasting (FIG 2E).  These findings indicate that 
neither fatty acid availability nor maladaptation of hepatic ketogenesis in response to fasting could 
account for the fasting-induced hyperketonemia in mKO mice.  To assess systemic ketolytic capacity in 
mice without contribution from hepatic ketogenesis, we measured βOHB-clearance in blood after a bolus 
injection of βOHB.  In line with the reduced levels of ketolytic enzymes in skeletal muscle, mKO mice had 
an impaired ability to clear βOHB from the blood, as indicated by the increased retention of βOHB in blood 
after the injection compared to CTRL mice (FIG 2F).  Taken together, these data demonstrate that muscle 
PGC-1α plays an important role in the regulation of systemic ketone body homeostasis.  To further 
characterize the impact of skeletal muscle-specific ablation of PGC-1α on ketone body homeostasis, we 
fed CTRL and mKO mice a low-carbohydrate ketogenic diet (LCKD) to induce a chronic state of ketosis. In 
line with our results from the fasting experiments, also after three weeks on a LCKD, mKO mice displayed 
elevated βOHB levels in blood compared to CTRL mice (FIG 2G).  However, in contrast to fasting induced 
ketosis, plasma AcAc levels were not significantly altered between CTRL and mKO mice with LCKD feeding 
(FIG 2H).  This effect could however be explained by an increased interconversion between AcAc and 
βOHB during LCKD feeding.  Again, we could not detect any differences in the transcriptional induction of 
ketogenic genes in liver between CTRL and mKO mice after 3 weeks LCKD feeding (FIG 2I), suggesting that 
an impaired ketolysis accounts for the LCKD-induced hyperketonemia in mKO mice.  Collectively, these 
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data demonstrate that ablation of PGC-1α in skeletal muscle leads to a reduction in ketolytic enzymes in 
muscle, and exacerbates systemic hyperketonemia in response to fasting or LCKD feeding. 
PGC-1α is necessary for the transcriptional induction of ketolytic genes with exercise 
Elevated ketone body levels can also be observed after an acute exercise bout, a phenomenon termed 
post-exercise ketosis.  To investigate whether muscle PGC-1α also affects post-exercise ketosis, CTRL and 
mKO mice were subjected to an acute exercise bout on a treadmill, and we measured βOHB levels in 
blood.  While no significant difference in βOHB levels were detected between CTRL and mKO mice at 
either 0 minutes or 30 minutes after exercise cessation, mKO mice displayed an exacerbated post-exercise 
ketosis compared to CTRL mice at 180 minutes after exercise (FIG 3A).  It has been shown that exercise 
modulates skeletal muscle ketone body metabolism, since muscles from trained rats display enhanced 
ketolytic enzyme activity [Askew et al. 1975].  We were therefore interested in whether PGC-1α was 
important for exercise-induced changes in ketone body homeostasis in skeletal muscle.  To this end, mice 
were given free access to running wheels in their home cages for 8 consecutive weeks to induce an 
exercised state.  After these 8 weeks, we measured βOHB clearance from the blood following a βOHB 
bolus injection.  Exercised CTRL mice displayed a faster clearance of βOHB from the blood as compared to 
sedentary CTRL mice (FIG 3B).  Interestingly, trained mKO mice did not show any improvement in βOHB 
clearance from the blood (FIG 3B).  Hence, muscle PGC-1α is required to improve ketolytic capacity with 
exercise.   To investigate the molecular changes in muscle that could account for the improved ketolytic 
capacity, we measured gene expression of ketolytic enzymes.  In agreement with the improved βOHB 
clearance in exercise trained CTRL mice, we observed a significant increase in transcript levels of ketolytic 
genes (Bdh1, Oxct1, and Acat1) in muscle of trained CTRL mice (FIG 3C).  Importantly, mKO mice did not 
display an induction of these genes in muscle in a trained state (FIG 3C).  The induction of Oxct1 and Acat1 
mRNA in CTRL mice did however not result in increased protein levels of these enzymes in muscle (FIG 
3D-E).  We could furthermore detect a normalization of OXCT1 protein levels in trained mKO mice to 
similar levels as trained CTRL mice (FIG 3D-E).  Intriguingly, this occurred despite no induction of Oxct1 
transcription in trained mKO mice (FIG 3C).  These data suggest that exercise training can normalize the 
levels of OXCT1 protein in mKO mice through a transcription-independent mechanism.  However, despite 
induction of OXCT1 protein levels in trained mKO mice, this did not result in a significant improvement in 
βOHB clearance.  A possible reason for the improved βOHB clearance in trained CTRL mice, despite no 
changes in OXCT1 or ACAT1 protein levels, could be due to an increased ketolytic enzyme activity, which 
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has been shown to occur in trained rats [Askew et al. 1975].  A possible explanation for the inability of 
mKO mice to improve their βOHB clearance rates with exercise training could be due to the reduced levels 
of ACAT1 protein levels observed in trained mKO mice (FIG 3D-E).  Moreover, mRNA levels of Mct1 and 
components of the TCA cycle were still down-regulated due to the loss of PGC-1α in mKO mice (FIG 3F, 
and could thus contribute to the reduced ability to remove βOHB from the blood. 
Overexpression of PGC-1α in skeletal muscle improves ketolytic capacity 
Muscle-specific ablation of PGC-1α affects several processes involved in ketone body homeostasis and 
leads to hyperketonemia in response to fasting, LCKD feeding and exercise.  We were therefore interested 
in whether overexpression of PGC-1α in skeletal muscle could enhance ketolytic capacity in this tissue, 
and improve systemic ketone body homeostasis.  To investigate this, we used mice with a muscle-specific 
overexpression of PGC-1α, muscle transgenic (mTG) mice.  PGC-1α mTG mice show a strong induction of 
PGC-1α transcript levels in skeletal muscle (FIG 4A).  In addition, mTG mice display increased mRNA levels 
of ketolytic enzymes (Bdh1, Oxct1, and Acat1) (FIG 4A), the main ketone body transporter (Mct1) and TCA 
cycle enzymes (Cs, Aco2, and Idh3a) (FIG 4B) in muscle.  Importantly, the increase in Oxct1 and Acat1 
mRNA (FIG 4A) led to significantly increased protein levels of these enzymes in muscle of mTG mice (FIG 
4C).  To elucidate whether the increased levels of ketolytic enzyme in skeletal muscle would result in an 
enhanced ketolytic capacity in mTG mice, we performed a βOHB clearance test.  In line with the increased 
levels of ketolytic enzymes in muscle, mTG mice displayed a faster βOHB clearance from blood after a 
bolus βOHB injection when compared to CTRL mice (FIG 4D).  Next we assessed whether overexpression 
of PGC-1α in skeletal muscle would also affect systemic ketone body homeostasis during either fasting, 
LCKD feeding or exercise.  In response to 24 hours fasting or 3 weeks LCKD feeding, we detected 
significantly reduced circulating βOHB (FIG 4E) and AcAc (FIG 4F) levels in mTG mice compared to CTRL 
mice. Moreover, mTG mice displayed a significant reduction in post-exercise ketosis at both 30 and 180 
minutes after exercise (FIG 4G).  Collectively, these data demonstrate that enhanced ketolytic capacity 
through overexpression of PGC-1α in skeletal muscle is sufficient to reduce circulating ketone body levels 
during physiological states of ketosis. 
ERRα is a transcriptional partner of PGC-1α in the regulation of ketolytic enzymes 
Since we have demonstrated that PGC-1α is a novel transcriptional regulator of ketolytic enzymes, we 
were interested in elucidating which is the transcriptional partner of PGC-1α in the regulation of these 
genes.  We used differentiated C2C12 myotubes to study the molecular mechanisms behind the 
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transcriptional regulation of ketolytic enzymes by PGC-1α.  By overexpressing PGC-1α in myotubes using 
adenoviral vectors, we could confirm that overexpression of PGC-1α led to a significant increase in Bdh1, 
Oxct1 and Acat1 mRNA levels (FIG 5A) compared to GFP-transduced cells.  Estrogen-related receptor alpha 
(ERRα) is an important transcriptional partner of PGC-1α in the regulation of mitochondrial and metabolic 
gene transcription [Mootha et al. 2004].  ERRα also displayed a matching transcriptional pattern to that 
of ketolytic enzymes in skeletal muscle, since ERRα mRNA levels were down-regulated in mKO mice (FIG 
5B) and accordingly up-regulated in mTG skeletal muscle (FIG 5C).  We thus hypothesized that ERRα might 
be a transcriptional partner of PGC-1α in the regulation of ketolytic enzymes in muscle.  To test this, we 
overexpressed PGC-1α in C2C12 myotubes in the absence or presence of the inverse ERRα agonist XCT-
790.  Inhibition of ERRα did not affect PGC-1α transcript levels, but it efficiently prevented the increase of 
ERRα and cytochrome c oxidase subunit Vb (Cox5b) mRNA levels induced by PGC-1α overexpression (FIG 
5D).  Importantly, inhibition of ERRα significantly blunted the induction of Bdh1, Oxct1 and Acat1 mRNA 
levels induced by PGC-1α overexpression (FIG 5E).  This indicates that ERRα is an important transcriptional 
partner of PGC-1α in the regulation of ketolytic gene transcription.  Moreover, ERRα was also required for 
the induction of Cs, Aco2 and Idh3a with PGC-1α overexpression (FIG 5F).  Conclusively, these findings 
indicate that ERRα together with PGC-1α regulates the expression of ketolytic- and TCA-cycle enzymes 
necessary for the complete oxidation of ketone bodies in skeletal muscle. 
Overexpression of PGC-1α in skeletal muscle ameliorates diabetic hyperketonemia 
As shown earlier, modulation of PGC-1α levels in skeletal muscle is sufficient to affect systemic ketone 
body homeostasis.  We were therefore interested in whether overexpression of PGC-1α in muscle could 
ameliorate pathological states of hyperketonemia.  An elevation of circulating ketone body levels is often 
encountered in patients suffering from diabetes [Jain et al. 2006].  Without intervention, this can progress 
to diabetic ketoacidosis, a potentially life-threatening state [Barski et al. 2012].  To study the role of 
muscle PGC-1α in the modulation of ketone body homeostasis during diabetic ketoacidosis, we injected 
mTG mice with streptozotocin (STZ) to induce an insulinopenic diabetic state in our mice.  At day 3 post-
injection, CTRL and mTG mice developed a significant hyperglycemia (FIG 5G), indicating that 
overexpression of PGC-1α does not affect the induction of a hyperglycemic diabetic state.  Moreover, at 
this time point, diabetic CTRL mice displayed a significant induction of circulating βOHB levels (FIG 5H).  
Importantly, in line with the enhanced ketolytic capacity in SKM, PGC-1α mTG mice displayed reduced 
circulating levels of βOHB during STZ-induced diabetes (FIG 5H).  Interestingly, in concurrence with the 
8.  Manuscript 3: A Novel Role for PGC-1α in the Regulation of Skeletal Muscle 
Ketolytic Capacity and Systemic Ketone Body Homeostasis 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
205 
reduced hyperketonemia in mTG mice after a STZ-injection, this group displayed a higher survival rate 
compared to STZ-injected CTRL mice post-injection (FIG 5I).  In conclusion, these data demonstrate that 
overexpression of PGC-1α in skeletal muscle is sufficient to reduced systemic hyperketonemia in diabetic 
mice, and can potently affect the survival rate of mice after a STZ-injection. 
 
Discussion 
It is well known that βOHB and AcAc serve as vital metabolic fuels during states of reduced nutrient 
availability [Robinson and Williamson 1980, Cahill 2006].  Induction of ketosis is also postulated to exert 
beneficial effects in several diseases characterized by metabolic impairments, such as cancer [Poff et al. 
2013, Poff et al. 2014] and neurodegenerative diseases [Prins 2008].  Despite the important role of ketone 
bodies as alternative energy substrates, relatively little is known as to how their oxidation in target organs 
is regulated.  We have now shown that the pivotal metabolic regulator PGC-1α is an important 
transcriptional regulator of ketolytic enzymes.  PGC-1α null mice are thus characterized by a reduced 
transcription of ketolytic enzymes in several organs.  Elevated ketone body levels is a sign of impaired 
ketolytic capacity in both rodents [Cotter et al. 2011, Cotter et al. 2013] and humans [Fukao et al. 2011, 
Shafqat et al. 2013], and PGC-1α null mice accordingly display an exacerbated hyperketonemia in 
response to fasting.  Ketone body oxidation is especially important during neonatal development.  This is 
evident in OXCT1 null mice, which die within 48 hours after birth due to an inability to generate energy 
through oxidation of ketone bodies [Cotter et al. 2011].  Interestingly, also PGC-1α null mice display 
increased neonatal mortality rates [Lin et al. 2004].  Based on our finding that PGC-1α is an important 
regulator of ketone body oxidation, we thus hypothesize that the reduced neonatal survival rate of PGC-
1α null mice could be due to the systemic ketolytic impairment in these mice. 
 Skeletal muscle is one of the major ketolytic organs in the body [Fukao et al. 1997] and genetic 
ablation of the key ketolytic enzyme OXCT1 in muscle leads to development of fasting-induced 
hyperketonemia [Cotter et al. 2013].  Hence, in this study we focused on the role of PGC-1α in the 
regulation of skeletal muscle ketone body oxidation.  We could confirm the crucial role of skeletal muscle 
in determining whole body ketolytic capacity, since muscle-specific PGC-1α knockout mice displayed a 
comparable increase in fasting-induced hyperketonemia as global PGC-1α knockout mice.  Hence, we have 
identified skeletal muscle PGC-1α as a critical component in the regulation of systemic ketone body 
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homeostasis.  Furthermore PGC-1α-ablation led to a reduced transcription of the major ketone body 
transporter MCT1 in muscle.  It is however difficult to assess the impact of reduced MCT1 levels on the 
hyperketonemic phenotype of PGC-1α mKO mice, since it has been suggested that the rate of ketone body 
uptake is not a rate-limiting factor of ketone body oxidation in skeletal muscle [Robinson and Williamson 
1980].  Apart from the regulation of ketone body transporters and ketolytic enzymes by PGC-1α, we and 
others [Burgess et al. 2006, Summermatter et al. 2013b] have demonstrated an important role of PGC-
1α in the transcription of TCA cycle genes.  Thus, in addition to the direct regulation of ketolytic enzymes, 
PGC-1α could indirectly affect the ketolytic capacity of skeletal muscle by modulating TCA cycle activity.  
Conclusively, our data demonstrates that PGC-1α is a transcriptional regulator of a genetic program 
responsible for terminal oxidation of ketone bodies within skeletal muscle mitochondria.  Importantly, 
the orphan nuclear receptor ERRα is required for the transcriptional induction of ketolytic- and TCA-cycle 
enzymes by PGC-1α in muscle cells.  It is well established that ERRα and PGC-1α mediate the transcription 
of several other metabolic processes, such as oxidative phosphorylation [Mootha et al. 2004] and β-
oxidation [Huss et al. 2004].  Hence, our data expand the metabolic transcriptional network regulated by 
PGC-1α/ERRα, further accentuating the central role of PGC-1α/ERRα in the regulation of oxidative 
metabolism.  Apart from skeletal muscle, the brain is a major contributor to systemic ketolytic capacity, 
since ablation of OXCT1 specifically in neurons results in a fasting-induced hyperketonemia in the range 
of what could be seen for OXCT1 muscle-knockout mice [Cotter et al. 2013].  It would thus be interesting 
in future studies to evaluate the role of neuronal PGC-1α in the regulation of energy homeostasis in the 
brain, especially in the context of long-term starvation, where ketone body oxidation is an important 
process for maintenance of energy homeostasis in the brain [Cahill 2006]. 
Exercise is a potent stimulus of hepatic ketone body production.  This is evident by a transient 
hyperketonemia after intense exercise, a phenomenon termed “post-exercise ketosis” [Johnson et al. 
1969].  Interestingly, exercise training has been demonstrated to improve the ketolytic capacity of skeletal 
muscle and to reduce the extent of post-exercise ketosis in both rodents [Adams and Koeslag 1988] and 
humans [Johnson et al. 1969].  In our study, we demonstrate a strong correlation between skeletal muscle 
PGC-1α levels, and the extent of post-exercise ketosis after an acute exercise bout.  Importantly, in the 
absence of PGC-1α in muscle, mice could not increase their systemic ketolytic capacity in response to 
endurance exercise training.  Collectively, these data show that PGC-1α plays an important role in the 
adaptation of ketolytic capacity during exercise training.  It has been demonstrated that PGC-1α is 
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increased in human skeletal muscle in response to exercise training [Pilegaard et al. 2003, Mathai et al. 
2008]. Hence, PGC-1α could play an important role in the reduced post-exercise ketosis observed in 
trained humans [Johnson et al. 1969].  In line with this, muscle-specific overexpression of PGC-1α resulted 
in reduced circulating ketone body levels in response to fasting, LCKD feeding and exercise.  Importantly, 
overexpression of PGC-1α in skeletal muscle was sufficient to ameliorate STZ-induced diabetic 
hyperketonemia in mice.  The blunted hyperketonemia in mTG mice was not associated with any 
amelioration of the hyperglycemic diabetic phenotype, since CTRL and mTG mice displayed similar blood 
glucose levels after STZ injection.  Intriguingly, overexpression of PGC-1α in skeletal muscle was sufficient 
to improve the survival rate of mice after a single STZ-injection.  A worsened health status of the mice and 
a moribund state was, when examined, associated with highly elevated βOHB levels (4.5 – 6.5 mM) 
(unpublished observation).  Hence, these data demonstrate that increased skeletal muscle PGC-1α can 
reverse pathological accumulation of ketone bodies in the circulation.  Moreover, this could provide a 
likely explanation for the increased survival of mTG mice after a STZ injection compared to CTRL mice.  
Activation of PGC-1α in skeletal muscle could thus be an important therapeutic strategy to ameliorate 
ketoacidosis in patients suffering from type 1 or type 2 diabetes. 
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Figure 1 – Global PGC-1α knockout mice display fasting-induced hyperketonemia 
(A)  Blood βOHB levels in fed and 24 hour fasted CTRL and PGC-1α global knockout (gKO) mice (n=4-
5/group).  (B)  mRNA levels of PGC-1α, Acat1, Hmgcs2 and Hmgcl in liver from fed and 24 hour fasted CTRL 
and PGC-1α gKO mice (n=5/group).  mRNA levels of PGC-1α, Bdh1, Oxct1 and Acat1 in kidney (C), brain 
(D), heart (E) and gastrocnemius muscle (F) of CTRL and PGC-1α gKO mice (n=6/group).  mRNA levels of 
PGC-1α, Bdh1, Oxct1 and Acat1 in soleus (G) and gastrocnemius (H) muscles of CTRL and PGC-1α muscle-
knockout (mKO) mice (n=8/group).  (I)  Representative immunoblots of OXCT1, ACAT1 and eEF2 protein 
levels in gastrocnemius muscle of CTRL and PGC-1α mKO mice.  Bar graph represents the band intensities 
of OXCT1 and ACAT1 normalized to eEF2 (n=6/group).  (J)  mRNA levels of Mct1, Cs, Aco2 and Idh3a in 
gastrocnemius muscle of CTRL and PGC-1α mKO mice (n=8/group).  All mRNA levels normalized to 18s 
rRNA.  Error bars represent mean ±SEM.  Significant differences (p-value <0.05) between CTRL and PGC-
1α mKO mice are indicated by an asterisk (*) and between fed/fasted groups with a number sign (#). 
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Figure 2 - PGC-1α muscle-specific knockout mice display fasting-induced hyperketonemia 
(A)  Blood βOHB levels in fed and 24 hour fasted CTRL and PGC-1α mKO mice (n=8/group).  (B)  Plasma 
acetoacetate (AcAc) levels in 24 hour fasted CTRL and PGC-1α mKO mice (n=7-8/group).  (C)  mRNA levels 
of CD36, Cpt1b and Lcad in liver from fed and 24 hour fasted CTRL and PGC-1α mKO mice (n=6-9/group).  
(D)  mRNA levels of Acat1, Hmgcl and Bdh1 in liver from fed and 24 hour fasted CTRL and PGC-1α mKO 
mice (n=6-9/group).  (E)  Plasma non-esterified fatty acid (NEFA) levels in fed and 24 hour fasted CTRL and 
PGC-1α mKO mice (n=6-9/group).  (F)  Blood βOHB levels at given time-points after a bolus intraperitoneal 
(I.P.) injection of 1.5 g/kg body weight βOHB in CTRL and PGC-1α mKO mice (n=6/group).  (G)  Blood βOHB 
levels in CTRL and PGC-1α mKO mice after 3 weeks on a low-carbohydrate ketogenic diet (LCKD) (n=7-
13/group).  (H)  Plasma acetoacetate (AcAc) levels in CTRL and PGC-1α mKO mice after 3 weeks on a LCKD 
(n=7-9/group).  (I)  mRNA levels of Hmgcl, Hmgcs2 and Bdh1 in liver from CTRL and PGC-1α mKO mice 
after 3 weeks on a LCKD (n=7-8/group).  All mRNA levels normalized to 18s rRNA.  Error bars represent 
mean ±SEM.  Significant differences (p-value <0.05) between CTRL and PGC-1α mKO mice are indicated 
by an asterisk (*) and between fed/fasted or chow/LCKD groups with a number sign (#).  
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Figure 3 - PGC-1α is necessary for the transcriptional induction of ketolytic genes with exercise 
(A)  Blood βOHB levels in CTRL and PGC-1α mKO mice pre-exercise and at 0, 30 and 180 minutes post-
exercise. (n=5/group).  (B)  Blood βOHB levels at given time-points after a bolus intraperitoneal (I.P.) 
injection of 1.5 g/kg bodyweight βOHB in either sedentary or trained CTRL and PGC-1α mKO mice 
(n=6/group).  (C)  mRNA levels of Bdh1, Oxct1 and Acat1 in skeletal muscle from either sedentary or 
trained CTRL and PGC-1α mKO mice (n=6-8/group).  (D)  Representative immunoblots of OXCT1, ACAT1 
and eEF2 protein levels in skeletal muscle of either sedentary or trained CTRL and PGC-1α mKO mice.  (E)  
Bar graph represents the band intensities of OXCT1 and ACAT1 normalized to eEF2 (n=6/group).  (F)  mRNA 
levels of Mct1, Cs, Aco2 and Idh3a in skeletal muscle from either sedentary or trained CTRL and PGC-1α 
mKO mice (n=6-8/group).  All mRNA levels normalized to 18s rRNA.  Error bars represent mean ±SEM.  
Significant differences (p-value <0.05) between CTRL and PGC-1α mKO mice are indicated by an asterisk 
(*) and between sedentary or trained groups with a number sign (#). 
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Figure 4 - Overexpression of PGC-1α in skeletal muscle increases ketolytic capacity 
(A)  mRNA levels of PGC-1α, Bdh1, Oxct1 and Acat1, and (B) Mct1, Cs, Aco2 and Idh3a in skeletal muscle 
of CTRL and PGC-1α muscle-transgenic (mTG) mice (n=8/group).  (C)  Representative immunoblots of 
OXCT1, ACAT1 and eEF2 protein levels in skeletal muscle of CTRL and PGC-1α mTG mice.  Bar graph 
represents the band intensities of OXCT1 and ACAT1 normalized to eEF2 (n=6/group).  (D)  Blood βOHB 
levels at given time-points after a bolus intraperitoneal (I.P.) injection of 1.5 g/kg body weight βOHB in 
CTRL and PGC-1α mTG mice (n=6/group).  (E)  Blood βOHB levels in CTRL and PGC-1α mTG mice in either 
fed state or after 24 hours fasting, or after 3 weeks of either chow- or low-carbohydrate ketogenic diet 
(LCKD) feeding (n=6-10/group).  (F)  Plasma acetoacetate (AcAc) levels in CTRL and PGC-1α mKO mice after 
24 hour fasting or after 3 weeks on a LCKD (n=7/group).  (G)  Blood βOHB levels in CTRL and PGC-1α mTG 
mice pre-exercise and at 0, 30 and 180 minutes post-exercise. (n=6/group).  All mRNA levels normalized 
to 18s rRNA.  Significant differences (p-value <0.05) between CTRL and PGC-1α mKO mice are indicated 
by an asterisk (*) and between fed/fasted or chow/LCKD groups with a number sign (#).  
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Figure 5 - ERRα is a transcriptional partner of PGC-1α in the regulation of ketolytic genes 
(A)  mRNA levels of PGC-1α, Bdh1, Oxct1 and Acat1 in C2C12 myotubes transduced by adenovirus 
expressing either GFP or bicistronic GFP-PGC-1α (n=3/experiment, performed in triplicates).  (B)  mRNA 
levels of ERRα in gastrocnemius and soleus muscles of CTRL and PGC-1α mKO mice (n=8/group).  (C)  
mRNA levels of ERRα in gastrocnemius and soleus muscles of CTRL and PGC-1α mTG mice (n=6-8/group).  
mRNA levels of (D) PGC-1α, ERRα, Cox5b, (E) Bdh1, Oxct1, Acat1 and (F) Cs, Aco2, Idh3a in C2C12 myotubes 
transduced by adenovirus expressing either GFP or bicistronic GFP-PGC-1α, and co-treated with either 
0.2% DMSO (Veh) or 10 µM XCT-790 (XCT).  Blood glucose (G) and βOHB (H) levels in mice 3 days after 
injection with either citrate buffer (Veh, n=2) or 150 mg/kg streptozotocin (STZ, n=9-11).  (I) Percent 
survival of mice injected with either citrate buffer (Veh, n=2) or 150 mg/kg streptozotocin (STZ, n=9-11).  
All mRNA levels normalized to 18s rRNA.  Error bars represent mean ±SEM.  Significant differences (p-
value <0.05) between adGFP or adPGC-1α infected cells or CTRL and PGC-1α mTG mice are indicated by 
an asterisk (*) and between Veh/XCT or Veh/STZ groups with a number sign (#).  
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SI Table I. qPCR Primer sequences. 
 
Target gene Forward primer Reverse primer 
18s AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Acat1 GTGAAGGAAGTCTACATGGGCA TGTGGTGCATGGAGTGGAAATA 
Aco2 ACATTGTCCGTAAACGGTTGAA TATGTCTTTCCCCGCTCGATCT 
Bdh1 TTTGCTGGCTGTTTGATGAAGG TTGAGCTGGATGGTTCTCAGTC 
Cd36 GGCAAAGAACAGCAGCAAAAT TGGCTAGATAACGAACTCTGTATGTGT 
Cox5b CTTCAGGCACCAAGGAAGAC TTCACAGATGCAGCCCACTA 
Cpt1b ATCATGTATCGCCGCAAACT CCATCTGGTAGGAGCACATGG 
Cs CCCAGGATACGGTCATGCA GCAAACTCTCGCTGACAGGAA 
Hmgcl CCAGCTTTGTTTCTCCCAAGTG GATGCCGGGAAACTTCTGAATG 
Hmgcs2 CCACAAGGTGAACTTCTCTCCA TGCATCTCATCCACTCGTTCAA 
Idh3a GCTGGTGGTGTTCAGACAGTAA CACTGAATAGGTGCTTTGGCAG 
Lcad CCAGCTAATGCCTTACTTGGAGA GCAATTAAGAGCCTTTCCTGTGG 
Mct1 TGCAACGACCAGTGAAGTATCA ACAACCACCAGCGATCATTACT 
Oxct1 CCCATACCCACTGAAAGACGAA CTGGAGAAGAAAGAGGCTCCTG 
PGC-1α AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
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9.  The role of PGC-1α in skeletal muscle – Discussion and future perspectives  
9.1 – Discussion 
Skeletal muscle displays a high metabolic plasticity and its oxidative capacity can be modulated through 
changes in physical activity [Egan and Zierath 2013].  The ability to modulate systemic energy expenditure 
through increased physical activity is considered an important therapeutic tool in the treatment of obesity 
and metabolic dysfunction in human patients [Strasser 2013].  Also dietary interventions, such as CR 
enhance the metabolic activity of skeletal muscle.  CR has been shown to enhance mitochondrial 
biogenesis and respiratory function of individual mitochondria in skeletal muscle of humans and mice 
[Civitarese et al. 2007, Gouspillou and Hepple 2013].  While exercise and CR elicit beneficial effects on 
whole body metabolism, increased calorie intake and reduced physical activity are the two major 
predisposing factors for obesity in humans and they are related to an increased prevalence of related 
metabolic comorbidities such as diabetes, cardiovascular disease and cancer [Handschin and Spiegelman 
2008, Booth et al. 2012].  The positive effects of exercise and CR on whole body metabolism have sparked 
an interest in developing pharmacological compounds that stimulate signaling pathways normally 
activated in skeletal muscle during either exercise or CR.  These compounds are envisioned to ameliorate 
metabolic dysfunction in obese human patients, either as a monotherapy, or as an adjuvant treatment in 
combination with exercise or CR.  In line with the postulated use of these compounds, they have aptly 
been termed exercise-mimetics or CR-mimetics [Ingram et al. 2006, Fan et al. 2013].  The distinction 
between exercise- and CR-mimetics is however in many cases superfluous.  For instance, activation of 
SIRT1 by RSV would fall under both categories, considering that this pathway is activated in skeletal muscle 
during both exercise and CR.  RSV, and the SIRT1-activating compound SRT1720, are accordingly suggested 
to be potential CR/exercise mimetic compounds and have received a lot of attention due to their ability 
to elicit beneficial metabolic effects in obese rodents [Baur et al. 2006, Lagouge et al. 2006, Milne et al. 
2007, Feige et al. 2008, Um et al. 2010, Park et al. 2012, Price et al. 2012].  An open question, however, 
is whether RSV and SRT1720 exert their effects through direct activation of SIRT1, or whether other 
signaling pathways are involved in mediating the effects of these compounds [Huber et al. 2010, Pacholec 
et al. 2010, Villalba et al. 2012].  Several recent studies have elegantly demonstrated that the effects of 
RSV are indeed pleiotropic and depend on more than one single signaling pathway.  For instance, the 
dependence of SIRT1 for the effects of RSV was dose-dependent in C2C12 myotubes.  High doses of RSV 
disrupted mitochondrial respiration and reduced ATP levels, thereby activating AMPK independently of 
SIRT1 [Um et al. 2010, Price et al. 2012].  Importantly, with a lower dose of RSV, AMPK was activated in 
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skeletal muscle in a SIRT1-dependent manner [Price et al. 2012].  RSV was recently shown to act as a PDE-
inhibitor and thereby activate AMPK and SIRT1 downstream of cAMP signaling and Epac1 in skeletal 
muscle cells [Park et al. 2012].  While the effects of RSV are pleiotropic, SRT1720 has been postulated to 
mediate its effects mainly through specific activation of SIRT1.  This idea however has been questioned 
[Huber et al. 2010].  Hence, in order to fully understand the therapeutic potential of RSV and SRT1720, it 
is important to elucidate which signaling pathways are mediating the effects of these compounds.  Since 
RSV and SRT1720 have been shown to increase PGC-1α activity and transcription of PGC-1α target genes 
in skeletal muscle [Lagouge et al. 2006, Feige et al. 2008], this coactivator has accordingly been postulated 
to be a major downstream mediator of these CR/exercise mimetic compounds.  Indeed, PGC-1α can be 
activated by AMPK-, SIRT1- and cAMP-signaling [Herzig et al. 2001, Rodgers et al. 2005, Jager et al. 2007], 
and would thus likely be activated in response to RSV and SRT1720 treatment regardless of the main 
upstream signaling pathway activated by these compounds.  Interestingly, despite the general consensus 
in the field that PGC-1α mediates the effects of RSV and SRT1720, this has not been conclusively 
demonstrated.   
Accordingly, in the second manuscript of this thesis we investigated the requirements for skeletal 
muscle PGC-1α in mediating the beneficial metabolic effects elicited by RSV and SRT1720 treatment in 
obese mice, both in skeletal muscle and on a whole body level.  To answer this question, we used mice 
with a skeletal-muscle specific knockout of PGC-1α, which were fed a HFD supplemented with either RSV 
or SRT1720.  This setup allowed us to study the role of skeletal muscle PGC-1α as a molecular effector of 
RSV and SRT1720 in a therapeutically relevant model, considering the ultimate use of RSV and SRT1720 
as treatments for obesity and metabolic dysfunction in humans.  Importantly, we demonstrated that RSV 
and SRT1720 elicited beneficial systemic metabolic effects in HFD-fed mice, such as an increased energy 
expenditure, improved glucose tolerance and a reduced fat mass.  Intriguingly, these effects occurred 
independently of skeletal muscle PGC-1α, thus indicating that skeletal muscle PGC-1α is not necessary for 
the systemic metabolic effects of RSV and SRT1720 treatment.  However, molecular analysis revealed that 
PGC-1α was required for the transcriptional induction of mitochondrial genes in skeletal muscle with both 
RSV and SRT1720 treatment.  Interestingly, our findings are analogous to those from a study by Finley et 
al. [Finley et al. 2012].  In this study, the authors showed that PGC-1α was necessary for the induction of 
mitochondrial genes in skeletal muscle during CR.  However, in analogy with our findings, skeletal muscle 
PGC-1α was dispensable for the alterations in energy expenditure and improved glucose tolerance in mice 
during CR [Finley et al. 2012].  The enhanced energy expenditure with SRT1720 treatment in our study 
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could be attributed to the increased mitochondrial number in skeletal muscle of mice treated with this 
compound, an effect which was independent of PGC-1α.  However, the enhanced metabolic rate during 
CR or in response to RSV/SRT1720 treatment could also be due to effects on other organs, and thus 
completely independent of any effect in skeletal muscle.  This hypothesis is supported by the fact that 
mice with a muscle-specific overexpression of PGC-1α, which have increased mitochondrial number and 
levels of oxidative enzymes in skeletal muscle, surprisingly do not display an enhanced metabolic rate 
[Choi et al. 2008].   
The minor effects of RSV and SRT1720 on skeletal muscle metabolism in our study were surprising, 
particularly in relation to other studies using RSV and SRT1720 in mice.  In these studies the transcriptional 
profile of skeletal muscle was altered and consequently oxidative capacity and exercise performance was 
increased [Lagouge et al. 2006, Feige et al. 2008].  However, two recent studies by Higashida et al. and 
Ringholm et al. could corroborate our findings, since neither of these studies found any increase in 
mitochondrial metabolism in skeletal muscle using the same dose of RSV as that used in our study (4g 
RSV/kg diet) [Higashida et al. 2013, Ringholm et al. 2013].  Interestingly, these doses are similar to those 
used by both Lagouge et al. and Um et al. in their studies [Lagouge et al. 2006, Um et al. 2010].  It is 
difficult to explain why our findings, together with the studies by Ringholm et al. and Higashida et al. show 
no major effects on mitochondrial protein levels in skeletal muscle with RSV treatment, especially when 
considering the clear effects in earlier studies [Lagouge et al. 2006, Um et al. 2010].  One reason for these 
disparate results could be due to differences in the batch as well as manufacturer of RSV when comparing 
our study and the study by Higashida et al. [Higashida et al. 2013] to earlier studies using RSV in mice 
[Baur et al. 2006, Lagouge et al. 2006, Um et al. 2010].  Another reason could be due to the type of HFD 
used in these initial studies, since both the studies by Baur et al. and Lagouge et al. used a high percentage 
of coconut oil in their diets [Baur et al. 2006, Lagouge et al. 2006], which in comparison to the long-chain 
fatty acid (LCFA) rich lard-based HFD used in our study, primarily consists of medium-chain fatty acids 
(MCFA).  MCFA-rich diets have been shown to induce mitochondrial metabolism and oxidative capacity in 
skeletal muscle [Turner et al. 2009, Montgomery et al. 2013] and could thus help boost the effect of RSV 
on mitochondrial transcription in these studies.  However, if we focus solely on our study, one likely 
explanation for the minor effects of RSV in muscle compared to other organs could be due to RSV 
bioavailability, since this compound has been shown to preferentially accumulate in liver and WAT of rats 
[Andres-Lacueva et al. 2012].  Indeed, in line with this, we found more prominent effects of RSV and 
SRT1720 in both WAT and liver.  Interestingly, we detected enhanced transcription of several PGC-1α-
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regulated gene programs in liver and WAT with SRT1720 and RSV treatment, respectively.  This would 
imply that PGC-1α could indeed play an important role in mediating the effects of RSV and SRT1720 in 
other organs than skeletal muscle.  This would however have to be confirmed in future studies, 
preferentially employing a similar setup as our study, but using mice with a liver or WAT-specific deletion 
of PGC-1α (see below).  In conclusion, we demonstrate improved systemic metabolic parameters with RSV 
and SRT1720 treatment, despite only a minor effect of these compound in skeletal muscle.  These findings 
would warrant a less muscle-centric view on the effects of RSV and SRT1720 and future research would 
thus benefit from evaluating the effects of exercise/CR-mimetic compounds such as RSV and SRT1720 also 
in other metabolic organs.   
Accordingly, in the second part of this study, we were interested in comparing the organ-specific 
effects of RSV and SRT1720 treatment in liver and WAT.  This is a pertinent question, since RSV has been 
shown to possess several effects apart from its ability to activate SIRT1, as it can act as an antioxidant, a 
phytoestrogen and also as an anti-inflammatory agent [Baur et al. 2006]. Furthermore, RSV inhibits the 
activity of a range of enzymes (reviewed in [Pirola and Frojdo 2008]), out of which PDE-inhibition was 
recently shown to be important for the metabolic effects of RSV [Park et al. 2012].  SRT1720 on the other 
hand has been suggested to be a more potent SIRT1 activator than RSV [Milne et al. 2007].  However, the 
direct effect of SRT1720 on SIRT1-activity has been questioned [Huber et al. 2010] and it is not yet clear 
whether RSV and SRT1720 can be considered to be analogous compounds concerning their effects in 
target organs.  Hence, in order to avoid potential caveats when using RSV or SRT1720 to treat humans, it 
is necessary to have a complete overview of the effects elicited by these compounds in all major metabolic 
organs.  However, to our knowledge, no extensive comparison between the in vivo effects of these two 
compounds has so far been made.  RSV and SRT1720 elicit similar changes on whole body metabolism, 
since both compounds improved glucose tolerance and enhanced metabolic rate in mice, both in our 
study and in others [Lagouge et al. 2006, Feige et al. 2008].  Despite similar effects on whole body 
metabolism, we could however demonstrate distinct organ-specific effects of both RSV and SRT1720 in 
HFD fed mice.  For instance, in our study, RSV treatment led to a reduced transcription of genes involved 
in lipogenesis in liver, together with a reduced hepatic triglyceride content.  Interestingly, SRT1720 
treatment resulted in the opposite effect, leading to enhanced transcription of lipogenic genes in liver.  
This however did not lead to an increase in hepatic triglyceride accumulation, which could be due to the 
concurrent induction of both hepatic β-oxidation and ketogenesis by this compound.  SRT1720 treatment 
also enhanced hepatic transcription of genes involved in cholesterol biosynthesis, which was associated 
9.  The role of PGC-1α in skeletal muscle – Discussion and future perspectives 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
227 
with an increase in circulating LDL and HDL cholesterol levels.  Contrariwise, RSV treatment led to a 
reduction in circulating LDL-cholesterol levels.  Hence, our findings indicate that RSV and SRT1720 exert 
differential effects on hepatic metabolism.  Importantly, our findings are corroborated in a study by Minor 
et al. [Minor et al. 2011], where the hepatic transcriptional profiles of RSV- and SRT1720-treated mice 
were compared.  Interestingly, the authors found only a small overlap between the hepatic transcriptional 
profiles of RSV- and SRT1720-treated mice [Minor et al. 2011].  To elucidate the main mechanism behind 
the effects of SRT1720 treatment on hepatic mitochondrial and metabolic processes, we assessed PGC-
1α acetylation as a readout of SIRT1 activity, but could detect no alterations in PGC-1α acetylation status.  
However, AMPK activity was increased in liver from SRT1720-treated mice.  AMPK is important for PGC-
1α expression and transcription of mitochondrial genes in liver [Guigas et al. 2007].  Enhanced AMPK-
activity could thus explain the improved hepatic mitochondrial transcription with SRT1720 treatment in 
our study.  Hepatic AMPK activation has however been associated with a reduced activity of hepatic 
gluconeogenesis, lipogenesis and cholesterol synthesis [Viollet et al. 2009], which are processes that were 
induced at a transcriptional levels with SRT1720 treatment.  Hence, AMPK activation could only partially 
explain the hepatic phenotype of SRT1720-treated mice, and the concomitant activation of both anabolic 
and catabolic processes in liver would strongly indicate that more than one signaling pathways would be 
involved in this regulation.  However, further studies are needed to elucidate the exact mechanism behind 
the effects of SRT1720 on mitochondrial and metabolic processes in liver, and whether these effects are 
cell-autonomous or could be attributed to inter-organ cross-talk.  To answer these open questions, it 
would be imperative to perform further experiments to elucidate the molecular effects of SRT1720 
treatment in liver cells in vitro.  Stimulation of cultured hepatocytes with SRT1720 and subsequent 
transcriptional analysis would help to delineate the transcriptional networks regulated by SRT1720 in liver 
cells.  These in vitro findings could then be compared to the transcriptional changes induced by SRT1720 
in liver in vivo.  This comparison would help to elucidate which processes are regulated directly by 
SRT1720, and which effects could be attributed to inter-organ cross-talk due to the alteration of metabolic 
processes in other organs.  Considering that many genes induced by SRT1720 in liver in our study were 
known PGC-1α target genes, it would be interesting to knock down PGC-1α in hepatocytes to directly 
investigate the role of this coactivator as a down-stream molecular effector of SRT1720 in this cell type.  
These findings could later be expanded to an in vivo setting, were mice with a liver-specific ablation of 
PGC-1α would be administered SRT1720.  This would allow us to validate the findings from our in vitro 
setup, but would also help characterize the functional outcome of hepatic PGC-1α deletion on the 
systemic metabolic effects of SRT1720 in mice.  While SRT1720 had a strong effects on liver metabolism 
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in our study, RSV treatment led to more prominent changes in WAT.  RSV improved the adipose tissue 
phenotype in HFD fed mice, which included increased mitochondrial protein levels, enhanced adiponectin 
transcription and reduced inflammation.  While AMPK activity in adipose tissue was unaltered with RSV 
treatment, we detected a significantly reduced cAMP response element-binding protein (CREB) 
phosphorylation in WAT in response to both short-term and long-term RSV treatment.  Increased CREB 
activity has been associated with transcriptional activation of ATF3 in adipose tissue, and an insulin 
resistant phenotype [Qi et al. 2009], and in line with this we could detect reduced ATF3 transcription and 
increased insulin-signaling in WAT with RSV treatment.  Importantly, overexpression of a dominant-
negative CREB in adipose tissue of obese mice improves whole body insulin sensitivity and reduces 
adipose tissue inflammation [Qi et al. 2009].  Hence, the inhibition of CREB-signaling by RSV specifically 
in adipose tissue depots could have a beneficial effect on whole body metabolism, and could thus 
contribute to the improved systemic phenotype of RSV-treated mice.  Intriguingly, CREB activity was also 
predicted to be reduced in adipose tissue depots of humans receiving RSV-treatment [Konings et al. 
2013].  These findings would warrant a closer examination of the beneficial effects of RSV-treatment on 
adipose tissue metabolism and inflammation during obesity, and the contribution of these effects on 
whole body glucose tolerance in rodents as well as humans patients.  In analogy with the above-
mentioned in vitro experiments for SRT1720 treatment in hepatocytes, a similar setup could be used to 
elucidate the molecular effects elicited by RSV treatment in adipocytes.  Also in this case, knockdown of 
PGC-1α in cultured adipocytes and subsequent transcriptional analysis would help define the exact role 
of PGC-1α as a molecular effector of RSV treatment in this cell type.  These experiments could also be 
extended to an in vivo setup, using mice with an adipocyte-specific ablation of PGC-1α.  Treatment of 
these mice with RSV would help determine whether adipose tissue PGC-1α is required to mediate the 
beneficial systemic effects of RSV treatment, such as enhanced oxygen consumption or improved glucose 
tolerance.  In extension, it would be important to treat additional cell types (i.e. myocytes, adipocytes, 
hepatocytes) with both RSV and SRT1720 in vitro.  This setup would help explain whether the differential 
effects of RSV and SRT1720 in different organs in vivo are due to cell-autonomous effects or whether it 
could be attributed to different in vivo bioavailability of these compounds in various organs.  In line with 
this, it would also be necessary to measure the concentrations of RSV and SRT1720 in the different tissues 
from mice treated with these compounds.  In conclusion, our data demonstrates that the effects of RSV 
and SRT1720 are non-analogous.  Moreover, these compounds exert differential effects on mitochondrial 
and metabolic processes in both liver and WAT, which is important to take into consideration when using 
these compounds in a clinical setting.  It also leaves us with the open question of how these compounds 
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exert their effects in target organs.  Both RSV and SRT1720 have been shown to activate SIRT1, however, 
considering the opposing effects of RSV and SRT1720 on hepatic metabolism, it is unlikely that one unique 
signaling pathway is responsible for these differential effects.  Thus, based on our findings, this warrant a 
closer examination of the signaling pathways activated by RSV and SRT1720 in liver and WAT.  Molecular 
dissection of the signaling pathways activated by these compounds will aid in our understanding of the 
therapeutic potential of RSV and SRT1720.  Moreover, it will also help with the design of new, more 
efficient CR/exercise-mimetic compounds, which could lead to novel treatments for obesity and related 
metabolic comorbidities. 
 In the third study of this thesis, we were interested in elucidating the regulation of ketone body 
oxidation by PGC-1α, and the impact of this regulation on systemic ketone body homeostasis.  Ketone 
bodies are important energy substrates during nutrient-deprived states, and are oxidized in most organs 
in a concentration-dependent manner.  Ketone body levels in the circulation are determined by the rate 
of ketogenesis in the liver, which in turn is regulated by the availability of fatty acids, which is the main 
ketogenic substrate.  Circulating ketone body levels thus rise in response to stimuli that increase 
circulating fatty acid levels, such as fasting, exercise, or in a pathological context, diabetes.  However, 
utilization of ketone bodies through oxidation is also an important determinant of circulating ketone body 
levels.  For example, reduced ketolytic capacity specifically in brain or skeletal muscle leads to increased 
circulating ketone body levels in mice [Cotter et al. 2013].  Moreover, ketone body levels are increased in 
humans with hereditary ketolytic deficiencies [Shafqat et al. 2013].  Hence, systemic ketone body 
homeostasis is dictated by both hepatic ketogenesis and extra-hepatic ketolysis.  Ketone bodies play a 
critical role in whole body energy homeostasis, since during starvation in humans, ketone bodies account 
for up to 50% of the oxygen consumption of most organs, and to an even higher degree in the brain [Cahill 
2006].  The importance of ketone body oxidation is further underscored in mice with a complete ketolytic 
deficiency, which die within 48 hours after birth [Cotter et al. 2011].  Interestingly, it was recently 
demonstrated that ketone bodies are more than just passive energy substrates.  The most abundant 
circulating ketone body, βOHB, was shown to act as an HDAC1-inhibitor, and thus influences 
transcriptional regulation and oxidative stress protection in kidney [Shimazu et al. 2013].  Intriguingly, 
HDAC1-specific inhibitors were also recently demonstrated to enhance oxidative capacity in skeletal 
muscle cells [Galmozzi et al. 2013].  In line with this, induction of a chronic state of ketosis by feeding 
rodents a ketogenic diet has been demonstrated to improve mitochondrial biogenesis in both brain 
[Bough et al. 2006], brown adipose tissue [Srivastava et al. 2013] and skeletal muscle [Ahola-Erkkila et 
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al. 2010].  The exact mechanism how mitochondrial biogenesis is enhanced during ketogenic diet feeding 
however is still unknown.  Dietary induction of ketosis has been suggested as a promising therapeutic 
strategy to treat various disorders such as diabetes, neurodegenerative disorders and cancer [Paoli et al. 
2013, Hashim and Vanitallie 2014].  Due to the therapeutic potential of dietary ketosis, and the 
importance of ketone bodies as metabolic fuels, it is essential to understand how ketone body oxidation 
is regulated in target organs.  This is especially pertinent in the context of skeletal muscle, which has a 
high capacity to oxidize ketone bodies.  PGC-1α has been shown to play an important role in the regulation 
of fatty acid oxidation in muscle, and it is known to regulate uptake of both glucose and fatty acids into 
muscle [Choi et al. 2008, Summermatter et al. 2013].  However, the role of PGC-1α in the regulation of 
ketone body oxidation has to our knowledge not been conclusively elucidated.  Thus, in the third 
manuscript of this thesis, we investigated the role of PGC-1α in the regulation of ketone body oxidation. 
 In this study, we demonstrated that PGC-1α is a transcriptional regulator of the rate-limiting 
ketolytic enzymes BDH1, OXCT1 and ACAT1.  Moreover, in C2C12 myotubes we demonstrated that ERRα 
is an important transcriptional partner of PGC-1α in the regulation of these genes.  However, further 
experiments using ChIP are needed to elucidate whether this is due to direct interaction of PGC-1α and 
ERRα on the promoters of these genes, or whether ERRα regulates these genes independently of PGC-1α.  
Importantly, in global PGC-1α null mice, ablation of PGC-1α was associated with a reduced transcription 
of ketolytic enzymes in kidney, heart, brain and skeletal muscle.  This is an important finding, since this 
demonstrates a global role of PGC-1α in the regulation of ketolytic capacity.  In line with this, global 
ablation of PGC-1α led to increased circulating βOHB-levels after 24 hours fasting, which is in line with a 
reduced ketolytic capacity in the absence of PGC-1α.  As mentioned earlier, mice with a global deletion of 
OXCT1, and thus a complete ablation of ketolysis, develop a severe hyperketonemia.  Due to the 
importance of ketone body oxidation in maintaining energy homeostasis during early extrauterine 
development [Platt and Deshpande 2005], OXCT1 knockout mice die during this neonatal period [Cotter 
et al. 2011].  Intriguingly, also PGC-1α null mice display an increased neonatal mortality [Lin et al. 2004], 
however not with the same frequency as OXCT1 null mice [Cotter et al. 2011].  Hence, we speculate that 
the increased neonatal mortality of PGC-1α null mice, could be linked to the systemic impairment in 
ketolytic capacity in these mice.  Closer examination of the ketone body levels in neonatal PGC-1α null 
mice would help confirm this hypothesis.  Next, we focused on the role of PGC-1α in the regulation of 
skeletal muscle ketolytic capacity.  Using mice with a muscle specific ablation or overexpression of PGC-
1α, we identified PGC-1α as an important regulator of the ketolytic capacity in this organ.  In skeletal 
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muscle, PGC-1α regulates the transcription, not only of ketolytic enzymes, but also of the main ketone 
body transporter MCT1 as well as TCA-cycle enzymes.  Hence, PGC-1α modulates the entire transcriptional 
program responsible for complete oxidation of ketone bodies in skeletal muscle.  Intriguingly, ablation of 
PGC-1α in skeletal muscle led to a fasting-induced hyperketonemia in the same range as that seen in 
global PGC-1α null mice, indicating that skeletal muscle is a major contributor to systemic ketolytic 
capacity.  Systemic hyperketonemia in mKO mice was also detected during ketogenic diet feeding and 
exercise.  Exercise training can reduce post-exercise ketosis in both rodents [Adams and Koeslag 1988] 
and humans [Johnson et al. 1969], and PGC-1α overexpression in skeletal muscle could mimic this effect 
in our mice, since mTG mice had significantly reduced post-exercise βOHB levels.  Accordingly, we were 
interested in whether PGC-1α was involved in the adaptation of skeletal muscle ketolytic capacity during 
exercise.  Whole body ketolytic capacity was enhanced in mice after being kept for 8 weeks in running-
wheel cages.  Importantly, this induction could not be seen in PGC-1α mKO mice, indicating that skeletal 
muscle PGC-1α plays an important role in this adaptation.  In line with this, transcription of ketolytic genes 
in skeletal muscle were induced in a PGC-1α-dependent manner in response to exercise.  However, we 
could detect no induction in protein levels of ketolytic enzymes in trained mice.  This suggests that long-
term exercise alters ketolytic enzyme activity rather than absolute protein levels of these enzymes in 
skeletal muscle.  In line with this, it has been shown that exercise training in rats led to an increase in 
enzymatic activity of both OXCT1 and ACAT1 in skeletal muscle [Askew et al. 1975].  An important future 
experiment would thus be to measure enzymatic activity of OXCT1 and ACAT1 in sedentary and trained 
PGC-1α mKO and control mice.  This would help to elucidate whether PGC-1α in skeletal muscle is required 
for an induction of ketolytic enzyme activity with exercise.  In the next part of this study, we were 
interested in how a basal increase in PGC-1α levels in skeletal muscle would impact systemic ketosis.  
Interestingly, increased PGC-1α levels specifically in skeletal muscle of mice led to a reduced systemic 
ketosis in response to fasting, ketogenic diet feeding and exercise.  Moreover, mice with a muscle-specific 
overexpression of PGC-1α displayed a significantly reduced hyperketonemia in response to 
experimentally induced diabetes.  Diabetic ketoacidosis is a potentially lethal complication found in 
diabetic patients [Laffel 1999].  Hence, based on our findings, activation of PGC-1α in skeletal muscle 
could be used as a therapeutic strategy to ameliorate diabetic ketoacidosis in patients suffering from type 
1 diabetes.  However, PGC-1α levels are shown to be increased in liver of type 1 and type 2 diabetic mouse 
models [Puigserver and Spiegelman 2003], and could thus contribute to both hyperglycemia and 
hyperketonemia during diabetes.  Hence PGC-1α activation in type 1 diabetic patients would have to be 
restricted to skeletal muscle to have a beneficial effect in this context. 
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As an extension of this study, we also worked on a side-project aimed at investigating the 
adaptation of skeletal muscle to a chronic state of ketosis, and the role of PGC-1α therein.  The role of 
PGC-1α in skeletal muscle adaptation to a ketogenic diet is important considering that a chronic ketogenic 
environment have been show to improve mitochondrial biogenesis and function in several organs.  For 
example, ketogenic diet feeding was shown to increase mitochondrial biogenesis in both brain [Bough et 
al. 2006] and BAT [Srivastava et al. 2013], and to improve mitochondrial function in skeletal muscle 
[Ahola-Erkkila et al. 2010] and heart [Krebs et al. 2011] of mice suffering from mitochondrial disorders.  
In this context, it was suggested that PGC-1α would act as an important down-stream mediator of these 
effects induced by ketogenic diet feeding.  Hence, we were interested in elucidating whether ketogenic 
diet feeding would improve mitochondrial number and function in skeletal muscle, and whether PGC-1α 
would be required to mediate these effects.  Since PGC-1α is an important regulator of skeletal muscle 
ketolytic capacity, we were also interested in whether a muscle-specific ablation of PGC-1α would 
influence the systemic adaptation to a ketogenic diet.  To this end we used mice with a muscle-specific 
deletion of PGC-1α (mKO), and fed these mice a ketogenic diet (95 kcal% fat, 5 kcal% protein, <0.1% 
carbohydrates) or a normal chow-diet as control, for a period of 12 weeks.  After 12 weeks on a ketogenic 
diet, we observed no differences between CTRL and PGC-1α mKO mice in either body weight (FIG 1A), 
calorie intake (FIG 1B) or relative fat mass (FIG 1C).  However, a ketogenic diet slightly reduced absolute 
body weight in both groups (FIG 1A) and led to a significant increase in their relative fat mass (FIG 1C).  
Interestingly, even after 12 weeks on a ketogenic diet, mKO mice still displayed a significant 
hyperketonemia (FIG 1D).  Moreover, both CTRL and mKO mice displayed reduced blood glucose levels 
(FIG 1E), which reflects the low carbohydrate content of the ketogenic diet.  Importantly, we detected 
increased circulating levels of cell damage markers such as alanine transaminase (ALT) (FIG 1F) and lactate 
dehydrogenase (LDH) (FIG 1G) in plasma of CTRL and mKO mice.  ALT is a liver-specific damage marker 
and indicates that the liver is damaged upon ketogenic diet feeding in our mice.  This finding is in line with 
other studies which also reported increased hepatic steatosis and liver inflammation in mice fed a 
ketogenic diet [Garbow et al. 2011].  Taken together, these findings suggest that a ketogenic diet leads 
to detrimental effects in liver, most likely as a result of the high fat content of the diet.  Importantly, 
increased incidence of hepatic steatosis is also associated with ketogenic diet feeding in humans [Schugar 
and Crawford 2012].  While the hyperketonemic phenotype of PGC-1α mKO mice was evident even after 
12 weeks of ketogenic diet feeding, no other differences were detected between CTRL and mKO mice.  
Next we were interested in whether long-term ketogenic diet feeding would affect transcription of 
mitochondrial genes.  In line with the known function of PGC-1α as a regulator of mitochondrial function, 
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we detected reduced transcript (FIG 2A) and protein (FIG 2B) levels of mitochondrial enzymes involved in 
oxidative phosphorylation.  Moreover ADP-induced respiration in mitochondria isolated from skeletal 
muscle was reduced in the absence of PGC-1α (FIG 2C-D).  However, in contrast to the results shown with 
ketogenic diet feeding in other studies [Bough et al. 2006, Ahola-Erkkila et al. 2010, Krebs et al. 2011, 
Srivastava et al. 2013], we could not find any differences in either transcript (FIG 2A) or protein (FIG 2B) 
levels of mitochondrial genes.  Moreover, ADP-induced complex I and II respiration in isolated 
mitochondria (FIG 2C-D) was not affected by ketogenic diet feeding.  Complex I activity was even 
significantly reduced in both CTRL and mKO mice fed a ketogenic diet (FIG 2C).  These data indicate that 
long-term feeding of a ketogenic diet does not induce protein levels of mitochondrial enzymes or 
mitochondrial function in skeletal muscle.   
We were furthermore interested in how skeletal muscle metabolism adapts to a high-fat/low-
carbohydrate diet such as a ketogenic diet.  Since we showed earlier in our study that PGC-1α is important 
for ketolytic enzyme expression in skeletal muscle, we accordingly measured transcript levels of the 
ketone body transporter MCT1 and the ketolytic enzymes BDH1, OXCT1 and ACAT1 in skeletal muscle.  As 
shown earlier, these genes were reduced in the absence of PGC-1α in skeletal muscle (FIG 2E).  Moreover, 
both BDH1 and OXCT1 transcript levels were significantly reduced in skeletal muscle by ketogenic diet 
feeding (FIG 2E).  Interestingly, at the protein level we detected the opposite effect, since OXCT1 protein 
levels were significantly increased in skeletal muscle with a ketogenic diet in both CTRL and mKO mice 
(FIG 2F).  This indicates that the induction of OXCT1 with ketogenic diet feeding is likely mediated through 
a transcription-independent mechanism, which could also explain that the increase in OXCT1 occurred to 
the same extent in PGC-1α mKO mice as in CTRL mice (FIG 2F).  Also ACAT1 protein levels were induced 
in skeletal muscle during ketogenic diet feeding, however this induction was slightly blunted in PGC-1α 
mKO mice (FIG 2F).  Conclusively, this indicates that skeletal muscle ketolytic capacity is induced in skeletal 
muscle during long term ketogenic diet feeding.  This increase is however not directly dependent on the 
transcriptional regulation of OXCT1 and ACAT1, and would warrant a closer examination of the 
mechanisms behind the increased levels of ketolytic enzymes in skeletal muscle.  Further investigation 
demonstrated a significant reduction in transcript levels of glucose transporter 4 (GLUT4), hexokinase 2 
(HKII), and pyruvate kinase, muscle isoform (PKM1) in both CTRL and mKO mice (FIG 2G), which reflects 
an adaptation to the reduced dietary carbohydrate intake.  Moreover, the strong induction of pyruvate 
dehydrogenase lipoamide kinase isozyme 4 (PDK4) transcription (FIG 2G) and enhanced transcript levels 
of proteins involved in fatty acid uptake (cluster of differentiation 36, CD36) and β-oxidation (carnitine 
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palmitoyltransferase 1B, Cpt1b; long chain acyl-CoA dehydrogenase, Lcad) (FIG 2H) indicate a shift in 
skeletal muscle substrate utilization towards a higher reliance on lipids as an energy substrate.  
Interestingly, this adaptation did not occur to the same extent in PGC-1α mKO mice, since the induction 
of CD36, Cpt1b and Lcad were blunted in the absence of PGC-1α (FIG 2H).  In conclusion, we demonstrate 
that PGC-1α is important for the induction of fatty acid transporters and β-oxidation enzymes in skeletal 
muscle during ketogenic diet feeding.  This is most likely an adaptation in skeletal muscle to the high lipid 
content of the ketogenic diet.  In contrast, induction of ketolytic proteins with ketogenic diet feeding 
occurred through a transcription-independent mechanism, and was accordingly independent of PGC-1α.  
Moreover, we did not detect any improvement of the mitochondrial phenotype in skeletal muscle during 
ketogenic diet feeding.  In light of this, and considering the negative systemic effects of a high-fat/low-
carbohydrate diet on accumulation of fat mass, and increased liver damage markers, we decided to 
discontinue this part of the study.  It would however in future studies be interesting to elucidated whether 
increased levels of ketone bodies could exert beneficial effects on mitochondrial metabolism in skeletal 
muscle when disconnected from the negative effects of the high fat content of a ketogenic diet.  
Preferably, this would be performed as an extension of our current study.  We could thus administer βOHB 
or ketone body esters [Hashim and Vanitallie 2014] to our mice through an implantable osmotic pump.  
We would try to match the ketone body levels in the circulation to those achieved in the mice fed a 
ketogenic diet and to perform the treatment for the same period of time.  Subsequently we would 
perform the same metabolic tests and molecular analyses as performed in LCKD-fed mice.  This would 
allow us to differentiate between the effects of increased βOHB levels and those elicited by the high lipid 
content of the ketogenic diet.  One important question would be to discern whether increased βOHB 
levels enhance skeletal muscle mitochondrial biogenesis in chow-fed mice.  As a positive control, we could 
use BAT where mitochondrial content was enhanced by ketogenic diet feeding in a recent study 
[Srivastava et al. 2013].  This would allow us to confirm the findings of this particular study and to 
conclusively answer whether a similar effect also occurs in skeletal muscle in vivo.  A careful mapping of 
the metabolic changes elicited by LCKD-feeding compared to βOHB administration in mice would also help 
elucidate any potential caveats of using these interventions as a therapeutic strategy.  These findings 
would provide important information that could be used to design future treatments using either 
ketogenic diets or βOHB-administration in humans. 
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Figure 1 - Low-carbohydrate ketogenic diet (LCKD) feeding results in enhanced adiposity and increased 
circulating liver damage markers. 
(A)  Body weight of mice after 12 weeks feeding of either a chow diet (CHOW) or a low-carbohydrate ketogenic diet 
(LCKD) (n=13-16/group).  (B)  Calorie intake of either chow-fed or LCKD-fed mice after 10 weeks on the respective 
diets (n=7-8/group).  (C)  Fat mass normalized to absolute body weight.  (D)  Blood βOHB levels in the fed state (n=7-
8/group).  (E)  Blood glucose levels in the fed state (n=7-9/group).  (F)  Plasma alanine transaminase (ALT) levels or 
(G)  Plasma lactate dehydrogenase (LDH) levels after 6 weeks on either a chow- or LCKD-diet (n=8/group).  Error 
bars represent mean ±SEM.  Significant differences (p value < 0.05) between chow-fed and LCKD-fed groups are 
indicated by a number sign (#), and between CTRL mice and mKO mice by an asterisk (*). 
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Figure 2 – LCKD feeding does not alter mitochondrial parameters in skeletal muscle, but 
leads to a shift in substrate utilization. 
(A)  mRNA levels of the mitochondrial proteins Sdhb, Uqcrc2 and Cs in skeletal muscle from CTRL and 
PGC-1α mKO mice after 12 weeks on a chow- or a LCKD (n=6-8/group).  (B)  Representative 
immunoblots of ATP5A, Uqcrc2, Ndufb8 and eEF2 in skeletal muscle from CTRL and PGC-1α mKO mice 
after 12 weeks on a chow- or a LCKD.  Basal and ADP-induced oxygen consumption rate (OCR) of 
complex I (C) and complex II (D) of mitochondria isolated from skeletal muscle of CTRL and PGC-1α 
mKO mice after 12 weeks on a chow- or a LCKD (n=4-6/group).  (E)  mRNA levels of Mct1, Bdh1, Oxct1 
and Acat1 in skeletal muscle from CTRL and PGC-1α mKO mice after 12 weeks on a chow- or a LCKD 
(n=6-8/group).  (F) Representative immunoblots of OXCT1, ACAT1 and eEF2 in skeletal muscle from 
CTRL and PGC-1α mKO mice after 12 weeks on a chow- or a LCKD.  mRNA levels of (G) GLUT4, HKII, 
PKM1, PDK4 and (H) CD36, Cpt1b, Lcad in skeletal muscle from CTRL and PGC-1α mKO mice after 12 
weeks on a chow- or a LCKD (n=6-8/group).  All mRNA levels normalized to 18s rRNA.  Error bars 
represent mean ±SEM.  Significant differences (p-value <0.05) between chow-fed and LCKD-fed 
groups are indicated by a number sign (#), and between CTRL mice and mKO mice by an asterisk (*). 
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9.2 – Future perspectives 
Obesity is a risk factor for the development of several severe diseases, such as diabetes, cardiovascular 
disease and cancer, amongst others.  Exercise and CR would be efficient ways to ameliorate metabolic 
dysfunction in humans.  However, it is not easy to maintain these diet- and exercise regimens.  Thus, it 
has been suggested that administration of compounds, which could mimic the effects of either exercise 
[Fan et al. 2013] or CR [Ingram et al. 2006] would elicit beneficial metabolic effects in obese human 
patients.  In this context, RSV and SRT1720 have been suggested to be potential candidates, since these 
compounds have been shown to activate SIRT1 [Milne et al. 2007], and to be able to ameliorate metabolic 
dysfunction in obese mice [Lagouge et al. 2006, Feige et al. 2008].  The effects of RSV are dependent on 
several down-stream effectors, since AMPK, SIRT1 and cAMP-signaling were required to mediate the full 
effects of RSV in skeletal muscle [Um et al. 2010, Park et al. 2012, Price et al. 2012].  Downstream of 
AMPK, SIRT1 and cAMP signaling, PGC-1α has been suggested to be an important mediator of the 
beneficial effects of both RSV and SRT1720 in skeletal muscle [Lagouge et al. 2006, Feige et al. 2008].  
However, it is not known whether the effects of these compounds are dependent on activation of PGC-
1α in skeletal muscle.  Accordingly, in the second manuscript of this thesis, we investigated whether 
skeletal muscle PGC-1α is an important down-stream mediator of the effects of RSV and SRT1720 in obese 
mice.  Surprisingly, while treatment with these compounds resulted in beneficial metabolic effects in 
obese mice, such as increased energy expenditure, reduced adiposity and improved glucose tolerance, 
neither of these effects were dependent on skeletal muscle PGC-1α.  Intriguingly, RSV and SRT1720 
exerted only mild effects on skeletal muscle metabolism, while the effects of these compounds were more 
prominent in liver and adipose tissue, resulting in profound metabolic alterations in these organs.  Hence, 
these findings indicate that modulation of PGC-1α activity, and in extension skeletal muscle metabolism, 
is not necessary for the ability of RSV and SRT1720 to ameliorate metabolic dysfunction in obese mice.  
However, the induction of several PGC-1α target genes in liver with SRT1720 treatment, and in adipose 
tissue with RSV treatment, indicates that PGC-1α might be an important mediator of the effects of RSV 
and SRT1720 in these organs.  Hence, further studies are needed to elucidate the role of PGC-1α in 
response to RSV/SRT1720 treatment in liver and adipose tissue.  As mentioned earlier, this could be 
achieved through the use of liver- and adipose tissue-specific PGC-1α knockout models and by employing 
a similar setup as used in our current study.  This experimental setup would allow the dissection of the 
transcriptional networks affected by RSV or SRT1720 treatment in liver and adipose tissue.  It would 
furthermore help elucidate whether PGC-1α is an important molecular effector of RSV and SRT1720 in 
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these organs.  Studies on the organ-specific effects of RSV and SRT1720 treatment in obese mice would 
thus help delineate the contribution of different organs to the improved metabolic rate and enhanced 
glucose tolerance with these compounds and would help guide the design of more potent and specific 
therapeutic drugs.  In line with this, to avoid potential caveats during RSV and SRT1720 treatment in 
humans, it is essential to identify the down-stream signaling pathways, which are affected by these 
compounds.  Since RSV and SRT1720 have been demonstrated to activate SIRT1 [Milne et al. 2007] and 
since they elicit similar effects on whole body metabolism [Lagouge et al. 2006, Feige et al. 2008], these 
compounds have been suggested to act through the same signaling pathways.  Contrariwise, our study 
clearly demonstrates that RSV and SRT1720 do not exert analogous effects on mitochondrial and 
metabolic processes in adipose tissue and liver. Hence, RSV and SRT1720 do not seem to cause their effect 
through modulation of similar signaling pathways.  Future studies should thus be aimed at elucidating the 
exact molecular mechanisms how RSV and SRT1720 exert their effects in target organs.  These 
experiments would preferably be performed using either adipocyte and hepatocyte cell lines or primary 
cells.  While such models cannot completely mimic the in vivo environment in a HFD-fed mouse, these 
experiments would be important to elucidate the molecular mechanisms how RSV and SRT1720 elicit their 
effects in these cell types.  To allow an unbiased approach to elucidating the molecular effectors of RSV 
and SRT1720 in liver or adipose tissue, high-throughput techniques such as microarrays, proteome 
analysis as well as phosphoproteomics and acetylomics could be utilized.  Bioinformatic approaches would 
then play an important role in confirming the predicted molecular effectors of these compounds (i.e. 
SIRT1, AMPK, PGC-1α) and to facilitate the discovery of any novel molecular effectors or target genes 
regulated by either RSV or SRT1720.  Finally, the requirement for these novel targets can then be tested 
in an in vivo model by deleting the gene of interest in the organ of interest, and to treat these mice with 
either RSV or SRT1720.  Due to the promising results obtained in rodent studies, there have been several 
clinical trials using both formulated RSV (SRT501) or other small-molecule activators of SIRT1, such as 
SRT2104 and SRT2379 in human subjects [Villalba et al. 2012].  However, in contrast to the unequivocal 
beneficial effects on metabolism in rodents, treatment of human patients did not result in clear beneficial 
effects.  These findings suggest that the effects of RSV and SIRT1 activators on whole body metabolism do 
not seem to be as straight forward as initially thought.  In line with this, activation of SIRT1 seems to be 
important to ameliorate metabolic dysfunction associated with obesity, but this is most likely not the only 
signaling pathway altered during exercise or caloric restriction. Hence, to successfully design CR/exercise 
mimetic compounds, a complete knowledge of the metabolic alterations occurring during exercise or CR 
must be obtained.  Hence, it is important to build on the findings regarding RSV and SRT1720 from our 
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current study and through further research gain novel insight into the mode of action of these 
compounds.  This will facilitate our understanding of the therapeutic potential of pharmacological 
CR/exercise mimetics and aid in the development of better and more efficient therapeutic strategies. 
In the third study of this thesis, we focused on the role of PGC-1α in the transcriptional regulation 
of ketolytic enzymes, and its impact on systemic ketone body homeostasis.  We found that PGC-1α is an 
important regulator of the ketolytic capacity in skeletal muscle, through its role together with ERRα as 
transcriptional regulators of the rate-limiting ketolytic enzymes, BDH1, OXCT1 and ACAT1.  Importantly, 
we demonstrated that skeletal muscle ketolytic capacity is an important determining factor of circulating 
ketone body levels during states of ketosis.  Interestingly, an increase in PGC-1α levels in skeletal muscle 
was sufficient to ameliorate hyperketonemia in diabetic mice.  Hence, our findings have implications for 
the management of hyperketonemia in patients suffering from either diabetic or alcoholic ketoacidosis.  
Importantly, PGC-1α was also required for the increase in ketolytic capacity with exercise training.  Hence, 
physical exercise could be beneficial not only for the management of glucose levels in diabetic patients 
[Lopes Souto and Paes de Miranda 2011], but also for ameliorating diabetic hyperketonemia.  Since PGC-
1α regulates transcription of ketolytic enzymes in several organs, an open question is whether modulation 
of the ketolytic capacity in these organs would have an equally significant impact on systemic ketosis as 
in skeletal muscle.  Cotter et al. showed that knockout of OXCT1 in neurons had a greater impact on 
circulating ketone body levels after 48 hours fasting in mice than ablation of OXCT1 in skeletal muscle 
[Cotter et al. 2013].  Hence, it would be interesting to study the adaptation of brain-specific PGC-1α 
knockout mice to long-term fasting.  However, based on our findings that global PGC-1α null mice do not 
develop a more severe hyperketonemia than skeletal muscle specific knockouts, this would point towards 
a more prominent role of skeletal muscle in this context.  However, these studies were only performed 
using a 24-hour fasting regime, and the individual contribution of different organs to the systemic ketolytic 
capacity could indeed be altered after 48 hours fasting.  Interestingly, ablation of PGC-1α in skeletal 
muscle did not affect the adaptation to long term ketogenic diet feeding.  A likely reason for this could be 
that the induction of OXCT1 protein in skeletal muscle during this chronic ketotic state occurred through 
non-transcriptional mechanisms.  In contrast to this, in a study by Wentz et al. the authors observed a 
decrease in both transcript and protein levels of OXCT1 in heart during a ketogenic diet [Wentz et al. 
2010].  Considering our findings, there might be fundamental differences in the adaptation to a chronic 
ketotic state between heart and skeletal muscle and understanding this regulation would be an important 
subject for future studies.  This is crucial, especially in the context of the widespread use of ketogenic diets 
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for both weight loss and anticonvulsant therapies [Paoli et al. 2013].  Recently, Schugar et al. published a 
study where the metabolic profile of mice with a cardiac-specific deletion of OXCT1 was characterized 
[Schugar et al. 2014].  It would be interesting in future experiments to replicate this experiment in OXCT1-
deficient skeletal muscle and thereby determine the metabolic profile in skeletal muscle in the absence 
of ketolytic capacity.  Surprisingly, we did not observe any increase in either mitochondrial protein or 
function in skeletal muscle with ketogenic diet feeding.  This is an interesting finding, considering that 
such an effect has been shown to occur for both BAT and brain [Bough et al. 2006, Srivastava et al. 2013].  
This could once again represent a differential adaptation to a chronic ketogenic state between different 
organs and would need to be studied in more detail.  It would also be interesting to investigate the role 
of chronic ketosis on mitochondrial capacity of skeletal muscle disconnected from the administration of a 
ketogenic diet.  This could be achieved through the administration of ketone body esters [Hashim and 
Vanitallie 2014] as discussed earlier in this chapter.  Such an approach would increase circulating ketone 
body levels without any negative impact on blood pH, or any negative metabolic impact from the elevated 
fat content of a ketogenic diet.  This is an intriguing question, since βOHB has been shown to function in 
vivo as an HDAC1-inhibitor [Shimazu et al. 2013] and treatment with other HDAC1-inhibitors was shown 
to increase mitochondrial biogenesis in C2C12 myotubes in a PGC-1α-dependent manner [Galmozzi et al. 
2013].  Hence, further studies are needed to elucidate whether βOHB can act as an HDAC-inhibitor also 
in skeletal muscle in vivo, and if disconnected from the negative effects of a high fat diet, whether it could 
lead to an activation of PGC-1α and mitochondrial biogenesis.  In line with this, it would be interesting to 
study the effects of βOHB administration in C2C12 myotubes.  Subsequent transcriptional analysis would 
provide important insight into the effects on gene expression elicited by βOHB.  Hence, this in vitro setup 
would allow the characterization of the molecular effects elicited by βOHB administration in skeletal 
muscle cells, devoid of any precluding effects due to the high lipid content of a ketogenic diet.  Moreover, 
this setup would enable us to characterize mitochondrial content and oxidative function of myotubes in 
the context of βOHB administration.  To this end we would use methods such as immunoblotting and 
transcriptional analysis to quantify mitochondrial transcript and protein levels.  Moreover, oxidative 
capacity and metabolic flux in βOHB-treated myotubes would be quantified using am extracellular flux 
analyzer such as the Seahorse system.  Would these experiments yield promising results, βOHB 
administration could also be performed in mice to study both the acute and the long-term effects of 
ketone bodies on skeletal muscle physiology and function.  In this context, whole body metabolic 
parameters such as metabolic rate, fat content and glucose tolerance would be assessed.  Moreover, 
mitochondrial content and function in skeletal muscle would be analyzed using similar methods as in our 
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in vitro setup mentioned above.  Conclusively, as far as we can tell, our study is the first to elucidate the 
transcriptional regulation of ketone body oxidation in skeletal muscle.  While previous studies have 
demonstrate the importance of skeletal muscle as a determinant of whole body ketolytic capacity [Cotter 
et al. 2013], we can show that by enhancing the ketolytic capacity in skeletal muscle through 
overexpression of PGC-1α, we can ameliorate diabetic hyperketonemia.  This provides important insight 
into the molecular regulation of ketolysis.  However, further studies are needed to identify additional 
molecular effectors which are important for both transcriptional and transcription-independent 
regulation of ketone body oxidation.  Together this will improve our understanding of systemic ketone 
body homeostasis and the therapeutic potential of a state of ketosis, especially in the context of metabolic 
and muscle-related disorders. 
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10.  Thesis – Conclusions and future perspectives  
PGC-1α is a versatile transcriptional coactivator which is important for transcriptional adaptation of 
cellular metabolism in response to various environmental cues, such as fasting, cold or exercise.  Since the 
first cloning of PGC-1α in 1998 and the subsequent characterization of its role as an important 
thermogenic regulator in BAT [Puigserver et al. 1998], a plethora of studies have expanded our 
understanding of PGC-1α biology and its role in physiological as well as pathophysiological states.  During 
the work on this thesis, several studies have been published that have discovered new aspects of PGC-1α 
biology, such as its role in regulation of myokine crosstalk between skeletal muscle and adipose tissue 
[Bostrom et al. 2012, Rao et al. 2014] or its novel roles in retinal and intestinal energy metabolism 
[D'Errico et al. 2011, Egger et al. 2012, Saint-Geniez et al. 2013], to name a few.  Moreover, through the 
use of high-throughput sequencing techniques, the global transcriptional network of PGC-1α has been 
mapped in both liver and muscle cells [Charos et al. 2012, Baresic et al. 2014].  Collectively, these and 
many other studies have increased our knowledge of the ubiquitous role of PGC-1α as a metabolic 
regulator in different organs.  However, these studies also reveal that there are still many aspects of PGC-
1α biology which are not fully elucidated.  Hence, in the scope of this thesis we have investigated several 
novel aspects of PGC-1α function. 
PGC-1α is an established transcriptional regulator of thermogenesis, gluconeogenesis and 
exercise adaptation.  Hence, the role of PGC-1α is best understood in metabolic organs such as BAT, liver 
and skeletal muscle.  In contrast, relatively little is known regarding the role of PGC-1α in the kidney.  
While the kidney is a highly metabolic organ with a high baseline PGC-1α expression, it does not contribute 
extensively to systemic metabolic homeostasis.  This could be one explanation for the lack of information 
on PGC-1α in this organ.  Nonetheless, mitochondrial and metabolic dysfunction have emerged as 
important components in the pathogenesis of renal disorders [Niaudet 1998, Sharma et al. 2013, Che et 
al. 2014].  Accordingly, this has sparked an interest in finding ways to ameliorate mitochondrial 
dysfunction in the kidney, potentially through activation of PGC-1α.  However, to recognize the full 
therapeutic potential of PGC-1α activation in the kidney, it is important to understand the role of this 
coactivator in basal renal physiology.  In this thesis we demonstrate that PGC-1α is an important regulator 
of mitochondrial and metabolic gene programs in the kidney.  Moreover, our data indicate that ERRα and 
PPARα are important transcriptional partners of PGC-1α in the kidney, which links PGC-1α to the 
regulation of renal mitochondrial biogenesis and fatty acid oxidation.  Intriguingly, several nuclear 
receptors display a heterogeneous expression pattern in different nephron segments [Krid et al. 2012].  
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This would in extension suggest that the transcriptional networks regulated by PGC-1α differ between 
different parts of the kidney, depending on the local transcription factor expression profile.  Accordingly, 
future studies should be aimed at dissecting the transcriptional networks of PGC-1α in each individual 
nephron segment or cell type.  This is of importance when considering the differential function, as well as 
mitochondrial and metabolic heterogeneity of different nephron segments [Valtin 1977, Kurokawa 1981].  
Hence, the transcriptional analysis from our study represents the combined effects of PGC-1α deletion in 
all nephron segments and thus the complete renal transcriptional program.  For a more detailed functional 
analysis, these transcriptional alterations would have to be mapped to a specific region along the renal 
nephron.  As discussed in chapter 5, this could be accomplished through microdissection of specific 
nephron segments.  Preferably, these experiments would be performed in PiNKO mice and subsequent 
microarray analysis could reveal the distinct transcriptional networks of PGC-1α in different segments of 
the nephron.  Such an approach would increase the resolution of the renal transcriptional networks 
regulated by PGC-1α, and would provide a more comprehensive overview of the effects of this coactivator 
in the kidney.  Surprisingly, despite the strong impact of PGC-1α deletion on metabolic and mitochondrial 
gene transcription networks, deletion of PGC-1α in tubular epithelial cells did not interfere with the ability 
of the kidney to regulate systemic ion, water or nutrient homeostasis.  However, we noticed that aged 
PiNKO mice had difficulties to adapt to a low-sodium environment.  Aging is related to a decline in renal 
mitochondrial function, combined with increased inflammation and reduced renal function [Weinstein 
and Anderson 2010, Schmitt and Melk 2012].  It has been shown that PGC-1α activation ameliorates 
mitochondrial dysfunction and confers therapeutic benefits in both skeletal muscle and heart during aging 
[Dillon et al. 2012].  Hence, absence of PGC-1α in the kidney might increase the risk of developing aging-
related renal dysfunctions.  So far it has not been investigated how PGC-1α influences aging-related renal 
dysfunctions and an important future direction would thus be to elucidate the precise role of PGC-1α in 
this process (as discussed in chapter 5).  In our study we have focused on elucidating the role of PGC-1α 
in the basal function of tubular salt and water reabsorption. However, future studies should be aimed at 
investigating whether PGC-1α is involved in regulation of other renal functions, for example 
gluconeogenesis.  Intriguingly, fasting has been shown to induce PGC-1α expression in the kidney [Teng 
et al. 2011] and several TFs known to interact with PGC-1α in the regulation of hepatic gluconeogenesis 
(i.e. HNF4a and CREB) are also expressed in the kidney [Mutel et al. 2011, Krid et al. 2012].  Considering 
that the kidney can match the gluconeogenic potential of liver in the post-prandial state [Mitrakou 2011], 
it will be important to elucidate whether PGC-1α also regulates this process in the kidney.  To evaluate 
the role of PGC-1α in renal gluconeogenesis, it is important to localize the main site of de novo glucose 
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production in the kidney.  Since the proximal tubules express high levels of gluconeogenic genes [Mather 
and Pollock 2011, Krid et al. 2012], this would be a good cell type to begin investigating.  The next step 
would be to assess whether HFD- or fasting-induced gluconeogenic gene transcription is altered in this 
cell type and whether the absence of PGC-1α would blunt the induction of the renal gluconeogenic gene 
program, preferably using the PiNKO mouse model.  While both liver and kidney use pyruvate as a 
gluconeogenic substrate, glutamine is preferentially used by the kidney.  Hence, glutamine administration 
and measurement of de novo glucose synthesis allows measuring the renal gluconeogenic potential in 
PiNKO mice.  If a connection between PGC-1α and renal gluconeogenesis would be apparent, the next 
step would be to confirm with ChIP experiments whether PGC-1α directly binds to the promoter region 
of gluconeogenic genes in the kidney and whether this binding can be enhanced by fasting.  These 
experiments would help widen our knowledge of how renal gluconeogenesis is regulated and the role of 
PGC-1α therein.  Taken together, we have demonstrated that PGC-1α has a central role as a regulator of 
metabolic and mitochondrial transcriptional programs in the kidney.  Despite the fact that PGC-1α is 
dispensable for basal renal function, it could still be a promising therapeutic target to ameliorate renal 
metabolic disorders associated with mitochondrial dysfunction and lipotoxicity.  Hence, future studies 
should be aimed at determining the therapeutic potential of PGC-1α activation in the kidney (as discussed 
in chapter 5).   
 Exercise and CR elicit several beneficial metabolic effects on skeletal muscle metabolism, such as 
improved mitochondrial function, reduced insulin resistance and increased fat oxidation [Schenk et al. 
2011, Lanza et al. 2012, Egan and Zierath 2013].  In line with this, overexpression of PGC-1α in skeletal 
muscle has been demonstrated to ameliorate mitochondrial and metabolic dysfunction in several rodent 
disease models [Svensson and Handschin 2014].  PGC-1α has a central role in metabolic regulation and is 
regulated by a multitude of upstream signaling pathways (see chapter 1).  Hence, PGC-1α is postulated to 
be the molecular effector of several drugs, which modulate mitochondrial and metabolic properties in 
oxidative organs.  Relevant examples are RSV and SRT1720, which are both SIRT1-activating compounds 
and in turn have been shown to activate PGC-1α in skeletal muscle [Lagouge et al. 2006, Feige et al. 2008].  
In the scope of this thesis we wanted to validate the role of PGC-1α as a molecular effector of the 
beneficial metabolic effects elicited by RSV and SRT1720 in skeletal muscle.  While we observed only mild 
effects on transcription of mitochondrial genes in skeletal muscle with RSV and SRT1720 treatment, these 
effects were dependent on PGC-1α.  Intriguingly, SRT1720 treatment could improve the oxidative 
phenotype of skeletal muscle and increase mitochondrial density even in the absence of PGC-1α and 
10.  Thesis – Conclusions and future perspectives 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________
252 
without any major alterations in mitochondrial gene transcription.  Unfortunately, due to the mild effects 
of RSV and SRT1720 on skeletal muscle metabolism and mitochondrial content, we cannot draw any 
strong conclusions regarding the role of PGC-1α as a molecular effector of RSV and SRT1720 in skeletal 
muscle.  We can however conclude that skeletal muscle PGC-1α is not necessary to confer the systemic 
metabolic effects of RSV and SRT1720, since both systemic metabolic rate and glucose tolerance were 
improved in the absence of skeletal muscle PGC-1α.  Importantly, the effects of RSV and SRT1720 were 
more prominent in liver and adipose tissue, resulting in profound metabolic alterations in these organs. 
The induction of several PGC-1α target genes in liver with SRT1720 and in adipose tissue with RSV 
treatment indicates that PGC-1α might be an important mediator of the effects of RSV and SRT1720 in 
these organs.  Hence, further studies are required to elucidate the role of PGC-1α in response to 
RSV/SRT1720 treatment in liver and adipose tissue (as discussed in chapter 9).  Since the results in this 
study were obtained in sedentary mice, this could preclude a more prominent role for muscle PGC-1α in 
the regulation of the metabolic phenotype of physically active mice.  Hence, it will be important to study 
the efficiency of RSV and SRT1720 as adjuvant therapies together with either exercise or CR in mice.  So 
far, RSV supplementation during exercise has not resulted in any conclusive positive results in neither 
mice nor humans [Gliemann et al. 2013, Olesen et al. 2013, Ringholm et al. 2013, Voduc et al. 2014].  
However, further studies should be aimed at investigating the beneficial effects of SRT1720 
supplementation on exercise performance and metabolic health.  Based on our findings, SRT1720 elicited 
a positive effect on skeletal muscle oxidative capacity and mitochondrial number that was not seen with 
RSV treatment.  Hence, SRT1720 could potentially boost the beneficial effects of exercise training on 
oxidative metabolism in skeletal muscle to a greater extent than RSV.  A similar setup as that used in our 
current study would provide a good basis for studying the effects of SRT1720 as an adjuvant therapy to 
exercise for the treatment of obesity and metabolic dysfunction.  Mice would be administered SRT1720 
in a HFD and kept either sedentary in their home cage or exercised by treadmill running 3 times a week 
for a duration of one month.  This specific setup has yielded significantly improved endurance capacity in 
mice in previous experiments (unpublished observation).  It would also be interesting to assess the ability 
of SRT1720 to boost the endurance exercise performance of chow-fed mice in combination with 
continuous exercise training.  In such as setup, the potential of SRT1720 to act as an exercise mimetic 
would be assessed without any confounding effects imparted by HFD-feeding.  In another direction, 
neither RSV nor SRT1720 have been extensively studied as adjuvant therapies together with CR.  This 
would be an interesting direction for future research, especially considering the beneficial effects of 
reduced calorie intake on metabolic health in both mice and humans [Mercken et al. 2012].  As indicated 
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by our study and by other recent studies investigating the effects of RSV in skeletal muscle [Higashida et 
al. 2013, Olesen et al. 2013, Ringholm et al. 2013], it is evident that skeletal muscle is not the main organ 
targeted by these SIRT1-activating compounds.  Hence, future studies should be aimed at elucidating the 
target-organs and molecular effectors of the beneficial metabolic effects elicited by CR/exercise mimetics 
such as RSV and SRT1720.  As mentioned earlier, these studies should be performed with an unbiased 
approach based on microarray analysis or proteomics/phosphoproteomics to map the molecular events 
occurring in liver, adipose tissue and skeletal muscle during treatment with either RSV or SRT1720.  Any 
novel molecular targets of these compounds identified by such a study could subsequently be 
characterized in more detail.  Initially this should be done in an in vitro setup.  However, at a later stage a 
similar setup as we have employed in this thesis could be used, where the protein of interest is knocked 
out and the metabolic effects of either RSV or SRT1720 are investigated on this genetic background. 
PGC-1α is an important transcriptional regulator of mitochondrial ATP-production and skeletal 
muscle metabolism.  PGC-1α increases the capacity of skeletal muscle to oxidize lipids and sustain 
oxidative metabolism during submaximal exercise.  Moreover, it is closely involved in muscle refueling 
through regulation of glucose uptake, glycogenesis and lipogenesis [Chan and Arany 2014].  Despite its 
central role in the regulation of mitochondrial metabolic processes, it is not known to which extent PGC-
1α contributes to skeletal muscle ketone body oxidation.  In this thesis we demonstrate that PGC-1α is an 
important regulator of skeletal muscle ketolytic capacity and that modulation of PGC-1α specifically in 
muscle is sufficient to affect systemic ketone body homeostasis in response to fasting, LCKD feeding or 
exercise.  Moreover, overexpression of PGC-1α in skeletal muscle was sufficient to ameliorate diabetic 
ketoacidosis in mice.  We furthermore show that PGC-1α is necessary for the transcriptional induction of 
ketolytic enzymes in skeletal muscle and the increased systemic ketolytic capacity with exercise.  
Importantly, ERRα is an important partner of PGC-1α in the transcriptional regulation of ketolytic 
enzymes.  Hence, in this thesis we have for the first time investigated the transcriptional regulation of 
ketolytic enzymes in muscle.  Further studies are now needed to map the complete transcriptional 
network responsible for regulation of skeletal muscle ketolytic capacity.  We have been able to link both 
NCoR1- and PGC-1β to the regulation of skeletal muscle ketolysis (unpublished data), indicating that PGC-
1α is not a unique regulator of this metabolic process.  Moreover, analysis of ChIP-sequencing data from 
the promoter regions of the ketolytic genes Acat1, Oxct1 and Bdh1 reveal that PGC-1α and ERRα bind only 
within the Oxct1-gene (unpublished observation).  Hence, these data point towards an indirect 
mechanism how PGC-1α affects the transcription of Acat1 and Bdh1.  However, these findings need to be 
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confirmed and the transcription factors relevant for the regulation of these genes need to be identified.  
This could be accomplished on one hand through bioinformatic-based de novo motif search, where TF 
binding sites are predicted based on the sequence of the promoter region of the gene of interest.  
Additionally, reverse ChIP could be used to extract a stretch of genomic DNA to assess which proteins 
interact with this specific region, for example the promoter region of the ketolytic genes Acat1, Oxct1 and 
Bdh1.  These methods could reveal novel putative transcriptional regulators of ketolytic gene 
transcription, and would subsequently have to be tested in an in vitro setup.  Considering the extensive 
network of transcriptional regulators known to interact with PGC-1α, it would be interesting to use either 
knockdown or pharmacological inhibition of the predicted TFs in combination with overexpression of PGC-
1α.  In analogy with the experiments using ERRα inhibition in our current setup, these experiments could 
reveal novel transcriptional partners of PGC-1α in the regulation of ketolytic gene transcription. 
Intriguingly, during long term LCKD-feeding, OXCT1 protein levels were increased in skeletal 
muscle despite a strong reduction in Oxct1 mRNA levels.  This divergence indicates that OXCT1 protein 
levels are also regulated through non-transcriptional mechanisms. In order to understand how the 
ketolytic capacity in skeletal muscle is controlled, it will be interesting to elucidate the molecular 
mechanisms responsible for the non-transcriptional regulation of OXCT1 protein levels.  Considering that 
enhanced OXCT1 protein levels during long-term LCKD feeding could be due to increased protein stability, 
it would be interesting to assess whether PTMs, such as phosphorylation or acetylation of OXCT1 differ 
between chow- and LCKD-fed mice.  To make a connection between OXCT1 protein stability and 
proteolytic breakdown, it would also be interesting to assess polyubiquitination of the OXCT1 protein.  
The initial step would be to perform immunoprecipitation of OXCT1 and evaluate these individual PTMs 
using specific antibodies.  Additional steps would be to map the specific residues of OXCT1 carrying PTMs 
in vivo by using a mass spectrometry approach.  Finally, mutations of one or several of these residue could 
help to evaluate the effect these PTMs would confer on OXCT1 protein stability.  Another interesting 
aspect would be to study the role of ketone bodies as a metabolic fuel in the context of exercise.  
Administration of ketone body-precursors has been postulated to enhance exercise capacity [Hashim and 
Vanitallie 2014] and the increase in circulating ketone bodies after exercise could potentially contribute 
to post-exercise muscle refueling.  Understanding ketone body metabolism in the context of exercise 
might thus provide novel insights into exercise physiology.  To study the impact of ketolytic capacity on 
exercise performance in mice, it would be interesting to use a skeletal muscle-specific OXCT1-knockout 
mouse model.  In these mice, the ketolytic capacity is ablated and it would thus be possible to specifically 
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evaluate the importance of ketone bodies as an energy substrate, both during and after endurance 
exercise.  It would furthermore be interesting to assess substrate utilization in skeletal muscle during 
exercise.  This could be accomplished by measuring parameters such as glucose, fatty acids, lactate and 
ketone bodies in the blood and in skeletal muscle before and after an acute endurance exercise bout.  
More importantly, mice could be exercised in a closed treadmill system, where oxygen consumption rates 
as well as respiratory quotient could be measured.  When combined with molecular analysis in skeletal 
muscle of different metabolic enzymes and transporter, and quantification of intramuscular energy stores 
and metabolic intermediates, this would give a comprehensive overview on how skeletal muscle 
metabolism is altered in the absence of ketolytic capacity.  In extension, muscle-specific OXCT1 knockout 
mice could be trained by either being kept in running wheel cages, or through treadmill running, as 
mentioned earlier.  By conducting similar experiments as mentioned above, this would help elucidate the 
importance of ketolytic capacity for the metabolic adaptation of skeletal muscle during long-term 
endurance exercise training.  Finally, future studies should be aimed at determining the impact of ketone 
bodies on PGC-1α activation and mitochondrial biogenesis in skeletal muscle.  While we could not observe 
any positive effects on these parameters in the context of ketogenic diet feeding, the beneficial effects of 
increased ketosis could however have been precluded by the high lipid content of the diet.  Hence, 
administration of ketone body precursors or ketone body esters would be a more suitable approach.  Since 
βOHB was recently shown to act as an HDAC-inhibitor in vivo [Shimazu et al. 2013], it is likely that βOHB 
administration would confer beneficial metabolic effects in mice and humans.  Especially since HDAC-
inhibitors have been demonstrated to improve mitochondrial function in skeletal muscle and BAT 
[Galmozzi et al. 2013] and to protect against pathogenic alterations in both heart and brain [Kazantsev 
and Thompson 2008, McKinsey 2012].  Moreover, HDAC-inhibition has been suggested as a novel 
therapeutic strategy to ameliorate diabetic complications [Christensen et al. 2011].  Hence, future studies 
should be aimed at determining the therapeutic potential of βOHB administration and its ability to 
improve the metabolic profile of skeletal muscle as well as other organs (as discussed in chapter 9). 
In the studies performed during this thesis we have revealed new insights into the role of PGC-1α 
in renal physiology and its potential role as a therapeutic target in kidney.  Moreover, we have evaluated 
the role of PGC-1α as a mediator of SIRT1-activating compounds in skeletal muscle and identified PGC-1α 
as a novel transcriptional regulator of skeletal muscle ketolytic capacity.  These studies demonstrate the 
importance of PGC-1α for many different biological processes, which are all ultimately connected to 
mitochondrial metabolism.  Due to the pervasive role of PGC-1α in metabolic regulation in oxidative 
10.  Thesis – Conclusions and future perspectives 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________
256 
organs, targeting this coactivator would be a potential therapeutic strategy to ameliorate many disorders 
with a metabolic or mitochondrial etiology.  Hence, the data presented in this thesis increases our 
understanding of the complex transcriptional networks and cellular processes regulated by PGC-1α and 
will help in the development of more efficient therapeutic strategies against metabolic disorders. 
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